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Abstract 
Background 
The World Health Organization recommends intermittent preventive treatment of malaria in 
pregnancy (IPTp) using sulphadoxine-pyrimethamine (SP) during antenatal visits in moderate to 
high transmission areas.  In some areas of Africa, recent efforts to control and eliminate malaria 
have yielded historic reductions in transmission intensity that have occurred alongside 
concomitant increases in parasite resistance to SP, compromising the efficacy of IPTp.  
Nevertheless, IPTp-SP continues to have beneficial effect on birth outcomes, and there is a 
suspicion that SP may protect against adverse birth outcomes attributable to curable sexually 
transmitted and reproductive tract infections (STIs/RTIs).  This doctoral thesis explores five 
research questions related to IPTp with methods noted in parentheses.   
Research questions and methods 
1. In the context of declining malaria transmission, is there a threshold of malaria transmission 
intensity below which IPTp-SP may no longer protect against the incidence of low birth 
weight?  (Methods: systematic review, meta-analysis, and meta-regression analysis) 
2. In the context of declining parasite sensitivity to SP, is there a threshold of the Plasmodium 
falciparum resistance to SP defined by the prevalence of dhps mutation at codon A581G 
above which IPTp-SP may no longer protect against the incidence of low birth weight?   
(Methods: systematic review and meta-analysis) 
3. In the context of declining malaria transmission and parasite sensitivity to SP, might 
protection conferred by IPTp-SP be explained partially by an effect against malaria infection 
as well as STIs/RTIs?  (Methods: descriptive analysis and multivariate logistic regression) 
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4. In the context of pregnant women attending antenatal care in sub-Saharan Africa, what is the 
prevalence of malaria infection and curable STIs/RTIs?  (Methods: systematic review and 
meta-analysis) 
5. In the context of a high dual burden of malaria infection and curable STIs/RTIs amongst 
pregnant women in sub-Saharan Africa, would azithromycin be an efficacious drug to be 
included as part of IPTp?  (Methods: systematic review and selected meta-analysis) 
Results  
Evidence suggests that IPTp-SP protects against low birth weight in all gravidae regardless of 
transmission intensity.  This protection persists among primi- and secundigravidae irrespective of 
the prevalence of the A581G mutation.  Protection appears to wane, however, as there is no 
evidence of protective effect against low birth weight 
amongst multigravidae where the prevalence of A581G is >10.1%.  Despite this finding, data 
from Zambia suggests that the protective effect of IPTp-SP may safeguard pregnancies against 
more than just the effects of malaria infection; women who received more doses of IPTp-SP 
during pregnancy were protected against adverse birth outcomes attributable to co-infection 
with malaria and several curable STIs/RTIs.  Meta-analysis of data from pregnant women 
attending antenatal care facilities in sub-Saharan Africa suggests that malaria infection and 
curable STIs/RTIs amongst pregnant women attending antenatal care facilities in sub-Saharan 
Africa is very high and, when considered collectively, curable STIs/RTIs may be more prevalent 
than malaria infection during pregnancy.  A potential response to this dual burden of disease in 
pregnancy is to explore combination therapies that address malaria and curable STIs/RTIs jointly 
and more effectively than IPTp-SP.  Research presented in this thesis suggests that curable 
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STIs/RTIs are sensitive to azithromycin and that policymakers need additional evidence to 
consider adding azithromycin to IPTp regimens. 
Conclusions 
Despite evidence of parasite resistance, IPTp-SP remains protective against the effects of malaria 
infection in most pregnant women, even where transmission intensities are very low, and may 
also reduce the burden of curable STIs/RTIs.  However, this protection is likely sub-optimal and, 
given the high prevalence of malaria and curable STIs/RTIs among pregnant women in sub-
Saharan Africa, alternative therapies that include azithromycin merit investigation in clinical 
trials with robust microbiological components. 
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Ithaca 
 
When you start on your journey to Ithaca, 
then pray that the road is long, 
full of adventure, full of knowledge. 
Do not fear the Lestrygonians 
And the Cyclopes and the angry Poseidon. 
You will never meet such as these on your path, 
if your thoughts remain lofty, if a fine 
emotion touches your body and your spirit. 
You will never meet the Lestrygonians 
And the Cyclopes and the fierce Poseidon, 
if you do not carry them within your soul,  
if your soul does not raise them up before you. 
 
Then pray that the road is long, 
That the summer mornings are many, 
That you will enter ports seen for the first time 
With such pleasure, with such joy! 
Stop at the Phoenician markets, 
and purchase fine merchandise, 
mother-of-pearl and corals, amber and ebony, 
and pleasurable perfumes of all kinds, 
buy as many pleasurable perfumes as you can; 
visit hosts of Egyptian cities, 
to learn and learn from those who have knowledge. 
 
Always keep Ithaca fixed in your mind. 
To arrive there is your ultimate goal. 
But do not hurry the voyage at all. 
It is better to let it last for long years; 
and even to anchor at the isle when you are old, 
rich with all that you have gained on the way, 
not expecting that Ithaca will offer you riches. 
 
Ithaca has given you the beautiful voyage. 
Without her you would never have taken the road. 
But she has nothing more to give you. 
 
And if you find her poor, Ithaca has not defrauded you. 
With the great wisdom you have gained, with so much experience, 
you must surely have understood by then what Ithaca means. 
 
 
Constantine P. Cavafy (1911) 
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Introduction 
Some 2,400 years ago in ancient Greece, Hippocrates observed that pregnant women 
were vulnerable to life-threatening fevers.14  The extent to which these fevers were 
attributable to malaria is unknown since the aetiology of malaria infection was poorly 
understood until 1880 when Alponse Laveran, aided by crude microscopy, first 
observed Plasmodium falciparum in the blood-film slides of febrile patients under his 
care in Algeria.15  Two years later he reported that women who experienced symptoms 
associated with P. falciparum infection had higher placental parasite densities than 
mothers who had been free of malarial symptoms throughout their pregnancies.16  In 
sub-Saharan Africa, one of the earliest published descriptions of the burden of malaria 
infection during pregnancy comes from D.B. Blacklock and R.M. Gordon who 
estimated in 1925 that women in Sierra Leone with placental parasitaemia at delivery 
were five times more likely to have their newborn die than mothers whose placentas 
had not been parasitised.17  Steketee et al. calculated that each year 75,000 to 200,000 
infant deaths in sub-Saharan Africa are attributable to malaria infection during 
pregnancy, whereas Murphy and Breman estimated that malaria-induced low birth 
weight (LBW) kills 62,000 to 363,000 newborns each year in the region.18,19  This 
mortality is largely attributable to the effect of malaria infection during pregnancy on 
low birth weight (LBW) associated with preterm birth (population attributable risk: 8% 
to 36%) and LBW associated with intrauterine growth retardation (population 
attributable risk: 13% to 70%).18  
 
To safeguard pregnant women against the consequences of malaria infection during 
pregnancy who are resident in areas of moderate (stable) to high transmission, the 
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World Health Organization (WHO) recommends the provision of intermittent 
preventive treatment in pregnancy (IPTp) using sulphadoxine-pyrimethamine (SP) at 
every scheduled antenatal care (ANC) visit from the second trimester until delivery.20  
Meta-analysis suggests that any chemoprophylaxis reduces the incidence of LBW 
amongst primi- and secundigravidae by 27% (Relative Risk [RR] = 0.73; 95% Confidence 
Intervals [CI]: 0.61, 0.87; 8 trials; N = 3,619), severe maternal anaemia by 40% (RR 
0.60, 95% CI: 0.47, 0.75; 3 trials, N = 2,503), and neonatal mortality 38% (RR = 0.62; 
95% CI: 0.37, 1.05; 2 trials; N = 2,156).21  The intervention also protects against 
asymptomatic parasitaemia, peripheral and placental infection that may be present at 
the time of dosing while, separately, shielding against new malaria infections that may 
occur after dosing and before the next ANC visit.22  The parasiticidal effect of SP 
against P. falciparum relies on pharmacological synergy between both drug 
components.23  Sulphadoxine inhibits dihydropteroate synthase (Pfdhps), an enzyme 
required by P. falciparum to biosynthesize folate, whereas pyrimethamine inhibits 
dihydrofolate reductase (Pfdhfr), an essential enzyme used by P. falciparum to 
produce tetrahydrofolate, a cofactor the parasite needs to biosynthesise DNA and 
protein.24,25  Several parasite mutations are associated with decreased SP sensitivity 
that vary geographically by type and prevalence.26  In West Africa, ‘partially resistant’ 
biomarkers are found in combinations of Pfdhfr N51I, N59R, and S108N with Pfdhps 
A437G, whereas parasites in East Africa express ‘fully resistant’ combinations of Pfdhfr 
N51I, N59R, and S108N with Pfdhps A437G and K540E.26  Epigenetic analyses suggest 
that there are three foci in East Africa where parasite populations have acquired the 
additional mutation of Pfdhps A581G to become ‘super resistant’ to SP.26   
 
22 
 
There have been historic reductions in malaria transmission intensity in some locales 
of sub-Saharan Africa over the past decade, accelerated by malaria control 
interventions that have included the use of indoor residual spraying, artemisinin-
combination therapies, and mass distribution of insecticide treated nets (ITNs).  Of the 
35 sub-Saharan countries where IPTp-SP is national policy, ITNs have been made 
available to pregnant women at no direct cost in 33 countries.27  This has resulted in 
an estimated 10.5 million women using ITNs during their pregnancies in 2010 across 
37 sub-Saharan countries, representing 38.8% of all births in the region (95% CI: 
34.6%, 43.0%).5  The concurrent increase in SP drug resistance and decline in malaria 
transmission intensity in some settings has raised competing questions of where and 
when IPTp-SP should be replaced with a more efficacious antimalarial drug – or where 
and when the intervention should be discontinued all together.  This doctoral thesis 
addresses these and other related questions. 
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Literature review 
Epidemiology of malaria in pregnancy 
Malaria infection during pregnancy is associated with a variety of adverse birth 
outcomes including maternal anaemia,28-31 stillbirth,32-34 intrauterine growth 
retardation,35,36 preterm birth, 36,37 and LBW,32,35,37-39 and infant mortality.39  Amongst 
these adverse birth outcomes, LBW is the most frequently reported outcome because 
of its ease and precision of measurement.  Arvo Ylppö, the acclaimed Finnish 
paediatrician and early advocate for child welfare clinics, defined LBW as newborns 
weighing less than 2.5 kg at delivery.40  A landmark cohort study in the 1980s showed 
that LBW infants in low-income settings were 4.3 times more likely to die during the 
neonatal period than newborns who were delivered weighing 2.5 kg or more.41  Low-
birth weight babies who survive infancy then go on to experience higher rates of 
respiratory infection and diarrhoeal disease than peers who were born above the 2.5 
kg threshold42,43 and, when fully grown, are more likely to suffer from micro-vascular 
conditions.44-46  Low birth weight girls, as adults, are at greater risk of developing pre-
eclampsia and delivering LBW babies themselves.47  Thus, reducing the incidence of 
LBW has public health implications that are lifelong and intergenerational. 
Entomological considerations 
Female Anopheles mosquitoes are the primary vectors of malaria parasites.  While in 
the process of collecting blood meals for egg development, infected Anopheles inject 
P. falciparum sporozoites into humans.  Anopheles are more likely to target expecting 
mothers compared to non-pregnant women for several reasons.  Female Anopheles 
are attracted to the carbon dioxide that humans exhale,48 with and without any 
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accompanying human scent.49  Although the extent to which emitted carbon dioxide 
and temperature may vary over the course of pregnancy, researchers in the Gambia 
found that expecting mothers with a mean gestational age of 28 weeks had 21% more 
expiratory lung volume and abdomens that were also 0.7⁰ Celsius warmer compared 
to non-pregnant women.50  A separate study, also in The Gambia, showed the extent 
to which pregnant women attract more A. gambiae, the most common malaria vectors 
in sub-Saharan Africa.  In total, 72 women, 36 pregnant and 36 non-pregnant, were 
given malaria chemoprophylaxis and bed-nets prior to sleeping in identical 
experimental huts.  Over three consecutive nights, twice as many Anopheles entered 
the huts of pregnant participants compared to non-pregnant women (P < 0.000).  
Adding to the risk of malaria exposure, pregnant women were observed stepping out 
of their protective nets an average of twice per night versus once amongst non-
pregnant participants (P = 0.019).51  
Physiological considerations 
In addition to being at elevated risk of exposure, pregnant women are at greater risk 
of adverse consequences resulting from malaria infection compared to non-pregnant 
women.  During pregnancy, maternal inflammatory responses are down-regulated for 
the benefit of embryonic implantation and foetal survival.52  Hence, pregnant women 
may be more vulnerable to new infections, relapsed infections (from latent or 
dormant phases), recrudescent infections (delayed clearance of infection), and re-
activated infections (from persistent chronic infections).53   Maternal parasitaemia 
triggers inflammatory responses that increase circulation of tumour necrosis factor 
alpha (TNF-α) and interleukin-1054 which are independently associated with adverse 
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birth outcomes.55  Chronic parasitaemia is associated with intrauterine growth 
retardation, while acute infection is more commonly the cause of miscarriage or 
stillbirth.56  Although placental malaria does not appear to interfere with the transport 
of vitamin A,57 iron,58 folic acid or vitamin B-12,53 general placental insufficiency may 
compromise the exchange of other vital nutrients required for healthy foetal 
development.59,60  In addition, parasitic invasion of the trophoblast may have an effect 
similar to pre-eclampsia, decreasing placental circulation by undermining normal 
remodelling of spiral arteries into utero-placental vessels.61  The risk of maternal 
hypertension may increase amongst primigravidae exposed to chronic placental 
malaria, potentially triggered by a foetal response to placental inflammation.62  
 
Amongst the five malaria parasites known to infect humans, P. falciparum is unique.  
Erythrocytes penetrated by P. falciparum in pregnant women will commonly adhere to 
chondroitin sulphate A (CSA) molecules and sequester along the endothelial and 
syncytiotrophoblast cells of the placenta.63  As a consequence, infected erythrocytes 
may not be detected with conventional assays that rely on samples of peripheral 
blood.64  Even still, malaria infection does not affect all pregnant women equally.  
Parasites that bind to CSA molecules also transcribe the var 2 CSA gene,65-67 triggering 
development of protective immunoglobulin G that is associated with maternal parity 
in malaria-endemic areas.68  Thus, multigravidae exposed to CSA-binding parasites 
during previous pregnancies are better able to control parasite densities than primi- 
and secundigravidae.  Maternal infection with the human immunodeficiency virus 
(HIV) compromises the acquisition of semi-immunity against malaria infection during 
pregnancy.63  
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Chemoprevention 
Chloroquine and pyrimethamine monotherapies 
The WHO first recommended the provision of chemoprophylaxis to all pregnant 
women living in malaria-endemic areas in 1986.  This involved weekly, self-
administered doses of 300 mg chloroquine or 25 mg pyrimethamine.69  Compliance 
with these regimens proved difficult,70,71 and the spread of P. falciparum resistance to 
chloroquine and, separately, to pyrimethamine undermined the protective effect of 
both regimens.70-72   
Sulphadoxine-pyrimethamine 
In 1993, Malawi became the first country to adopt a national strategy of directly-
observed chemoprevention using SP administered to pregnant women during ANC 
visits.73  This operational experience, coupled with clinical trial data from Kenya74,75 
and Malawi,38,76 was sufficient for the WHO to make its first IPTp-SP policy 
recommendation.22  At present, 35 of the 36 countries worldwide that have an IPTp-SP 
policy are in sub-Saharan Africa.27    
Decreasing malaria transmission 
Over the past decade, as ITN provision has become part of the standard of care, nets 
have been used in IPTp-SP trials.  This has greatly affected trial outcomes and the 
transmission intensity to which participants have been exposed.  A randomised 
placebo-controlled trial in Mozambique conducted between 2003 and 2005 (N = 
1,030) amongst women of all gravidae, 90% of whom used ITNs, showed that two 
doses of IPTp-SP had no protective effect against LBW (Relative Risk [RR], 0.99; 95% CI: 
0.70, 1.39), nor against placental infection (RR = 1.0; 95% CI: 0.88, 1.13; P = 0.964) 
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when compared to placebo.  It is not clear the extent to which this observation was 
attributable to lost parasite sensitivity to SP, or to women having been exposed less 
malaria infection, or both.  Despite these findings, IPTp-SP conferred some important 
benefits.  Women who received SP versus no doses had 40% fewer clinical malaria 
cases (95% CI: 7.4%, 61.2%]; P = 0.02), and one-half the prevalence of peripheral 
parasitaemia (7.10% versus 15.15%) (P = 0.001).  Moreover, compared to ITNs alone, 
IPTp-SP provided greater protection against parasitaemia (RR = 0.52; 95% CI: 0.27, 
0.99; P = 0.044) in the first eight weeks post-partum,77 representing an important 
chemoprophylactic effect because the maternal risk of malaria infection has been 
shown to increase following delivery into the early post-partum period.78  Specifically, 
the risk of malaria infection is three times greater in the second (adjusted risk ratio = 
2.8; range 1.1 to 7.4; P = 0.04) and third trimesters (adjusted risk ratio = 3.1; range 1.2 
to 7.9; P = 0.02) compared to the first trimester, and is four times greater in the 60-day 
post-partum period (adjusted risk ratio = 4.1; range 1.8 to 9.5; P = 0.001).78  Secondary 
analysis of data from a Mozambique trial noted above found that IPTp-SP reduced 
early neonatal ( < 7 days of life) mortality by 61.3% (95% CI: 7.4%, 83.8%); P = 0.024] 
(20 deaths overall; 15 in the placebo group versus five in the IPTp-SP group; P = 
0.039).79  Protection was also reported against neonatal ( < 28 days of life) mortality 
(25 deaths overall; 18 in the placebo group versus seven in the IPTp-SP group; P = 
0.041), a trend that was no longer statistically significant against infant (first 12 
months of life) mortality (58 deaths overall; 35 in the placebo group versus 23 in the 
IPTp-SP group; P = 0.136).79 
Another placebo-controlled trial amongst pregnant multigravidae (N = 1,035) 
conducted in The Gambia between 2002 and 2004 showed that IPTp-SP offered no 
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greater protection against LBW than ITNs alone (effect difference = 28 g; 95% CI: 11, 
67; P = 0.16); 78% of women in both groups reported using ITNs.80  Researchers 
reported no protective effect of IPTp-SP in an un-blinded randomised trial carried out 
from 2004 to 2007 amongst women of all gravidae (N = 5,775) in a low-transmission 
area of Uganda.  No difference in the percentage of LBW infants was seen across the 
three intervention groups: IPTp-SP alone (6.48%), ITNs alone (6.28%) and IPTp-SP plus 
ITNs (6.85%); P = 0.80.81  Table 1 contains selected studies that illustrate outcomes 
following the provision of placebo verses IPTp-SP with and without ITNs .  The first 
three are trials that suggest IPTp-SP may be no better than placebo in settings where 
ITN coverage is very high, thereby reducing exposure to malaria transmission.  The 
fourth is an observational study in which ITN use was low and, unexpectedly, SP use 
appeared to increase the risk of placental parasitaemia.   
  
29 
 
Table 1. Selected studies of placebo vs. IPTp-SP with and without ITNs  
Country [ref] 
 
Site Gravidae Placebo (with ITNs) SP (2 doses without ITN) SP (2 doses with ITNs) Malaria transmission 
and ITN use 
Key findings 
LBW Peripheral Placental LBW Peripheral Placental LBW Peripheral Placental 
Mozambique 77 Manhiça Primigravidae 20.7% 
(25/121) 
23.6% 
(30/127) 
52.3% 
(219/419) 
- - - 
21.8% 
(29/133) 
13.5% 
(18/133) 
52.1% 
(222/426) 
Perennial transmission 
with seasonal variation;  
self-reported use of ITNs 
was 90% in both 
treatment groups 
SP as effective as 
placebo 
1-3 pregnancies 6.7% 
(13/195) 
16.1% 
(31/193) 
- - - - 
10.3% 
(20/194) 
6.3% 
(12/192) 
>4 pregnancies 11.7% 
(21/180) 
8.0% 
(14/175) 
- - - - 
5.4% 
(9/167) 
30.4% 
(51/168) 
The Gambia 80 Farafenni 
 
Secundigravidae 6.9% 
(63/917) 
3.3% 
(34/1,035) 
- - - - 
5.5% 
(51/931) 
9.0% 
(91/1,010) 
- 
Ben-net usage including 
ITNs was ~ 70% 
SP as effective as 
placebo Multigravidae 
Uganda 81 Kabale Primigravidae 5.5% 
(18/329) 
12.9% 
(201/1,559) 
2.6% 
(16/622) 
5.1% 
(16/313) 
14.6% 
(231/1,580 
4.3% 
(28/651) 
8.1% 
(27/333) 
15.3% 
(231/1,510) 
3.1% 
(19/613) 
ITN coverage was 
estimated to be > 97% 
ITNs alone,  
SP-IPTp alone, and 
ITNs plus SP-IPTp 
were non-inferior 
to each other 
Secundigravidae 5.8% 
(16/277) 
- - 
7.7% 
(22/287) 
- - 
5.1% 
(14/276) 
- - 
2 to 4 previous 
pregnancies 
5.9% 
(37/631) 
- - 
6.6% 
(40/610) 
- - 
7.2% 
(44/614) 
- - 
>5 pregnancies 8.3% 
(27/325) 
- - 
6.1% 
(21/347) 
- - 
6.7% 
(21/315) 
- - 
Tanzania 82 Muheza Primigravidae 
- - 
35.3% a 
(6/17) 
- - 
45.5% b 
(35/77) 
- - 
50.0% c 
(5/10) 
Perennial transmission;  
ITN use summarised in 
the table notes. 
SP use increased 
the risk of 
placental 
parasitaemia 
Secundigravidae 
- - 
41..2% a 
(7/17) 
- - 
28.6% b 
(22/77) 
- - 
40.0% c 
(4/10) 
Multigravidae 
- - 
23.5% a 
(4/17) 
- - 
26.0% b 
20/77) 
- - 
10.0% c 
(1/10) 
Notes:  
a Women who never received IPTp-SP and 0% used ITNs 
b Women who received ‘early’ IPTp-SP as noted on ANC card and 14% used ITNs 
c Women who received ‘recent’ IPTp-SP as noted on ANC card and 30% used ITNs 
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Decreasing parasite sensitivity 
Several factors have contributed to the decline in the protective effect of IPTp-SP.  
Historic use of pyrimethamine monotherapy is partially responsible for the emergence 
of parasite resistance.  The experience of Tanzania is illustrative.  During the 1950s, 
Tanzania introduced pyrimethamine monotherapy.  At the time, treatment for 
uncomplicated malaria infection was a single 25 mg dose which produced a clinical 
cure within seven days.83  The first known treatment failure was recorded in 1953 
during a clinical trial in Mingeza village, near Muheza town, north-east Tanzania.83  
Unrestricted pyrimethamine use continued in the area until 1965 when treatment 
failures were observed 160 kilometres from the original foci of resistance.84  In the 
same year, Tanzania suspended imports of pyrimethamine, as well as progunil, an 
antimalarial drug that can select for pyrimethamine resistance.85   No Pfdhfr/Pfdhps 
inhibitors were available in Tanzania for malaria chemoprevention or treatment 
purposes until 1980 when researchers conducted a trial in Bagamoyo, 137 kilometres 
south of Muheza, where there had never been any previously reported treatment 
failures involving pyrimethamine.  In this setting, despite 15 years of suspended SP 
drug pressure, 47.8% (N = 23; 95% CI: 26.8%, 69.4%) of patients with uncomplicated 
malaria experienced recrudescent infections within seven days of pyrimethamine 
treatment.  This suggests that the fitness-cost of mutating in response to 
pyrimethamine exposure is minimal and, consequently, parasite reversion to a 
sensitive state may not occur following the withdrawal of SP drug pressure.  
 
Alarming evidence of SP resistance comes from a cross-sectional survey conducted in 
Muheza, Tanzania, between 2002 and 2005.  Placental parasitaemia was significantly 
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higher in women given any dose of IPTp-SP compared to women who received no 
doses, 84% [87 of 104] versus 16% [17 of 104], respectively (P = 0.03).  Bed-net use 
was lowest amongst those who received no IPTp-SP doses (23.5%) in contrast to 
women given treatment early in pregnancy (36%) or shortly before delivery 
(30%).82,86,87  Investigators suggest that the increase in placental parasitaemia amongst 
women given IPTp-SP was likely the result of extreme drug resistance.  The day-28 
treatment failure rate was 82% amongst children under five-years of age in an area 
near Muheza where the parasite population exhibited near saturation of the 
Pfdhfr/Pfdhps quintuple mutation with concurrent mutation along Pfdhps gene at 
codon 581.88  Investigators in the IPTp study postulated that parasites in locales with 
very high pyrimethamine resistance may be able to repopulate a human host more 
rapidly than parasites in the same area that remain sensitive to pyrimethamine, 
thereby increasing overall parasite densities amongst recipients of preventive 
treatment.89,90  Despite these findings of apparent ‘harm’ attributable to IPTp-SP 
exposure, a more recent study in Malawi did not observe similar results.91   
 
Potential for azithromycin use in IPTp 
Several trials over the past decade have tried to identify therapies to replace SP where 
parasite resistance is high.  Azithromycin-based combination therapies have been 
amongst these candidates and may confer dual protection against malaria infection 
and curable STIs/RTIs. 
Azithromycin monotherapy 
Synthesised in the 1980s, azithromycin is the first compound of the azalide family of 
antibiotics.  Animal studies have shown that quantities 2 to 4 times the human daily 
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dose do not reduce fertility, nor cause foetal harm.92  Pregnant women have received 
up to 2 g azithromycin in a single dose in all trimesters without teratogenic effect.92   In 
adults, a one-time dose of 1 g azithromycin is associated with mild to moderate side-
effects including diarrhoea or loose stools (7%), nausea (5%), vomiting (2%), and 
vaginitis (2%) with fewer than 1% of recipients experiencing dizziness, headache, 
vertigo, and/or somnolence.92  Azithromycin has demonstrated better tolerability than 
erythromycin with shorter dosing regimens required to achieve the same therapeutic 
effect.93  HIV-infected patients, however, poorly tolerate azithromycin when taken 
long-term as chemoprophylaxis.94,95   
Azithromycin functions as a slow-acting macrolide that causes the progeny of exposed 
parasites to inherit an apicoplast that is incapable of protein synthesis, thereby 
producing a delayed-death in parasites.96  This slow clinical response makes 
azithromycin monotherapy an unsuitable choice for treating uncomplicated or sever P. 
falciparum infections.97  However, azithromycin monotherapy is efficacious against P. 
vivax with 1 g to 2 g98,99 and, against P. falciparum, 100 has been used as a 
chemoprophylaxis in Kenya, Indonesia and Thailand conferring modest protection as 
shown in Table 2.      
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 Table 2. Azithromycin chemoprophylactic efficacy relative to placebo  
 
Not all potential partner compounds are pharmacologically compatible.  An in vitro 
study suggests that azithromycin has an additive effect against P. falciparum when 
combined with either mefloquine or pyronaridine.101  Artesunate and azithromycin, in 
contrast, have demonstrated antagonism when combined against fresh P. falciparum 
samples.101,102  Antagonism, and resultant poor efficacy, may partially explain why a 
paediatric trial that used azithromycin plus artesunate was halted prematurely,103 
although two studies of semi-immune adults have shown favourable results.104,105  
Azithromycin could be combined with piperaquine, a quinolone compound related to 
chloroquine, but better tolerated.106  The combination of azithromycin and 
dihydroartemisinin has shown additive-to-synergistic in vitro effect.104  Only two 
azithromycin combination therapies have undergone investigation in clinical trials: SP 
plus azithromycin, and azithromycin plus chloroquine.  There is burgeoning interest in 
combining azithromycin with dihydroartemisinin-piperaquine for use in IPTp.  The 
European & Developing Countries Clinical Trials Partnership (EDCTP) and the Medical 
Country Treatment regimen and protective efficacy relative to placebo 
 AZ 250 mg daily AZ 1 g weekly 750 mg loading  
250 mg daily 
Notes 
PE% 95% CIs PE% 95% CIs PE% 95% CIs 
Kenya 100 82.7 
 
68.5, 91.1 64.2  
 
47.1, 77.1 - - Plasmodium species unspecified 
59 subjects = 250 mg daily dose   
58 subjects = 1 g weekly dose 
10 week follow-up 
Indonesia98  - 
 
- - 
 
- 
 
71.6  
98.9 
84.7 
50.3, 83.8 
93.1, 99.9 
75.6, 90.7 
Plasmodium falciparum 
Plasmodium vivax 
All malaria  
148 subjects  
20 week follow-up period 
Thailand99  - 
 
- - 
 
- 
 
70.8 
98.0 
91.8 
 
-14.0, 93.7 
87.8, 99.9 
78.6, 97.5 
Plasmodium falciparum 
Plasmodium vivax 
All malaria  
179 subjects 
20 week follow-up period 
PE = Protective efficacy; CI = Confidence interval 
34 
 
Research Council in the UK are currently supporting two such trials that will begin 
recruitment by early 2018. 
Azithromycin plus sulphadoxine-pyrimethamine 
 
To date, three clinical trials have compared birth outcomes following exposure to the 
standard of care, IPTp-SP, versus IPTp-SP plus azithromycin as summarised in Table 3.  
Two of these trials were conducted in Malawi and yielded contradictory results.  The 
first was a three-arm trial between 2002 and 2006 in which pregnant women received 
routine IPTp-SP, or monthly IPTp-SP, or monthly IPTp-SP plus 1 g azithromycin two 
times during the antenatal period.  The prevalence of LBW was 12.9% (52 of 402), 
9.1% (36 of 394), and 7.9% (32 of 406) in women receiving IPTp-SP, monthly IPTp-SP or 
monthly IPTp plus azithromycin, respectively, and primi- and secundigravidae were 
protected more by preventive therapy against the consequences of malaria infection 
during pregnancy than multigravidae.107  In contrast, the APPLe study (Azithromycin 
for the Prevention of Preterm Labour) in Malawi, carried out between 2004 and 2005 
showed that 1 g azithromycin, administered twice during the antenatal period, had no 
effect on birth-weight, nor on the incidence of preterm delivery.108  These results 
require cautious interpretation.  There were several differences between the studies.  
The APPLe trial combined azithromycin with IPTp-SP given two times, whereas women 
in the other Malawi trial received IPTp-SP monthly, either with or without 
azithromycin.  In addition, participants in the APPLe trial were more often 
primigravidae and were more likely to have syphilis at enrolment.  Finally, syphilis 
treatment administered to women in the APPLe trial was not in accordance with WHO 
recommendations for pregnant women.  These women were given 1g benzyl penicillin, 
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treatment for individuals with neurosyphilis,109 instead of 2.4 mµ of benzathine 
penicillin G.110   Moreover, treatment with azithromycin may have cleared maternal 
syphilis, but may not have altered birth outcomes; the compound does not perfuse the 
placenta in sufficient concentrations.  Thus, neither the benzyl penicillin nor the 
azithromycin administered twice were likely to have cured congenital syphilis.111   
A recent trial in Papua New Guinea, also summarised in Table 3, compared monthly SP 
plus azithromycin (1 g twice daily for 2 days; 4 g AZ total during antenatal period) 
against SP and chloroquine (450 to 600 mg, daily for three days) given once, followed 
by SP and chloroquine placebo (control).  Intention-to-treat analysis showed the 
incidence of LBW to be 12.8% (130 of 1,013) amongst women given SP plus 
azithromycin and 17.4% (175 of 1,008) for women who received SP plus chloroquine.  
Per-protocol analysis was comparable; LBW was 12.6% (122 of 967) amongst women 
administered SP plus azithromycin versus 16.7% for women given SP plus chloroquine 
(159/952).112  
Azithromycin plus chloroquine 
 
The combination of azithromycin plus chloroquine has demonstrated an additive-to-
synergistic effect in vitro against P. falciparum.101  When used against chloroquine-
sensitive strains, azithromycin plus chloroquine produced an additive effect, and 
synergy when exposed to chloroquine-resistant P. falciparum.  Two studies have been 
conducted using azithromycin plus chloroquine amongst pregnant women with a 
three-day regimen involving a daily dose of 1 g azithromycin and 620 mg chloroquine 
base (four tablets of azithromycin plus chloroquine each containing 250 mg/155 mg).  
A single-arm parasite clearance trial amongst 163 women with asymptomatic 
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infections showed the day 28 cure rate to be 99.4% (95% CI: 97.8, 100) when corrected 
using polymerase chain reaction (PCR) methods and intention-to-treat analysis.113  At 
day 35 and day 42, PCR-corrected cure rates dropped slightly to 96.7% (95% CI: 93.4%, 
99.9%), and 95.2% (95% CI: 91.3%, 99.0%), respectively.  The uncorrected PCR 
prevalence rates at day 28, day 35, and day 42 were 95.5% (95% CI: 91.8%, 99.1%), 
87.7% (95% CI: 82.1%, 93.2%), and 78.4% (95% CI: 71.6%, 85.3%), respectively.113   A 
multi-centre IPTp trial compared azithromycin plus chloroquine versus SP with the 
primary endpoint being the proportion of sub-optimal pregnancy outcomes (LBW, 
premature birth, stillbirth, abortion, lost to follow-up prior to observation of 
pregnancy outcome, or missing birth weight) under intention-to-treat analysis.  The 
trial was terminated early on grounds of futility; the prevalence of sub-optimal birth 
outcome amongst recipients of azithromycin plus chloroquine was 26.2% (95% CI: 
23.9%, 28.4%) versus 23.7% (95% CI: 21.5%, 25.9%) for women given SP.114   
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Table 3. Selected IPTp studies of azithromycin  
 
Country 
[ref] 
 
Site Gravidae IPTp (standard) IPTp monthly IPTp monthly + AZ x 2 AZ+CQ Malaria transmission and 
ITN use 
Key notes 
LBW Preterm LBW Preterm LBW Preterm LBW Preterm 
Malawi 
107 
Mangochi 0 previous 
pregnancies 
12.9% 
52/402 
30.0% 
33/110 
9.1% 
36/394 
18.7%  
20/107 
7.9% 
32/406 
14.6% 
13/89 
- - 
Holoendemic-transmission; 
self-reported use of nets 
previous night ranged between 
59.4% and 61.0% across 
treatment groups (data not 
collected on whether nets were 
treated) 
T. vaginalis was 16.8% (69/411) 
in IPTp (standard) group vs. 
11.0% (46/419) amongst 
women who received IPTp 
monthly plus AZ x 2. 
1 previous 
pregnancy 
17.4% 
15/86 
24.4% 
19/78 
18.8% 
15/80 
- - 
2 previous 
pregnancies 
12.6% 
30/239 
11.3% 
29/256 
8.9% 
24/271 
- - 
All gravidae 17.9% 
78/435 
15.4% 
68/441 
11.88% 
52/440 
- - 
Malawi 
108 
Southern All gravidae 2.99 kg 
(n=769) 
17.4% 
189/1,087 
- - 
3.03 kg 
(n=739) 
16.8% 
184/1,096 
- - 
Malaria transmission not 
reported; net use not  reported 
AZ+SP was no more protective 
than SP alone, but sub-optimal 
Rx was given to women with 
syphilis in both groups. 
Papua 
New 
Guinea 112 
 
Madang 
Province 
All gravidae 17.4%2 
175/1,008 
- - - 
12.8% 
130/1,013 
RR = 0.62 95% 
CI: 0.43,0.89, P 
= 0.010 
- - 
Women without nets were 
given an ITN; due to local stock-
outs 8% of women did not have 
or receive an ITN. 
Prevalence in cross-sectional 
survey 115:   
N. gonorrhoeae = 9.7% 
C. trachomatis = 11.1% 
T. vaginalis = 21.3% 
33.7% had at least one 
infection. 
 Pfizer 116 Multicentre All gravidae 5.7% 
68/1188 
3.7% 
45/1211 
- - - - 
5.0% 
57/1138 
4.0% 
47/1164 
Field workers verified 
installation of new ITNs during 
home visits following 
enrolment: AZCQ (98.5%) and 
SP (98.3%)  
Per regulatory requirement, all 
participants for whom there 
was a missing birth outcome 
were categorised as a 
treatment failure (ITT analysis 
versus per protocol analysis) 
Note: (1) participants were given insecticide treated bed nets unless otherwise noted; (2) The control group in Papua New Guinea received SP+CQ per national policy 
IPTp = Intermittent preventive treatment of malaria in pregnancy; SP = sulphadoxine-pyrimethamine; AZ = azithromycin; CQ = chloroquine; LBW = low birth weight; ITT = Intention to treat 
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Epidemiology of STIs/RTIs in pregnancy 
The infective agent of syphilis is Treponema pallidum, a highly motile, Gram-negative 
spirochete bacterium that can be transmitted from mother to child by placental 
invasion or through contact of a maternal syphilitic lesion during delivery.  Although 
vertical transmission is uncommon prior to 18 weeks of gestation,117 T. pallidum can 
gain access to the foetal compartment as early as 9 to 10 weeks.123,124  In some 
populations, 40% of spontaneous abortions are attributable to untreated syphilis 
during pregnancy.118,119  Syphilis infection is associated with an 18-fold increase in the 
risk of stillbirth (Risk ratio [RR] = 18.1; 95% CI: 5.5, 59.6), double the risk of intrauterine 
growth retardation (RR = 2.1; 95% CI: 1.0, 4.2), a six-fold increase in the risk of preterm 
birth (RR = 6.1; 95% CI: 2.5, 15.3), and treble the risk of LBW (RR = 3.3; 95% CI: 2.0, 
5.4).120   
 
Transmission of the Gram-negative diplococci bacterium Neisseria gonorrhoeae 
usually occurs from mother to child during delivery, although foetal infection can 
occur during prolonged rupture of the membranes.  Maternal infection with N. 
gonorrhoeae was associated with a two-fold increase in the odds of preterm birth in 
the United States (OR = 2.0; 95% CI: 1.0, 4.0)121 and a three-fold increase in Kenya (OR 
= 3.2; 95% CI: 1.3, 8.4).122   These same studies also reported a statistically significant 
increase in LBW amongst babies born to infected women.  A common co-infection 
with N. gonorrhoeae, Chlamydia trachomatis is also a Gram-negative bacterium and is 
associated with intrauterine growth retardation (OR = 2.4; 95% CI: 1.3, 4.2),123 preterm 
delivery (OR 1.6; 95% CI: 1.0, 2.5),123  LBW (OR = 2.7; 95% CI: 1.3, 5.7),124 premature 
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rupture of the membranes (OR = 2.4; 95% CI: 1.1, 5.4),124 and preterm birth (OR = 4.0; 
95% CI: 1.7, 9.2).124   
 
Trichomonas vaginalis, a protozoan parasite, is responsible for one-half of all curable 
STIs worldwide125 and has been shown to increase the odds of preterm delivery 
between 30% (OR = 1.3; 95% CI: 1.1, 1.4),126 40% (OR = 1.4; 95% CI: 0.7, 2.8),121 and 
50% (OR = 1.5; 95% CI: 0.1, 8.1).127  Infection by T. vaginalis increases the odds of LBW 
by 30% (OR = 1.3; 95% CI: 1.1, 1.5),126  by 50% (OR = 1.5; 95% CI: 0.9, 2.6),121 by two-
fold (OR = 2.1; 95% CI: 1.0, 4.7).128  Bacterial vaginosis is a syndrome caused by a 
disequilibrium in the vaginal microbiota with a concomitant decline in the number of 
naturally occurring lactobacilli, and is widely associated with adverse birth outcomes.  
Meta-analysis suggests that bacterial vaginosis increases the odds of a spontaneous 
abortion by ten-fold (OR = 9.9; 95% CI: 2.0, 49.3)129 and has been shown to increase 
the risk of premature rupture of the membranes by 3.5-times (3.5 = RR; 95% CI: 1.4, 
8.9).130  One study in the United Kingdom associated bacterial vaginosis infection with 
a 13-fold increase in risk of preterm birth (RR = 13.1; 95% CI: 4.0, 42.6),131  although 
most studies suggest that the risk of preterm birth attributable to bacterial vaginosis is 
increased by one- or two-fold, levels that are similar for LBW.  The effects of these five 
curable STIs/RTIs on pregnancy outcomes are summarised in Table 4.    
Management of curable STIs/RTIs in pregnancy 
 
As noted earlier, the WHO recommends syphilis screening and treatment for pregnant 
women at their first antenatal visit.  For other curable STIs/RTIs, the WHO suggests 
using syndrome-based algorithms to guide diagnosis and treatment.  The approach has 
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been useful amongst men for whom STIs/RTIs are more commonly symptomatic.  In 
contrast, the vast majority of gonococcal (80%) and chlamydial (70% to 75%) infections 
amongst women are asymptomatic125 and, therefore, never diagnosed.  Consequently, 
the algorithm based on vaginal discharge syndrome has a low sensitivity (30% to 80%) 
and specificity (40% to 80%) for N. gonorrhoeae and C. trachomatis amongst pregnant 
women.132-134  Syndromic management has slightly higher sensitivity for T. vaginalis 
(54% to 83%) and bacterial vaginosis (51% to 69%) with moderate specificity (40% to 
54% for T. vaginalis; 40% to 58% for bacterial vaginosis).    
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Table 4. Effect of curable STIs/RTIs on birth outcomes 
 
Reference  Country Year(s) 
Spontaneous 
abortion (95% CI)  
Stillbirth (95% CI) IUGR (95% CI) PROM (95% CI) Preterm birth (95% CI) LBW (95% CI) 
Treponema pallidum 
Watson-Jones (2002) 120 Tanzania 1998-2000 NR 18 (5.5, 59.6) RR 2.1 (1.0, 4.2) RR NR 6.1 (2.5, 15.3) RR 3.3 (2.0, 5.4)a 
Temmerman (1995 135 Kenya 1991 NR 3.34 RR NR NR NR 4.01a 
McDermott (1993) 136 Malawi 1987-1990 NR 10.98 NR NR NR NR 
Donders (1993) 137 South 
Africa 
1988 NR NR NR NR 33%; 5 of 15 cases NR 
Elliott (1990) 122 Kenya 1985 NR NR NR NR 1.4 (0.5, 4.1) NR 
Ratnam (1982) 119 Zambia NR 42% of cases NR NR NR NR NR 
Williams (1923) 118 United 
States 
1923 40% of cases NR NR NR NR NR 
Neisseria gonorrhoeae 
Johnson (2011) 121 United 
States 
1996-2002 NR NR NR NR 2.0 (1.0, 4.0) 0.8 (0.3, 2.3) 
Donders (1993) 137 South 
Africa 
1988 NR NR NR NR 56%; 5 of 9  cases P<0.005 
Elliott (1990) 122 Kenya 1985 NR NR NR NR 3.2 (1.3, 8.4) NR 
Chlamydia trachomatis 
Rours (2011) 138 Nether- 
lands 
2003-2005 NR NR NR NR 4.4 (1.3, 15.2)a;; 2.7 (1.1, 
6.5)b; 1.17 (0.6, 2.4)c       
1.0 (0.4, 2.2) 
Silveira (2009) 139 United 
States 
2005-2008 NR NR NR NR 0.7 (0.4 to 1.4) NR 
Wilkowska-Trojniel 
(2009) 140 
Poland 2003-2006 12 v 2% P=0.029 NR NR NR NR NR 
Blas (2007) 141 United 
States 
2003 NR NR NR 1.5 (1.0, 2.2) RR 1.5 (1.1, 2.0) RR 1.1 (0.7, 1.7) 
Odendaal (2006) 142 South 
Africa 
2002-2003 NR NR NR NR 22.2%; 8 of 36 cases vs.  
10.4%;  32 of 307 cases; 
P=0.037 
NR 
Johnson (2011) 121 United 
States 
1996-2002 NR NR NR NR 1.0 (0.6, 2.0) 2.1 (1.0, 4.2) 
Kovacs (1998) 143 Hungary 1994-1995 NR NR 7.3 v 5.8% 
P>0.05 
20 v 21% 
P>0.05 
NR 15.5% vs. 
13.2% P>0.05 
Donders (1993) 137 South 
Africa 
1988 NR NR NR NR 27%; 6 of 22 cases NR 
Elliott (1990) 122 Kenya 1985 NR NR NR NR 0.7 (0.4, 1.4) NR 
Johns Hopkins (1989) 123 United 
States 
1983-1985 NR NR 2.4 (1.3 to 4.2) 
aOR 
NR 1.6 (1.0, 4.2) NR 
Gravett (1986) 124 
United 
States 
1983 
NR NR NR 
2.4 (1.7, 5.4)  
aOR 
4.0 (1.7, 9.2) aOR 2.7 (1.3, 5.7)  
aOR 
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Table 4. Effect of curable STIs/RTIs on birth outcomes (continued)
Reference Country Year(s) 
Spontaneous 
abortion (95% CI)  
Stillbirth (95% CI) IUGR (95% CI) PROM (95% CI) Preterm birth (95% CI) LBW (95% CI) 
Trichomonas vaginalis 
Johnson (2011) 121 United 
States 
1996-2002 NR NR NR NR 1.4 (0.7, 2.8) 1.5 (0.9, 2.6) 
Meis (1995) 127 United 
States 
1992-1994 NR NR NR NR 1.5 (0.1, 8.1) wk 24;  
0.9 (0.2, 3.6) wk 28 
NR 
Sutton (1999) 128 DR Congo 1989-1990 NR NR NR NR NR 2.1 (1.0, 4.7) 
Minkoff (1984) 144 United 
States 
NR NR NR NR P<0.03 NR NR 
Cotch (1997) 126 United 
States 
1984-1989 NR NR NR NR 1.3 (1.1, 1.4) 1.3 (1.1, 1.5) 
Bacterial vaginosis 
Johnson (2011) 121 United 
States 
1996-2002 NR NR NR NR 1.3 (0.9, 2.1) 1.1 (0.6, 1.8) 
Svare (2006) 145 Denmark 1998-2002 NR NR NR NR 2.5 (1.6, 3.9) 2.0 (1.3, 2.9) 
Watson-Jones (2007) 146 Tanzania 1997-2000 NR NR NR NR 3.0 (1.3, 6.6) NR 
Leitich meta-analysis 
(2003) 129 
Multiple Multiple 9.9 (2.0, 49.3) NR NR NR 2.2 (1.5,  3.1) NR 
Meis (1995) 127 United 
States 
1992-1994 NR NR NR NR 1.4 (0.9, 2.05)  wk 24; 
1.8 (1.2, 3.0) wk 28   
NR 
McGregor (1995) 130 United 
States 
1991-1992 NR NR NR 3.5 (1.4, 8.9) RR 1.9 (1.2, 3.0);  
1.5 (0.7, 3.0)e RR 
NR 
Hillier (1995) 147 United 
States 
1984-1989 NR NR NR 1.1 (0.8, 1.6) 1.4 (1.1, 1.8) 1.5 (1.2, 1.7) 
Hay (1994) 131 United 
Kingdom 
NR 5.5 (2.3, 13.3)f  NR NR NR 13.1 (4.0, 42.6)f NR 
Elliott (1990) 122 Kenya 1985 NR NR NR NR 1.0 (0.6, 1.8) NR 
Gravett (1986) 124 United 
States 
1983 NR NR NR 2.0 (1.1, 3.7) NR 1.5 (0.8, 2.0) 
Results reported as odds ratios unless otherwise noted and 95% confidence intervals are in parentheses; IUGR=Intrauterine growth retardation; PROM=Premature rupture of membranes; NR=Not 
reported; RR=Risk ratio; a Preterm delivery before 32 weeks; b Preterm delivery before 35 week; c Preterm delivery before 37 weeks; d Bacterial vaginosis at 16-20 weeks; e Bacterial vaginosis at 28-32 
weeks; fIntermediate flora (Nugent score 4-7) and bacterial vaginosis (Nugent score 7-10);  aOR = adjusted odds ratio 
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Rationale and research questions 
The rationale underlying the five research questions to be addressed in this doctoral 
thesis is presented below along with a description of current knowledge gaps.   
Q 1.  Malaria transmission intensity threshold 
The antenatal intervention of IPTp-SP was formally recommended by the WHO in 2004 
to protect against the adverse effects of malaria infection amongst pregnant women 
who reside in areas of moderate (stable) to high transmission.20  Meta-analysis 
suggests that chemoprophylaxis reduces the incidence of LBW amongst primi- and 
secundigravidae by 27% (RR = 0.73; 95% CI: 0.61, 0.87; 8 trials; N = 3,619).21  The same 
review reported a trend of protection against LBW in favour of IPTp-SP use amongst 
multigravidae, but neither the three trials included, nor the pooled analysis 
demonstrated standard levels of statistical significance (RR = 0.86, 95% CI 0.64 to 1.17; 
3 trials; N = 2,743 participants).  However, IPTp-SP does not feature in the WHO 
malaria elimination guidelines for countries with moderate and low endemicity.148  
Thus, what is the malaria transmission intensity-threshold below which IPTp-SP may 
no longer protect against the incidence of LBW and the intervention could be 
withdrawn?  
 
Q 2.  A581G prevalence threshold 
The evidence supporting the original IPTp-SP policy recommendation in 2004 by the 
WHO originated from clinical trials and field experience in Kenya74,75 and Malawi38,76 
dating to the 1990s when parasite epigenomics was in its infancy.   
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Accumulated mutations in the P. falciparum genes that encode Pfdhfr and Pfdhps, 
alleles implicated in SP resistance25,149-151 were present during this same period.  
Mutations at seven Pfdhfr codons (16, 50, 51, 59, 108, 140 and 164) and five Pfdhps 
codons (436, 437, 540, 581 and 613) have since been isolated as molecular markers for 
SP resistance.152  The protection conferred by IPTp-SP against LBW has been shown to 
decrease as the population prevalence of the Pfdhps K540E mutation increases—a 
proxy for the resistant quintuple Pfdhfr and Pfdhps mutants.153  Of particular concern, 
however, in areas where the Pfdhps A581G mutation has emerged alongside the Pfdhfr 
and Pfdhps quintuple mutant, producing sextuple mutant parasites, IPTp-SP fails to 
inhibit the growth of parasites.91  Within the context of declining parasite sensitivity to 
SP, is there a threshold of P. falciparum resistance to SP defined by the prevalence of 
Pfdhps mutation at codon A581G above which IPTp-SP may no longer protect against 
the incidence of LBW?  
Q 3.  Effect of IPTp-SP on malaria and curable STIs/RTIs in pregnancy 
Desai and colleagues recently reported outcomes from the first investigation of an 
artemisinin combination treatment, dihydroartemisinin–piperaquine (DP), in IPTp.154  
Women received IPTp-SP or IPTp-DP, or were screened for peripheral parasitaemia 
and treated, if infected, with DP.  The trial was conducted in a region of western Kenya 
where 96% of parasites had the quintuple mutation and 5.8% carried the A581G 
mutation.  This trial was designed to test parasite clearance with a sample size capable 
of detecting a 50% decrease in maternal malaria infection at delivery, defined as a 
composite of peripheral or placental parasitaemia as detected by placental histology, 
microscopy, or RDT.  The prevalence of malaria infection at delivery was lowest 
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amongst women given IPTp-DP, 3.0% (15 of 457), followed by recipients of IPTp-SP, 
10.2% (47 of 459), compared to 12.6% (57 of 452) of women who were provided 
screening and treatment services.   
The incidence of any adverse birth outcome – a composite of small for gestational age, 
LBW, preterm birth or foetal loss – was comparable between recipients of IPTp-DP and 
IPTp-SP, 10.6% (48 of 452) and 11.9% (54 of 454), respectively.  In contrast, stillbirth 
was experienced by 0.9% (4 of 452) of women in the IPTp-DP group compared to 3.5% 
(16 of 453) recipients of IPTp-SP, a statistically significant observation (P = 0.013).  
IPTp-DP reduced the incidence of clinical malaria during pregnancy by 83.9% (37.9 vs 
6.1 episodes) and the risk of maternal anaemia by 22.0% at delivery (crude prevalence 
ratio 0.78, 95% CI 0.64 to 0.96) compared to IPTp-SP.  Secondary analysis showed that 
women given intermittent screening and treatment had the highest prevalence of 
peripheral or placental malaria at delivery: 42.5% (199 of 452) women versus 30.6% 
(140 of 457) women in the IPTp-DP group and 36.2% (166 of 459) women in the IPTp-
SP group.  Interestingly, despite the protective effect conferred by IPTp-DP against 
many secondary endpoints, recipients of IPTp-SP delivered babies weighing on average 
(corrected) 87.3 grams more, a statistically significant observation (P = 0.001).  This 
was reflected in superior birth weight for gestational age (Z-score) among mothers 
who received IPTp-SP versus IPTp-DP (P = 0.001).  The incidence of LBW, small-for-
gestational age, and preterm birth were slightly lower amongst women given IPTp-SP 
compared to IPTp-DP, but the differences were too small to draw conclusions in these 
three secondary endpoints.   
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Sulphadoxine-pyrimethamine has been used to prevent Pneumocystis jiroveci 
pneumonia and Toxoplasma gondii infection.155  Sulphadoxine is pharmacologically 
related to sulphamethoxazole, a compound co-formulated with trimethoprim for the 
treatment of urinary tract infections and to prevent P. jiroveci amongst HIV-infected 
patients.156  Prior to the development of penicillin, sulphonamides were used to treat N. 
gonorrhoeae.157 Based on historical use, sulphonamides could exert some effect on C. 
trachomatis, Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus 
influenzae, amongst many other pathogens.158  Sulphonamides have also been used to 
treat Gardnerella vaginalis,159 a bacterium that is commonly found in high 
concentrations amongst women with bacterial vaginosis.   
Thus, because IPTp-SP was more protective against the incidence of LBW, small-for-
gestational age, and preterm birth, might the protection conferred to pregnant 
women by IPTp-SP be explained, in part, by an effect against curable STIs/RTIs as well 
as malaria infection?  If so, what is the burden of STIs/RTIs in areas where IPTp-SP is 
being implemented? 
Q 4.  Prevalence of malaria and curable STIs/RTIs in pregnancy 
The dual burden of malaria and curable STIs/RTIs in pregnancy has never before been 
characterised by systematic review and meta-analysis.  In the case of malaria infection 
during pregnancy, two seminal reviews have defined the burden in the sub-Saharan 
Africa.  Brabin’s 1983 paper summarised prevalence estimates of peripheral and 
placental parasitaemia from 12 sub-Saharan studies conducted between 1925 and 
1978.160  Peripheral parasitaemia ranged from 5.5% (N = 3,582)161 in Freetown, Sierra 
Leone to 76.0% (N = 50)162 in the former Belgian Congo (present-day Kisangani, 
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Democratic Republic of Congo).  The low and high estimates of placental parasitaemia 
were also from the former Belgian Congo, ranging between 2.0% (N = 55)163 in 
Leopoldville (present-day Kinshasa) and 74.0% (N = 50) from Stanleyville.162   
The 2001 review by Steketee et al. contained data from 20 sub-Saharan countries 
collected between 1985 and 2000.18  The lowest maternal parasite prevalence across 
16 studies from East and Southern Africa was 10.2% (N = 503) from Kilifi, Kenya.30  
However, authors of the Kilifi study stated their estimate was based on placental blood 
smears, and went on to report that 77.4% (n = 53) of women had placental infections 
which represents the highest point estimate included in the review.  The lowest 
prevalence measure from East and Southern Africa was in Chikawa, Malawi, where 
19.0% (N = 3,913) of pregnant women had peripheral malaria infections.164  In West 
and Central Africa, the studies that had the highest prevalence of placental 
parasitaemia did not also report peripheral measures of infection.  Estimates ranged 
from 19.0% (N = 904) in Banfora, Burkina Faso165 to 57.8% (N = 120) in Ebolowa, 
Cameroon.166   
The review by Brabin separated peripheral versus placental infection estimates, while 
Steketee et al. did not.  Neither review contained data more recent than the year 
2000, nor attempted to pool the prevalence data.  Moreover, both were published 
before the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) were created to standardise methods of conducting systematic 
reviews.167  Thus, a contemporary systematic review and meta-analysis of malaria 
infection in pregnancy is overdue.  Moreover, pooled estimates stratified by East and 
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West African sub-regions can assist policymakers and programme managers with 
planning and advocacy efforts related to malaria infection during pregnancy. 
As for the burden of curable STIs/RTIs, there did not appear to have been a prior 
systematic review and meta-analysis of data from pregnant women attending ANC 
facilities in sub-Saharan Africa at the time this investigation was conducted.  A review 
by Mullick et al.168 in 2005 does contain a summary of point estimates for curable 
STIs/RTIs amongst pregnant women, although no attempt was made to pool the data.  
Thus, a systematic review to quantify the dual burden of malaria infection and 
STIs/RTIs in sub-Saharan Africa is needed to make rational choice of drug to replace SP 
in areas where the drug is failing to protect against adverse birth outcomes. 
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Q 5.  Effect of azithromycin on curable STIs/RTIs in pregnancy 
Potential replacements for SP will likely need to confer protection against adverse 
birth outcomes attributable to malaria infection and other non-malarial causes.  
Azithromycin is a broad-spectrum antibiotic and a leading partner-drug for use with DP 
in IPTp.  Azithromycin is the WHO-recommended treatment for pregnant women with 
C. trachomatis infections and in vivo studies amongst high- and low-risk populations 
with syphilis and N. gonorrhoeae suggest potential therapeutic value, despite shifts 
during the past two decades of in vitro sensitivity testing.  It is relatively unknown 
whether azithromycin might confer some protective effect against T. vaginalis or 
bacterial vaginosis.  In the context of a high dual burden of malaria infection and 
curable STIs/RTIs amongst pregnant women, would azithromycin be an efficacious 
drug to include as part of IPTp? 
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Methods outline and monograph structure 
The methods used to address each research question are described in detail within their 
respective chapters.  A brief outline is presented herein.  Questions related to 
estimating the lower threshold of malaria transmission intensity and the upper 
prevalence threshold of the SP resistance were addressed first by a systematic review of 
published literature followed by relevant pooled analyses.  The question about the 
effect of IPTp-SP on adverse birth outcomes attributable to malaria infection and 
curable STIs/RTIs was determined by secondary analysis of data collected for a 
prospective cohort study of the burden of malaria and curable STIs/RTIs in Zambia.  The 
question related to the prevalence of malaria and curable STIs/RTIs in sub-Saharan 
Africa was addressed by a systematic review and meta-analyses, as was the last 
question concerning the efficacy of azithromycin against curable STIs/RTIs.   
The next section of the monograph is entitled, “Methods, results and discussion by 
research question” and contains five sub-sections, one for each of the five research 
questions.  Within each of the five sub-sections, the methods, results and discussion are 
presented in their entirety.  The section thereafter, “Monograph discussion”, contains a 
broader discourse that relates to the research questions as a whole.  The last section, 
“Monograph summary and conclusions”, highlights key findings from these research 
questions and closes with a research pathway forward. 
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Methods, results and discussion by research question 
Q 1.  Malaria transmission intensity threshold 
Methods 
Estimating the malaria transmission intensity below which IPTp-SP no longer protects 
against LBW would be straight forward if there were data from multiple placebo-
controlled randomised clinical trials (RCTs) that had been conducted in malaria-
endemic areas characterised by narrowly different strata of transmission.  However, it 
would only be ethical to conduct such trials in countries that have not already adopted 
IPTp-SP as policy.  Thus, the question must be addressed using data extracted from 
trials as found in the literature alongside robust estiamtes of transmission intensity at 
the trial sites.   
 
For this, data from IPTp-SP studies were first compiled by systematic review of 
published literature from sources that included PubMed, MEDLINE, EMBASE, the WHO 
International Clinical Trials Registry, and reference lists from the identified texts.  The 
medical subject headings and free text terms used are shown in Table 1.1 below. 
Table 1.1 Medical subject headings and free text terms 
Medical subject headings Free text terms  
Topic=("Malaria") AND 
Topic=(Prenatal OR Antenatal OR 
Pregnancy OR Pregnant) OR 
Topic=(women) AND Topic=(Africa)  
Malaria AND Pregnant AND Africa 
Malaria AND Pregnancy AND Africa 
Screen AND Malaria AND Pregnant AND Africa 
Screen AND Malaria AND Pregnancy AND Africa 
Test AND Malaria AND Pregnant AND Africa 
Test AND Malaria AND Pregnancy AND Africa 
 
Studies that had reported the: (i) proportion of pregnant women who were exposed to 
> 2 doses of IPTp-SP compared to placebo, or to no doses of IPTp-SP, and (ii) the 
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incidence of LBW by treatment group and gravidae were included in this analysis.  
EndNote X7 software was used to important and manage records.  Duplicates were 
removed and the remaining records were screened against eligibility criteria.  Full-text 
articles were then reviewed against the same criteria.  Data were abstracted without 
blinding author names or publication titles, and then appraised for quality using 
methods developed by Grading of Evidence, Assessment, Development and Evaluation 
(GRADE) Working Group.  The resulting data set was analysed using Stata/IC version 13 
software.  This involved pooling of LBW estimates by gravidae (primi- and 
secundigravidae versus multigravidae) and exposure to IPTp-SP doses ( > 2 doses 
versus placebo or no doses).   
 
The optimal time to measure transmission intensity in IPTp-SP trials would be at 
enrolment when maternal parasitaemia is likely highest.  Evidence suggests that 
parasite densities peak between gestational weeks nine and 16, tapering until 
delivery.169  This is because the prevalence of malaria infection estimated from 
samples colleced at ANC booking, rather than later in pregnancy, would not be biased 
by cumulative IPTp-SP exposure during the antenatal period, particularly near-to-term 
dosing that would skew downward the meausrements of infection.  Despite these 
reasons, parasitaemia is rarely measured at enrolment.  Active screening with 
miscroscopy or rapid diagnostic tests obliges investigators to treat women who are 
found to have asymptomatic parasitaemia with an artemisinin combination treatment, 
thereby fundamentally altering the investigation.  Thus, if parasitaemia is measured, it 
is done almost exclusively at delivery and, for reasons stated, fails to reflect the true 
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transmission intensity.  Thus, a proxy measure is needed to define malaria 
transmission intensity at the trial sites to answer this research question. 
 
To identify a proxy measure of the prevalence of malaria infection at the IPTp-SP study 
sites, data were used from the Malaria Atlas Project (MAP),170 the largest repository of 
malaria prevalence estimates in the world.  These data were used in two ways to 
estimate the malaria transmission intensity that was likely to have been present in 
each IPTp-SP study site.  The first approach was simply to apply the 2007 prevalence 
estimates of P. falciparum infection amongst children 2 to 10 years of age (2007 PfPR2-
10) as calculated by the MAP for the same locations where IPTp-SP studies had been 
conducted.  However, all IPTp-SP studies identified by the systematic review had been 
conducted prior to 2007, with the exception of one multi-year trial that ended in 2007.  
Thus, a second method was used to identify data that aligned better with the years of 
the IPTp-SP trials.   
National cross-sectional survey datasets were obtained from MAP of P. falciparum 
prevalence estimates from each of the 12 countries where the IPTp-SP trials had been 
conducted, and neighbouring countries if pregnancy trials had been conducted near 
border areas.  Four matching rules based on space and time parameters shown in 
Table 1.2 were then used to select point estimates from these surveys that were most 
likely to reflect the malaria transmission intensity to which pregnant women had been 
exposed.  However, before applying these matching rules, geospatial coordinates were 
obtained for each IPTp-SP study and cross-sectional survey using the GEOnet Names 
Server.171  ArcGIS 10 software was then used to calculate straight-line distances 
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between the specific locations where IPTp-SP studies and cross-sectional surveys had 
been conducted.  Doing so allowed matching the point estimates from surveys to 
within < 100 miles of IPTp-SP studies as described in rule 1.  This same criterion of < 
100 miles had been used in previous malaria modelling of pregnancy and paediatric 
data.172  In the same way, elevation estimates were obtained from the Consortium for 
Spatial Information173 for locations of the IPTp-SP studies and survey data.  These 
estimates were used as part of an elevation criterion in rule 3 based on evidence that 
malaria infection in children declines sharply at altitudes > 1,200 metres above sea 
level compared to lower elevations.174  A temporal criterion was included, as well, in 
the matching rules stipulated survey data to have been collected within plus or minus 
two years of the IPTp-SP trials.  To account for the possibility that IPTp-SP studies and 
cross-sectional surveys may have been conducted in proximate locations that 
happened to have had very different intensities of malaria transmission, the matching 
rules required that cross-sectional surveys and IPTp-SP trials had to have been 
conducted in areas from the same malaria transmission category as designated by 
MAP: high ( > 40% P. falciparum prevalence amongst 2 to 10 year olds), intermediate 
(5 to 40%), and low ( < 5%).   
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Table 1.2 Matching rules  
   
Rules Criteria 
1 Prevalence estimates will be paired to IPTp-SP studies if they were both conducted: 
a. In an area with the same risk of malaria infection (high, intermediate or low), AND 
b. Within two years (±) of each other, AND 
c. < 100 miles of each other. 
2 Prevalence estimates will be paired to IPTp-SP studies if they were both conducted: 
a. In an area with the same risk of malaria infection (high, intermediate or low), AND 
b. Within two years (±) of the pregnancy study, AND 
c. In the same country. 
3 Prevalence estimates will be paired to IPTp-SP studies if they were both conducted: 
a. In an area with the same risk of malaria infection (high, intermediate or low), AND 
b. At the same elevation, either < 1200 metres OR > 1201 metres, AND 
c. In the same sub-region of Africa (East/Southern OR West/Central)  
4 If no prevalence estimates can be paired, then IPTp-SP studies will be matched to the 
2007 PfPR2-10 estimate 
To reflect the gravidae-specific nature of parasitaemia amongst pregnant women 
when pairing prevalence estimates of malaria infection, assumptions were made 
based on old reports from Sierra Leone161 and Kenya160 that suggest levels of 
parasitaemia amongst children are comparable to maternal parasitaemia as presented 
in Table 1.3.   
Table 1.3 Age structure of paediatric data matched to gravidity 
 
Paediatric descrition Age structure Gravidity 
Infancy  Birth to < 1 Primigravidae 
Childhood 1 to 4 Segundigravidae 
School-aged 5 to 15 Multigravidae 
 
Matching rules were then applied sequentially.  If survey data could not be matched to 
an IPTp-SP study using rule 1, then rule 2 was applied, and so on until all point 
prevalence estimates had been identified from the survey data that could be 
considered the best possible matches for each IPTp-SP study.  Survey data paired to 
IPTp-SP studies under rules 1, 2 or 3 were pooled using random-effects models.175  If 
survey data could not be matched under these rules, then the 2007 PfPR2-10 estimate 
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for the same location where the IPTp-SP study had been conducted was imposed on 
the model under rule 4.  Whether based on the 2007 MAP estimate, or the pooled 
prevalence estimate, standard meta-regression models were applied to LBW 
outcomes from the IPTp-SP studies. 
 
Results  
Systematic review  
A total of nine pregnacy studies met inclusion criteria involving 10,279 pregnant 
women.  Figure 1.1, the PRISMA flowchart for the systematic reivew, summarises the 
selection process, the number of studies excluded and the reasons for their exclusion 
according to PRISMA guidelines.  Pregnancy studies stratified by gravidae that met 
inclusion criteria are summarized in Table 1.4.77,80,81,176-181  As shown in Figure 1.2, the 
PRISMA flowchart for matching studies, data on LBW came from seven studies and 12 
unique sites for primi- and secundigravidae who were exposed to > 2 doses of IPTp-SP 
(n = 2,314) versus placebo or no doses (n = 1,954).  In contrast, seven studies from 10 
unique sites reported LBW outcomes amongst multigravidae who received > 2 doses 
of IPTp-SP (n = 2,941) compared to placebo or no doses (n = 3,070).   
 
Funnel-plot analysis in Figure 1.3 suggests that IPTp-SP studies that were 
comparatively small and failed to protect against LBW may have been under-
represented in the sample.  Risk of bias among individual studies was appraised using 
GRADE methods and is summarised in Table 1.5.  Figure 1.4 illustrates the risk of bias 
within these individual IPTp-SP studies, and Figure 1.5 shows the combined risk of bias 
across IPTp-SP studies, both of which were prepared using RevMan 5.2 software.    
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Figure 1.1 PRISMA flowchart for systematic review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,273 Records identified from 
database searches and reference lists 
380 Duplicate records excluded 
1,893 Records screened 
1,651 Articles excluded                   
 
0   242bbbbPrior to 1990                                        
0,0 1bbb bOutside sub-Saharan Africa                                   
1,392bbb Unrelated endpoints                                
0,0 2bbbbSelective ANC population                  
0,0 9bbbbActive comparator                    
0,0 5bbbbSame data in > 2 articles  
233 Articles excluded                   
 
224bbbbUnrelated endpoints                      
00     5bbbbSelective ANC population0
 0  4bbbbActive comparator 
242 Full-text articles reviewed 
9 Pregnancy studies 
Id
e
n
ti
fi
ca
ti
o
n
 
Sc
re
e
n
in
g 
an
d
 e
lig
ib
ili
ty
 
In
cl
u
d
e
d
 
58 
 
Table 1.4 Summary of included studies by gravidae 
 
References Countries Sites Years Type IPTp-SP (2 doses or more) Placebo or no IPTp-SP 
No. 
LBW 
No. 
Weighed 
LBW 
% 
95% CI 
No. 
LBW 
No. 
Weighed 
LBW % 95% CI 
Primi- and secundigravidae 
Gies (2009) 177 Burkina Faso Boromo 2004-06 1 104 812 12.8 10.5, 15.1 19 52 36.5 23.5, 49.6 
Likwela (2012) 176 DR Congo Kisangani 2007 2 2 28 7.1 -2.4, 16.7 7 12 58.3 30.4, 86.2 
Likwela (2012) 176 DR Congo Mikalayi 2007 2 1 28 3.6 -3.3, 10.5 11 56 19.6 9.2, 30.0 
Likwela (2012) 176 DR Congo Rutshuru 2007 2 11 94 11.7 6.0, 20.0 5 15 33.3 9.5, 57.2 
Menendez (2008) 77 Mozambique Manhiça 2003-05 1 29 133 21.8 14.8, 28.8 25 121 20.7 13.5, 27.9 
Ndyomugyenyi (2011) 81  Uganda Kabale 2004-07 1 16 313 a 5.1 2.7, 7.6 18 329 5.5 3.0, 7.9 
Ramharter (2007) 178 Gabon Lambaréné 2006 2 4 49 8.2 0.5, 15.8 6 30 20.0 5.7, 34.3 
Ramharter (2007) 178 Gabon Libreville 2006 2 14 168 8.3 4.2, 12.5 19 106 17.9 10.6, 25.2 
Ndyomugyenyi (2011) 81  Uganda Kabale 2004-07 1 22 287 b 7.7 4.6, 10.7 16 277 5.8 3.0, 8.5 
Sirima  (2006) 180  Burkina Faso Koupéla 2004 2 21 173 a 12.1 7.3, 17.0 22 183 12.0 7.3, 16.7 
Sirima  (2006) 180  Burkina Faso Koupéla 2004 2 6 46 c 13.0 3.3, 22.8 23 186 12.4 7.6, 17.1 
van Eijk (2004) 179  Kenya Kisumu 1999-2000 1 10 122 8.2 3.3, 13.1 78 513 15.2 12.1, 18.3 
Sub-totals  241 2,253  249 1,880  
Multigravidae 
Likwela (2012) 176 DR Congo Kisangani 2007 2 4 59 6.8 0.4, 13.2 9 37 24.3 10.5, 38.1 
Likwela (2012) 176 DR Congo Mikalayi 2007 2 1 86 1.2 -1.1, 3.4 24 307 7.8 4.8, 10.8 
Likwela (2012) 176 DR Congo Rutshuru 2007 2 28 397 7.1 4.5, 9.6 11 162 6.8 2.9, 10.7 
Mbaye (2006) 80 The Gambia Farafenni 2003-04 1 51 931 5.5 4.0, 6.9 63 917 6.9 5.2, 8.5 
Menendez (2008) 77  Mozambique Manhiça 2003-05 1 29 361 e 8.0 5.2, 10.8 34 375 9.1 6.2, 12.0 
Ndyomugyenyi (2011) 81 Uganda Kabale 2004-07 1 40 610 b 6.6 4.6, 8.5 37 631 5.9 4.0, 7.7 
Ndyomugyenyi (2011) 81  Uganda Kabale 2004-07 1 21 347 d 6.1 3.5, 8.6 27 325 8.3 5.3, 11.3 
Rogerson (2000) 181 Malawi Blantyre 1997-99 2 30 291 10.3 6.8, 13.8 50 218 22.9 17.4, 28.5 
Sirima  (2006) 180 Burkina Faso Koupéla 2004 2 2 17 11.8 -3.6, 27.1 7 61 11.5 3.5, 19.5 
van Eijk (2004) 179 Kenya Kisumu 1999-2000 1 2 36 5.6 -1.9, 13.0 23 232 9.9 6.1, 13.8 
Sub-totals  208 3,135  285 3,265  
 
Note: Presented in alphabetical order based on reference; IPTp-SP = Intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine; LBW = Low birth weight; CI = Confidence 
interval; NA = Not applicable; Study type 1 =  Randomised trial and type 2 =  Observational study;  a = primigravidae;  b = secundigravidae; c = 2-4 pregnancies; d = 5 or more pregnancies; e = 1-3 pregnancies 
(likely to have contained some secundigravidae) and 4 or more pregnancies 
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Figure 1.2 PRISMA flowchart for matching studies 
 
  
Multigravidae                                             
Rule 1: 4 studies matched  
Rule 2: 0 studies matched                                                  
Rule 3: 2 studies matched                                                          
Rule 4: 2 studies matched 
 
Primi- and secundigravidae: reported by 12 study sites 
Multigravidae: reported by 10 study sites 
9 pregnancy studies 
11,548 point prevalence estimates from 
MAP database applied to matching rules               
Primi- and secundigravidae                                       
Rule 1: 6 studies matched  
Rule 2: 0 studies matched                                                       
Rule 3: 5 studies matched                              
Rule 4: 1 study matched 
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Figure 1.3 Funnel plot 
 
 
 
This figure is a funnel plot of low birth weight estimates from pregnancy studies 
identified through systematic review and that stratified results by gravidae.  Data 
points extracted from the pregnancy studies show that SP-IPTp is protective against 
LBW and, therefore, the midline of the funnel has shifted to the left of the number 
zero.  Larger studies cluster around the upper area of the funnel as expected, 
reflecting smaller standard errors in these studies and within the 95% CIs.  In contrast, 
small studies that reported the failure of IPTp-SP to protect against the incidence of 
LBW may have been under-represented in the sample of eligible pregnancy studies.  
This is reflected by the comparatively empty space towards the bottom right-hand side 
of the funnel. 
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Table 1.5 Risk of bias amongst individual pregnancy studies 
 
Reference Type of bias Description Risk  Support for judgement of bias 
 
Gies 
(2009) 177 
Selection  Random sequence 
generation 
High Although not randomised at the individual level, the study 
involved 12 peripheral health centres that had been selected for 
a community-based trial on IPTp-SP effectiveness; four health 
centres implemented IPTp-SP, while the others did not and 
served as controls.  There was a statistically significant 
difference reported (P < 0.05) in the proportion of pregnant 
women residing > 5 km from the nearest health facility and the 
number of SP doses given: 0 doses (76.5%; 62/81) and > 2 doses 
(23.0%; 202/877). 
Selection  Allocation 
concealment 
Unclear All primigravidae and secundigravidae enrolled in the study 
were identified by field assistants through monthly rounds in 
the villages.  It is unclear whether the absence of allocation 
concealment introduced bias. 
Performance  Blinding of 
participants and 
personnel 
Unclear It is not clear how participants and personnel were blinded in 
this community-based trial. 
Detection  Blinding of outcome 
assessment 
Low Although outcome assessment did not appear to be blinded, 
newborns were weighed to the nearest 25 g as soon as possible 
after birth using a hanging scale; weights obtained 1–8 days 
after delivery were corrected for physiological change. 
Attrition  Incomplete outcome 
data 
Low The proportion of women lost to follow-up was low at 8.4% 
(158/1,883).  Women not included into the analysis (9.6%; 
181/1,883) did not differ in parity and age from women 
included. 
Reporting  Selective reporting Low There did not appear to be evidence of selective reporting. 
Other   Low No other sources of potential bias were identified. 
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Table 1.5 Risk of bias amongst individual pregnancy studies (continued) 
 
Reference Type of bias Description Risk  Support for judgement of bias 
 
Likwela 
(2012) 176 
Selection  Random sequence 
generation 
Unclear All women who gave birth in 2007 in the study maternity clinics, 
attended ANC at least once during pregnancy, and whose 
antenatal card was available for analysis were included in this 
study.  Demographic and anthropometric characteristics of women 
are not stratified according to IPTp-SP exposure and, therefore, it is 
unclear whether there was selection bias. 
Selection  Allocation 
concealment 
Low Authors noted that each maternity unit kept the ANC cards for all 
pregnant women from their catchment area. Hospital records and 
ANC cards were fully reviewed and the information transcribed.  
Although this does not conceal group allocation, bias was not 
necessarily introduced as a result of these procedures. 
Performance  Blinding of 
participants and 
personnel 
Low Newborns were weighed by a standard procedure in the three 
maternity wards using mechanical baby scales with a precision of 
10 g. As reported, “The tendency of rounding the birth weight 
probably occurred in all three sites and should not significantly 
affect the results." 
Detection  Blinding of outcome 
assessment 
Low Analysis appeared to minimise the potential for detection bias. 
Attrition  Incomplete outcome 
data 
Unclear As a retrospective analysis of birth weight following exposure to 
IPTp-SP, it is unclear how data may be incomplete and contribute 
to attrition bias. 
Reporting  Selective reporting Low There is no evidence of selective reporting and a dose-response 
relationship was observed across gravidae. 
Other   Unclear It is unclear how a statistically significant difference in the age of 
women between sites in Kisangani and Mikalayi may affect pooled 
outcomes. 
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Table 1.5 Risk of bias amongst individual pregnancy studies (continued) 
 
 
  
Reference Type of bias Description Risk  Support for judgement of bias 
 
Mbaye 
(2006) 80 
Selection  Random sequence 
generation 
Low Random sequence was maintained with the use of group 
assignments in locks of 12. 
Selection  Allocation 
concealment 
Low As a placebo-controlled trial, SP and placebo tablets were identical 
in shape and colour, and were pre-packed in envelopes that had 
been placed in a wallet bearing the subject’s number and packet 
number. 
Performance  Blinding of 
participants and 
personnel 
Low Identical SP and placebo tablets were used. 
Detection  Blinding of outcome 
assessment 
Unclear Outcome assessment was blinded, although the method of 
measuring birth weight was not mentioned.  It is unclear whether 
the fact that 87% of newborns were weighed between 3 and 5 days 
after birth introduced any detection bias. 
Attrition  Incomplete outcome 
data 
Low Attrition rate was not unlike other IPTp-SP trials. Loss to follow up 
of 17.1% (459/2,688) overall, 16.6% (223/1,346) in the SP group 
and 17.6% (236/1,342) in the placebo group. 
Reporting  Selective reporting Low There is no apparent risk of selective reporting. 
Other   Unclear It is unclear what bias, if any, could have been introduced given the 
difference in ages amongst women 40-50 in the SP vs. placebo 
groups, 61% (28/1,346) vs. 39% (18/1,342), respectively. 
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Table 1.5 Risk of bias amongst individual pregnancy studies (continued) 
 
 
Reference Type of bias Description Risk  Support for judgement of bias 
 
Menendez 
(2008) 77 
Selection  Random sequence 
generation 
Low A computer-generated sequential list contained the study 
numbers linked to treatment identification letters that were 
randomly ordered in blocks of 10. 
Selection  Allocation 
concealment 
Low SP and placebo tablets were ‘identical in shape and colour’ 
Performance  Blinding of 
participants and 
personnel 
Low Blinding was maintained with the use of placebo tablets. 
Detection  Blinding of outcome 
assessment 
Low Although outcome assessment was not blinded, group 
allocation was maintained and newborns were weighed on a 
digital scale, accurate to the nearest gram. 
Attrition  Incomplete outcome 
data 
Low Loss to follow up was minimal. In the SP group 6.8% (35/515) 
of women did not receive 2 doses and birth weight was not 
measured for 1.4% (7/501) live births, whereas 5.6% (29/515) 
of women in the placebo group did not receive 2 doses and 
birth weight was not measured for 1.4% (7/503) live births. 
Reporting  Selective reporting Low No evidence of selective reporting and the study protocol is 
available. 
Other   Unclear A statistically significant difference in the prevalence of 
syphilis was reported between the IPTp-SP and placebo 
groups, 14% (72/515) vs. 10% (50/515). There was no 
discussion as to whether women were informed of the 
syphilis status, offered a referral or treatment and, if 
treatment, what therapy was administered. 
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Table 1.5 Risk of bias amongst individual pregnancy studies (continued) 
 
  
Reference Type of bias Description Risk  Support for judgement of bias 
 
Ndyomugyenyi 
(2011) 81 
Selection  Random sequence 
generation 
Low Selection bias was minimised by using a computer-
generated random number list with individually sealed 
envelopes, arranged in blocks of 12.  
Selection  Allocation 
concealment 
Low Tablets of SP or placebo, identical in shape and colour, 
were used. 
Performance  Blinding of 
participants and 
personnel 
Low All study participants, health staff and researchers were 
blind to drug assignment (SP or placebo), and newborns 
were weighed on a digital scale that was accurate to the 
nearest 10 g. 
Detection  Blinding of outcome 
assessment 
Low Data were examined to identify any imbalances in 
covariates and potential confounders in a blinded manner.  
Attrition  Incomplete outcome 
data 
Low 5,775 women were assigned to treatment groups; 4,713 
women contributed to the final analysis of the primary 
endpoint. Attrition was 18.4% overall. However, data on 
birth weight were recorded for > 90% of women enrolled 
into the study 
Reporting  Selective reporting  Low No evidence of selective reporting was observed. 
Other   Low No other sources of potential bias were identified. 
66 
 
Table 1.5 Risk of bias amongst individual pregnancy studies (continued) 
 
 
  
Reference Type of bias Description Risk  Support for judgement of bias 
 
Ramharter 
(2007) 178 
Selection  Random sequence 
generation 
Unclear Pregnant women attending health facilities for delivery at 
two different sites were invited to participate.  General 
demographic data was presented for 2004 and 2006, but 
not stratified by IPTp dosing and gravidae, making it 
difficult to determine whether the selection process 
introduced a systematic bias. 
Selection  Allocation 
concealment 
Unclear It is unclear whether the lack of allocation concealment 
introduced selection bias. 
Performance  Blinding of 
participants and 
personnel 
Low Although participants and personnel were not blinded, 
newborn birth weights were measured to the nearest 5 g 
immediately after delivery. 
Detection  Blinding of outcome 
assessment 
Unclear  It is unclear if analysis of birth weight outcomes and 
exposure to IPTp-SP was blinded.   
Attrition  Incomplete outcome 
data 
Unclear Amongst 389 women in 2004, birth weights were reported 
for 385 newborns (99.0%); amongst 1,014 women in 2006, 
birth weights were reported for 788 newborns (77.7%). 
Reporting  Selective reporting Unclear Comparison of data with historical controls may be 
affected by bias and confounding. 
Other   Unclear One hundred thirty-one of 389 (33.7%) women reported 
regular chemoprophylaxis with chloroquine during 
pregnancy in survey 2004.  To what extent this affected 
the outcomes of controls is unclear. 
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Table 1.5 Risk of bias amongst individual pregnancy studies (continued) 
 
 
  
Reference Type of bias Description Risk  Support for judgement of bias 
 
Rogerson (2000) 
182 
Selection  Random sequence 
generation 
Unclear Pregnant women in active labour, and likely to deliver 
during working hours, were asked to participate in the 
study.  From this group, data related to IPTp-SP exposure 
was collected.  Although education on schooling was 
available for 50.4% of participants (526/1,044), 
demographic data were limited for comparing 
differences amongst women. 
Selection  Allocation 
concealment 
Unclear Allocation was based on prior exposure to IPTp-SP; it is 
unclear if this may have introduced any bias into the 
analysis. 
Performance  Blinding of 
participants and 
personnel 
Unclear Method and timing of weighing newborns was not 
reported. 
Detection  Blinding of outcome 
assessment 
Unclear It is unclear if analysis of birth weight outcomes and 
exposure to IPTp-SP was blinded.   
Attrition  Incomplete outcome 
data 
Low There appears to be no evidence of incomplete outcome 
data. 
Reporting  Selective reporting Low There is no evidence of selective reporting  
Other   Low No apparent risk of other bias. 
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Table 1.5 Risk of bias amongst individual pregnancy studies (continued) 
 
Reference Type of bias Description Risk  Support for judgement of bias 
 
Sirima (2006) 180 Selection  Random sequence 
generation 
Unclear Pregnant women (n=826) from six antenatal care facilities 
and from two delivery units (n=1,188) were enrolled.  
Because 20 eligible women (2.4%) refused enrolment at 
antenatal care facilities and 33 (2.8%) at delivery units, 
selection bias is likely low amongst recipients of SP.  
However, it is unclear if and to what extent bias was 
introduced when comparing these women to who did not 
receive SP and demographic data did not appear to be used 
to control for potential differences.  
Selection  Allocation 
concealment 
Unclear It is unclear whether the lack of allocation concealment 
introduced selection bias. 
Performance  Blinding of 
participants and 
personnel 
Low Neonates were weighed to the nearest 10 grams using an 
electronic digital scale. 
Detection  Blinding of outcome 
assessment 
Low Although it is unknown whether outcome assessment was 
blinded, clear and consistent gravidae-specific trends were 
associated with malaria infection as well as a dose-response 
relationship between SP and low birth weight. 
Attrition  Incomplete outcome 
data 
Low Amongst enrolled women, 97.4% had a baby whose birth 
weight was measured. 
Reporting  Selective reporting Low There is no evidence of selective reporting. 
Other   Unclear An unknown number of pregnant women took IPTp-SP 
doses at home rather than ingesting them while observed in 
at the health facility; it is possible that not all of these doses 
were actually taken as reported. 
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Table 1.5 Risk of bias amongst individual pregnancy studies (continued) 
 
 
Reference Type of bias Description Risk  Support for judgement of bias 
 
van Eijk (2004) 
179 
Selection  Random sequence 
generation 
Unclear All women were invited to participate who received ANC 
services at the study hospital and delivered at the same 
facility between June 1999 and June 2000.  The number of 
SP doses on the ANC card was confirmed with the mother. 
Selection  Allocation 
concealment 
Unclear See above 
Performance  Blinding of 
participants and 
personnel 
Unclear Methods of neonatal weighing and post-partum timing of 
weighing were not reported. 
Detection  Blinding of outcome 
assessment 
Unclear It is unclear if analysis of low birth weight was conducted in 
a blinded manner. 
Attrition  Incomplete outcome 
data 
Low Only women who delivered in the hospital, and had 
previously visited the ANC of the hospital, as well as 
complete information on their birth card (n=1,498) were 
included in the analysis, representing 89.5% of eligible 
women. 
Reporting  Selective reporting Low No selective reporting observed 
Other   Low No apparent risk. 
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Figure 1.4 Risk of bias amongst individual pregnancy studies 
 
 
Figure 1.5 Risk of bias across pregnancy studies 
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Meta-analysis  
There was strong evidence of protection against LBW conferred by > 2 doses versus 
placebo or no doses of IPTp-SP.  Random-effects models showed that amongst primi- 
and secundigravidae > 2 doses cut the odds in half of delivering a LBW newborn (odds 
ratio [OR] = 0.54; 95% CI: 0.35, 0.84; P < 0.00) compared to no doses or placebo.  The 
odds of LBW were reduced by 30% amongst multigravidae (OR = 0.70; 95% CI: 0.51, 
0.95; P = 0.04). 
In order to estimate the transmission intensity at each of the IPTp-SP study sites, 12 
national cross-sectional datasets were used from MAP containing 11,548 surveys.  
Pooled prevalence estimates were calculated as a second means of estimating the 
malaria transmission intensity at 10 sites under rule 1, and for eight sites by applying 
rule 3.  The remaining four study sites were matched based on rule 4.  Matching by 
gravidae was as follows: (i) six of 12 primi- and secundigravidae IPTp-SP study sites 
were matched under rule 1; (ii) three study sites were paired under rule 3; (iii) three 
study sites were matched using rule 4.  Amongst studies with multigravidae, four were 
matched using rule 1, five were paired under rule 3, and one study site was matched 
based on rule 4.  As shown in Table 1.6, parasite prevalence amongst primi- and 
secundigravidae derived from MAP estimates were between 20.5% and 66.4%, 
whereas the pooled prevalence estimates were slightly narrower, 25.1% and 59.1%.  
Amongst multigravidae, MAP estimates were between 20.5% and 66.4%, and the 
pooled prevalence estimates were also narrower from 6.7% and 39.3%.  
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Table 1.6 Malaria transmission estimates based on matching rules 
References Country Site Elevation Rule used Pooled prevalence (%) 2007 PfPR2-10 (%) 
Primi- and secundigravidae 
Likwela (2012) 176 DR Congo Rutshuru 1212 4 29.6 a 29.6 
Ndyomugyenyi (2011)* 81  Uganda Kabale 2118 4 25.1 a 25.1 
Ndyomugyenyi (2011)† 81   Uganda Kabale 2118 4 25.1 a 25.1 
Likwela (2012) 176 DR Congo Kisangani 401 1 30.4 40.2 
Menendez (2008) 77 Mozambique Manhiça 21 1 31.2 48.1 
Gies (2009) 177 Burkina Faso Boromo 258 1 44.2 57.4 
Likwela (2012) 176 DR Congo Mikalayi 618 3 55.8 38.5 
Ramharter (2007) 178 Gabon Libreville 13 3 55.8 37.1 
Ramharter (2007) 178 Gabon Lambaréné 39 3 55.8 42.8 
van Eijk (2004) 179 Kenya Kisumu 1166 1 57.5 20.5 
Sirima (2006)* 180  Burkina Faso Koupéla 290 1 59.1 66.4 
Sirima (2006)† 180  Burkina Faso Koupéla 290 1 59.1 66.4 
Multigravidae 
Ndyomugyenyi (2011)‡ 81  Uganda Kabale 2118 3 6.7 25.1 
Ndyomugyenyi (2011)§ 81  Uganda Kabale 2118 3 6.7 25.1 
Mbaye (2006) 80 The Gambia Farafenni 25 1 8.3 23.9 
Rogerson (2000) 181 Malawi Blantyre 989 3 11.3 24.9 
Menendez (2008)¶ 77  Mozambique Manhiça 21 3 11.3 48.1 
van Eijk (2004) 179 Kenya Kisumu 1166 1 25.0 20.5 
Likwela (2012) 176 DR Congo Rutshuru 1212 4 29.6 a 29.6 
Sirima  (2006) 180 Burkina Faso Koupéla 290 1 32.9 66.4 
Likwela (2012) 176 DR Congo Kisangani 401 3 34.0 40.2 
Likwela (2012) 176 DR Congo Mikalayi 618 1 39.3 38.5 
Note: Studies are presented in ascending order of malaria transmission intensity; a Under rules 1-3, no matches were made and, therefore, the 2007 PfPR2-10 estimates from MAP are 
used.  * = primigravidae; † = secundigravidae;  ‡  = 2-4 pregnancies; § = 5 or more pregnancies; ¶ = 1-3 pregnancies (likely contained some secundigravidae) and 4 or more pregnancies 
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Meta-regression analysis 
To explore the potential effect of malaria transmission intensity on the association 
between IPTp-SP and LBW, four separate meta-regression models were conducted.  
Models one and two applied the odds ratios of protection conferred by > 2 doses of 
IPTp-SP versus placebo or no doses amongst primi- and secundigravidae with model 
one employing transmission intensity estimates from MAP, and model two using 
pooled prevalence estimates for transmission intensity.  Models three and four were 
constructed using the odds ratios from analyses of multigravidae and transmission 
intensity estimates from MAP and, separately, pooled prevalence estimates derived 
from cross-sectional surveys.  Not one of these four models suggested that variation in 
the ORs of LBW could be explained by malaria transmission intensity: model one (P = 
0.83); model two (P = 0.78); model three (P = 0.30); model four (P = 0.93).  Sensitivity 
testing amongst matching rules did not produce any statistically significant difference 
in these results. 
Discussion  
This analysis demonstrates that there is no level of malaria transmission intensity 
below which > 2 doses of IPTp-SP no longer protects against the incidence of LBW.  
The inability of this study to detect a malaria transmission threshold may be a 
consequence of there being too few data points for analysis, particularly from lower 
transmission settings.  Data from Ndyomugyenyi et al. in Uganda complicates 
interpretation because women in the no-SP group were provided ITNs.  Consequently, 
the difference between women in the ‘protected’ versus ‘unprotected’ groups was 
likely harder to detect because there was less total exposure to malaria infection 
rather than IPTp-SP being compromised.  However, an unpublished analysis of 
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Multiple Indicator Cluster Surveys with several thousand data points also found that 
IPTp-SP continued to protect against LBW until very low levels of transmission and, 
similar to this study, could not define a cut-off point of transmission below which IPTp-
SP is no longer protective against LBW (Eisele TP, personal communication).   
There may be other factors that have contributed to not being able to detect a 
transmission threshold.  Little is known about the prevalence of placental infection in 
very low transmission settings and it is entirely possible that declines in peripheral 
parasitaemia are not reflected in equivalent reductions in placental infection.  If that is 
the case, then IPTp-SP may provide important and continued protection against 
placental carriage, as well as the incidence of LBW in areas of very low endemicity.  
Another possible explanation is that the causal pathway to LBW is multifactorial and 
that IPTp-SP offers some protection against other non-malarial causes of LBW.  Indeed, 
this is what was observed in the study conducted under Q 3.  Although not common, 
SP can be used as an efficacious chemoprophylactic drug against Pneumocystis jiroveci 
pneumonia and Toxoplasma gondii infection.155  Moreover, sulphadoxine is related to 
sulphamethoxazole, the partner compound used with trimethoprim to form 
cotrimoxazole, a treatment often provided to cure urinary tract infections and to 
prevent P. jiroveci in HIV-infected patients.156 Sulphonamides have also been used to 
treat Gardnerella vaginalis,159 a bacterium found in women with bacterial vaginosis 
that can double the odds of having a low birth weight baby (OR = 2.0; 95% CI: 1.3, 2.9) 
compared to pregnant women without bacterial vaginosis.12   
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The MAP PfPR2-10 estimates from 2007 were not the best temporal match for the 
pregnancy studies; all but one of the studies occurred before 2007.  However, 
individual survey data available through MAP did produce more precise estimates of 
parasitaemia with narrower confidence intervals.  However, these data only contained 
the age range of participants from whom samples had been collected.  Thus, it was 
sometimes necessary to make assumptions about which age group to assign survey 
data, i.e. 0 to > 5 years of age to primi- and secundigravidae versus 5-15 years of age 
to multigravidae, to create a binomial structure of data that might mirror the parity-
specific epidemiology of malaria in pregnancy.   
The results from this analysis should be interpreted with caution for several reasons.  
This analysis has been conducted with the limited data available that relate the 
efficacy of IPTp-SP to the intensity of malaria exposure during pregnancy and that can 
also be stratified by gravidae.  Moreover, there may have been selection bias in six of 
the nine studies identified through systematic review for lack of random sequence 
generation or allocation concealment.  In addition, there was considerable 
heterogeneity amongst IPTp-SP studies, making it more difficult to generalise about 
them as a group.  However, stratifying studies by design, observational versus RCT, did 
not consistently reduce heterogeneity, nor change the observed results.   
 
Q 2.  A581G prevalence threshold 
Methods 
The data set of IPTp-SP studies developed to answer the first research question was 
used as the starting point to estimate the prevalence threshold of the Pfdhps mutation 
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at codon A581G above which IPTp-SP may no longer protect against the incidence of 
LBW.  A geographical database of SP resistance markers183, originally developed to 
guide policy recommendations specific to intermittent preventive treatment of 
malaria using SP amongst African infants, was used to identify surveys containing point 
prevalence estimates of the A581G mutation that had been collected from < 100 miles 
and plus or minus two years of the IPTp-SP trials.  The geographic range was extended 
100 to 250 miles if no data were available from < 100 miles.  If multiple point 
estimates were found, then data were pooled using standard meta-analysis.  
Results 
Point prevalence estimates of Pfdhps A581G were identified from 44 sites having been 
measured within plus or minus two years of when the IPTp-SP trials had been 
conducted.  Twenty sites were within < 100 miles of IPTp-SP trials and 24 sites within 
100 to 250 miles.  All IPTp-SP trial sites had at least one corresponding point estimate 
of A581G as shown in Table 2.1 between these two distance parameters.184-198  The 
highest prevalence of A581G was 52.6% (95% CI: 47.6, 57.5) based on 740 samples as 
measured at four sites < 100 miles of the IPTp-SP study in Kabale (Uganda).  
Prevalence estimates for the other sites ranged from 0.0% to 10.1% (95% CI: 3.5, 16.8).   
 
There was a binomial structure in the A581G prevalence data that lent itself to 
stratification of IPTp-SP studies where there A581G prevalence of < 10.1% and > 
10.1%.  Based on random-effects models, > 2 doses of IPTp-SP reduced the odds of 
LBW amongst primi- and secundigravidae (OR = 0.49; 95% CI: 0.29, 0.81; P < 0.00) and 
multigravidae (OR = 0.56; 95% CI: 0.37, 0.86; P < 0.03) in areas where there A581G 
prevalence was < 10.1%.  Two or more doses of IPTp-SP continued to protect primi- 
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and secundigravidae against LBW (OR = 0.54; 95% CI: 0.35, 0.84).  This protective 
effect was no longer statistically significant in areas where A581G prevalence was > 
10.1% (OR = 0.73; 95% CI: 0.29, 1.18).  Where are also geographic areas where malaria 
transmission intensity was lowest according to pooled and MAP prevalence estimates 
(range: 25.1% to 29.6%).  Amongst multigravidae, IPTp-SP conferred protection against 
LBW in areas where the prevalence of A581G was < 10.1% (OR = 0.56; 95% CI: 0.37, 
0.86; P = 0.07).  However, there was no evidence from fixed-effects or random-effects 
models that multigravidae continued to be protected against LBW where the 
prevalence of A581G was > 10.1% (OR = 0.96; 95% CI: 0.70, 1.34; P < 0.47).  These 
results are illustrated in Figures 2.1 and 2.2.  The interaction between malaria 
transmission intensity and the prevalence of A581G was borderline significant: P = 
0.06 amongst primi- and secundigravidae, and P = 0.04 amongst multigravidae.  Thus, 
meta-regression of malaria transmission, stratified by A581G prevalence, could only 
explain some variation in IPTp-SP protection against LBW.   
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Table 2.1 A581G Prevalence at IPTp-SP study sites 
  
Pregnancy studies Pfdhps codon A581G surveys 
References Countries Sites 
Distance from 
IPTp-SP trial 
No. 
sites 
No. 
tested 
No. 
positive 
Prevalence 
(%)  
95% CI 
Heterogeneity 
(I2) 
Prevalence 
across sites (%) 
Refs 
Gies (2009)  Burkina Faso Boromo 100-250 m 3 250 26 1.7*  0.2 to 3.2 93.8% 0.0 to 37.8 184-186 
Likwela (2012)  DR Congo Kisangani 100-250 m 1 18 1 5.6 -5.0 to 16.1 NA NA 187 
Likwela (2012)  DR Congo Mikalayi 100-250 m 0 0 0 0.0 NA NA NA 187 
Likwela (2012)  DR Congo Rutshuru < 100 m 6 747 367 52.4 1 47.5 to 57.4 79.6% 28.6 to 61.1 187-190 
Mbaye (2006)  The Gambia Farafenni < 100 m 1 27 0 0.0 1 NA NA 0.0 191 
Menendez (2008)  Mozambique Manhiça 100-250 m 4 279 0 0.0 1 NA NA 0.0 192 
Ndyomugyenyi 
(2011)  
Uganda Kabale < 100 m 5 740 365 52.6 47.6 to 57.5 83.3% 30.2 to 61.1 187-190 
Ramharter (2007)  Gabon Lambaréné 100-250 m 2 118 0 0.0 NA NA 0.0 193,194 
Ramharter (2007)  Gabon Libreville 100-250 m 2 236 4 2.0 2 0.06 to 3.9 2 NA 0.0 to 2.0 11,12 
Rogerson (2000)  Malawi Blantyre < 100 m 3 318 3 3.4 2 -0.4 to 7.1 2  100% 0.0 to 3.4 195,196 
Sirima  (2006)  Burkina Faso Koupéla < 100 m 1 79 8 10.1 2 3.5 to 16.8 2  NA 10.1 186 
van Eijk (2004)  Kenya Kisumu < 100 m 6 825 4 2.7† 0.1 to 5.4 2 100% 0.0 to 2.7 197,198 
 
NA = Not applicable 
1 No mutations were detected and, therefore, the prevalence shown is the point estimate of the one study that did yield positive samples 
2 Only one of the studies detected mutations; models exclude studies in which there are no positive tests and, therefore, the prevalence shown is a point estimate of the one study that 
did yield positive samples. 
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Figure 2.1 Forest plot – primi- and secundigravidae  
Odds ratio of low birth-weight delivery amongst primi- and secundigravidae following two or more doses of IPTp-SP versus placebo or no 
IPTp-SP stratified by estimates of the A581G resistance mutation amongst malaria parasites at study sites 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Studies are presented in ascending order of malaria transmission intensity * Secundigravidae; † Primigravidae; Vertical red line (dashed) = Pooled odds ratio; 
I–V overall: fixed-effects estimate; D + L overall: random-effects estimate; Diamond shapes = Pooled estimate and 95% CIs  
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Figure 2.2 Forest plot – multigravidae  
Odds ratio of low birth-weight delivery amongst multigravidae following two or more doses of IPTp-SP versus placebo or no IPTp-SP 
stratified by estimates of the A581G resistance mutation amongst malaria parasites at study sites 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Studies are presented in ascending order of malaria transmission intensity; * = 2-4 pregnancies; † = 5 or more pregnancies; Vertical red line (dashed) = Pooled 
odds ratio; I–V overall: fixed-effects estimate; D + L overall: random-effects estimate; Diamond shapes = Pooled estimate and 95% CIs 
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Discussion 
In this analysis IPTp-SP studies were stratified by primi- and secundigravidae versus 
multigravidae, and the effect that the A581G mutation on protection conferred against 
LBW was investigated.  This biomarker-based measure of SP resistance provides some 
clarity on where, geographically, a replacement for SP might be appropriate amongst 
multigravidae. 
Given the lack of prevalence estimates for the A581G mutation between 10.1% and 
52.4%, it is only reasonable to conclude that the prevalence threshold of this mutation 
is > 10.1% above which IPTp-SP no longer protects against the incidence of LBW 
amongst multigravidae.  It may be tempting to state the cut-off should be > 52.4%, or 
a convenient level such as 50%.  The actual threshold may be much lower, however, 
especially considering the alarming results from Muheza, Tanzania, where researchers 
found placental infection significantly higher in 84% of women (n = 104) who were 
given any IPTp-SP compared to 16% of women (n = 104) who received no doses of 
IPTp-SP (P = 0.03).86,199   The prevalence of the A581G mutation in this study area was 
55% (95% CI: 44.7, 65.2; N = 87).88 
The results from this analysis should be interpreted with caution for the same reasons 
noted in the investigation of transmission intensity.  This analysis has been conducted 
with the limited data available.  As previously mentioned, there may have been 
selection bias in six of the nine studies identified through systematic review for lack of 
random sequence generation or allocation concealment.  In addition, there was 
considerable heterogeneity amongst IPTp-SP studies, making it more difficult to 
generalise about them as a group.  However, stratifying studies by design did not 
consistently reduce heterogeneity, nor change the results.   
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The A581G mutation is not widely found throughout sub-Saharan Africa, although the 
codon has been detected in 10 countries152 and the codon can be selected rapidly.  A 
study in Kenya reported the prevalence of A581G to be 85.1% (95% CI: 80.0%, 89.4%) 
where no parasites had expressed the mutation when surveillance testing was 
conducted three years earlier.200  However, before declaring a specific level of malaria 
transmission or A581G prevalence at which IPTp-SP no longer provides a cost-effective 
benefit, placebo-control trials may be need in a range of low-transmission settings that 
are sufficiently powered for sub-analysis by gravidae.     
 
Q 3.  Effect of IPTp-SP on malaria and curable STIs/RTIs in pregnancy 
Methods 
To estimate the effect of IPTp-SP on malaria infection and curable STIs/RTIs in 
pregnancy, a secondary analysis was conducted using data collected for a prospective 
cohort study of the burden of malaria and curable STIs/RTIs carried out between 
November 2013 and April 2014 in the Nchelenge District of Zambia.201,202  Nchelenge is 
in the Luapula province, 290 km (180 miles) from Mansa, the provincial capital, and 
along the shores of Lake Mweru in north-east Zambia.  In total, 1,086 pregnant women 
were recruited on their first ANC visit to health centres operated by the Zambian 
Ministry of Health.  As part of determining eligibility for participation, women had 
their gestational age calculated according to their last menstrual period, symphysis-
fundal height measurement, and sonography.  Women who were not already known 
to have the AIDS virus were tested for HIV per Ministry practices.  HIV-infected women 
were given triple antiretroviral therapy if their CD4 count dropped below 500 cells per 
cubic millimetre of blood, representing a variation on ‘Option B’ treatment originally 
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recommended by the WHO in 2010.203  Study staff tested women for syphilis using 
rapid plasma reagin (RPR) methods and, if positive, the results were sent to 
participants with a notice to return to the health facility with their partners for 
treatment.  Biological samples for malaria and other curable STIs/RTIs were also 
collected at enrolment and transported to a reference laboratory for retrospective 
batch testing where PCR techniques were used.  At delivery, placental samples were 
collected for malaria histology.  During scheduled ANC visits, women received IPTp-SP 
and were followed by study staff until delivery to record birth outcomes.  Women 
were encouraged to deliver at a health facility for maximum care and to ease data 
collection.  If willing to do so, women were provided free transport to and from the 
only hospital in the district, Saint Paul’s Mission Hospital, or Kashikishi Health Centre.  
At the time, Nchelenge Health Centre did not offer maternity services.  Data were 
analysed using Stata version 13 (Stata Corp, College Station, Texas) software.  
Descriptive analysis 
Categorical variables were summarised as whole numbers and percentages, whereas 
continuous variables were described by means and standard deviations if the data 
appeared to be normally distributed.  Differences in the characteristics of participants 
at the time of enrolment were compared between women who had received 0 to 1 
dose and > 2 doses of IPTp-SP and, separately, 2 doses versus > 3 doses, using 
Wilcoxon test for continuous variables and Fisher’s exact test for categorical variables.  
These variables are listed in Table 3.6.  Crude odds ratios were then calculated of 
adverse birth outcomes amongst pregnant women who received 0 to 1 dose 
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compared > 2 doses and, separately, 2 doses compared to > 3 doses using logistic 
regression models.   
Assessment of potential confounding and effect modification factors 
HIV status and gravidae were considered to confound the protective effect of IPTp-SP 
on birth outcomes based on studies from the literature.204,205  Common statistical 
methods were applied to identify other potential confounders,206 entering variables 
into a logistic regression model that included categories of doses of IPTp-SP exposure.  
Variables were considered a priori to be confounders if they produced a change in the 
odds ratios of crude versus adjusted by 10% or more as shown in Tables 3.1 to 3.5.  
Effect modification was tested by adding an interaction term between these potential 
confounders and the number of IPTp-SP doses, and then applying a likelihood ratio 
test to determine whether there was evidence of interaction.  Some evidence of effect 
modification with malaria and STI/RTI co-infection was observed which is dealt with 
separately below.  The co-infection of malaria and STIs/RTIs was also considered a 
confounder.  All confounding variables were entered in a multivariable logistic 
regression model to estimate overall adjusted odds ratios.   
Assessment of association between IPTp-SP and maternal malaria and STIs/RTIs 
Seven mutually exclusive maternal infection categories were constructed to examine 
the distribution of mono- and co-infection: (i) malaria only, (ii) malaria and N. 
gonorrhoeae and/or C. trachomatis, (iii) malaria and T. vaginalis and/or bacterial 
vaginosis, (iv) syphilis and any other infection(s), (v) N. gonorrhoeae, C. trachomatis 
only, (vi) T. vaginalis and/or bacterial vaginosis only, and (vii) no identified infection.  
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Odds of IPTp-SP exposure to 0-1 dose versus > 2 doses of IPTp-SP were calculated for 
each infection category by adverse birth outcome using a multivariable logistic 
regression model that included all potential confounders and interaction terms. 
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Table 3.1 Potential confounding factors for any adverse birth outcome 
 
Potential confounding variable 
Crude analysis Adjusted analysis % change in 
crude odds 
ratio5 
P-value for 
homogeneity 
Missing 
values6 Odds 
ratio 
95% CI P-value4 
Odds 
ratio 
95% CI P-value4 
Gravidae 0.57 (0.38, 0.84) 0.004 0.52 (0.35, 0.77) 0.001 8.89 0.302 0 
Prior preterm birth1 0.42 (0.15, 1.19) 0.092 0.38 (0.13, 1.11) 0.067 7.88 * 620 
Sex of baby 0.57 (0.38, 0.84) 0.004 0.59 (0.40, 0.87) 0.007 3.86 0.240 0 
Co-infection (malaria and/or STI/RTI) 0.57 (0.38, 0.84) 0.004 0.54 (0.37, 0.81) 0.002 3.81 0.125 0 
Maternal age at enrolment (years) 0.57 (0.38, 0.84) 0.004 0.55 (0.36, 0.82) 0.003 3.55 0.736 0 
Prior miscarriage1 0.42 (0.15, 1.19) 0.092 0.40 (0.14, 1.15) 0.079 3.39 0.424 620 
Placental malaria (PCR diagnosis) 0.58 (0.39, 0.85) 0.005 0.56 (0.38, 0.83) 0.004 2.63 0.853 7 
Delivery type 0.57 (0.38, 0.84) 0.004 0.58 (0.39, 0.86) 0.006 2.38 0.929 0 
Treatment of malaria infection during pregnancy2 0.58 (0.39, 0.86) 0.006 0.57 (0.38, 0.84) 0.004 2.23 0.256 3 
Marital status 0.57 (0.38, 0.84) 0.004 0.55 (0.38, 0.81) 0.002 2.22 0.001 0 
Number of lifetime sexual partners 0.56 (0.38, 0.83) 0.004 0.57 (0.39, 0.85) 0.005 2.06 0.564 6 
Hypertension at enrolment or delivery 0.54 (0.36, 0.82) 0.003 0.55 (0.37, 0.83) 0.004 1.93 0.213 86 
Type of personnel attending birth 0.57 (0.38, 0.84) 0.004 0.58 (0.39, 0.85) 0.005 1.78 0.042 0 
HIV status 0.57 (0.38, 0.84) 0.004 0.57 (0.39, 0.85) 0.005 1.42 0.946 0 
Age of sexual debut (years) 0.57 (0.38, 0.84) 0.004 0.57 (0.39, 0.85) 0.005 1.38 0.243 0 
Prior stillbirth1 0.42 (0.15, 1.19) 0.092 0.42 (0.14, 1.25) 0.108 1.33 0.358 620 
Indoor residual spraying in preceding 12 months 0.53 (0.36, 0.80) 0.002 0.53 (0.35, 0.79) 0.001 1.30 0.896 26 
Syphilis at enrolment (high titre)  0.57 (0.38, 0.84) 0.004 0.56 (0.38, 0.83) 0.004 1.16 0.400 5 
Labour type 0.57 (0.39, 0.85) 0.005 0.57 (0.38, 0.84) 0.004 1.14 * 15 
Bed net ownership 0.57 (0.38, 0.84) 0.004 0.57 (0.39, 0.85) 0.005 1.10 0.750 0 
Bed net usage (on night prior to survey) 0.56 (0.38, 0.83) 0.004 0.55 (0.37, 0.82) 0.003 1.09 0.826 3 
Delivery location 0.57 (0.38, 0.84) 0.004 0.57 (0.38, 0.85) 0.005 1.05 0.070 0 
T. vaginalis co-infection (malaria and/or STI/RTI) 0.57 (0.38, 0.84) 0.004 0.57 (0.39, 0.84) 0.004 0.89 0.011 0 
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Table 3.1 Potential confounding factors for any adverse birth outcome (continued) 
Potential confounding variable 
Crude analysis Adjusted analysis % change in 
crude odds 
ratio5 
P-value for 
homogeneity 
Missing 
values6 Odds 
ratio 
95% CI P-value4 
Odds 
ratio 
95% CI P-value4 
Wealth quintiles 0.57 (0.38, 0.84) 0.004 0.56 (0.38, 0.83) 0.004 0.84 0.503 0 
Maternal haemoglobin level at delivery3 0.60 (0.40, 0.90) 0.012 0.60 (0.40, 0.90) 0.012 0.56 0.101 32 
Treatment of STIs/RTIs during pregnancy including 
syphilis 
0.76 (0.46, 1.23) 0.259 0.76 (0.47, 1.23) 0.265 0.49 0.250 258 
STI/RTI co-infection 0.57 (0.38, 0.84) 0.004 0.57 (0.38, 0.84) 0.004 0.39 0.483 5 
N. gonorrhoeae co-infection (malaria and/or 
STI/RTI) 
0.57 (0.38, 0.84) 0.004 0.56 (0.38, 0.84) 0.004 0.39 0.318 0 
Bacterial vaginosis and STI co-infection 0.57 (0.38, 0.84) 0.004 0.57 (0.39, 0.84) 0.004 0.33 0.067 5 
Recruitment site 0.57 (0.38, 0.84) 0.004 0.56 (0.38, 0.84) 0.004 0.24 0.991 0 
Treatment of STIs/RTIs during pregnancy excluding 
syphilis 
0.57 (0.38, 0.84) 0.004 0.57 (0.38, 0.84) 0.004 0.19 0.492 0 
C. trachomatis co-infection (malaria or STI/RTI) 0.57 (0.38, 0.84) 0.004 0.57 (0.38, 0.84) 0.004 0.04 0.770 0 
 
CI = Confidence Interval; PCR = Polymerase Chain Reaction; STI = Sexually Transmitted Infection; RTI = Reproductive Tract Infection; HIV = Human immunodeficiency virus 
1 Excludes women who have not been previously pregnant 
2 Therapy against malaria infection (apart from IPTp) after enrolment and before delivery 
3 Anaemia was defined as haemoglobin level < 11grams/decilitre 
4 Confounding is not reflected in P-values 
5 Confounding is assessed by observing the difference between the crude odds ratio and adjusted odds ratio.  When there is no difference (adjusted / crude – 1) between these two 
estimates, the observed exposure–outcome effect is not confounded by the potential confounding variable.  Variables with odds ratios that changed by 10% or more were considered a 
priori to be potential confounders and we retained for the multivariable model.  In this table, only the variable.  In this table, no variables demonstrated evidence of confounding on the 
outcome effect ‘any adverse birth outcome’. 
6 Missing values were excluded from the crude odds ratio 
* Insufficient events to perform stratified analysis for interaction 
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Table 3.2 Potential confounding factors for stillbirth 
 
 
  Potential confounder 
 
Crude analysis Adjusted analysis % change in 
crude odds 
ratio5 
P-value for 
homogeneity 
Missing 
values6 Odds 
ratio 
95% CI P-value4 
Odds 
ratio 
95% CI P-value4 
Hypertension at enrolment or delivery 0.88 (0.18, 4.21) 0.875 1.00 (0.19, 5.32) 1.000 13.39 0.422 86 
Labour type 0.43 (0.13, 1.46) 0.163 0.39 (0.11, 1.35) 0.122 9.96 *  15 
Treatment of malaria infection during pregnancy2 0.56 (0.15, 2.15) 0.392 0.51 (0.13, 2.02) 0.328 9.31 0.333 3 
Indoor residual spraying in preceding 12 months 0.43 (0.13, 1.46) 0.162 0.39 (0.11, 1.36) 0.128 8.22 0.584 26 
Gravidae 0.42 (0.12, 1.42) 0.149 0.39 (0.11, 1.34) 0.121 7.42 0.573 0 
Delivery location 0.42 (0.12, 1.42) 0.149 0.39 (0.11, 1.39) 0.132 6.08 0.459 0 
HIV status 0.42 (0.12, 1.42) 0.149 0.44 (0.13, 1.49) 0.175 4.98 0.794 0 
Wealth quintiles 0.42 (0.12, 1.42) 0.149 0.44 (0.14, 1.37) 0.144 4.92 0.043 0 
Delivery type 0.42 (0.12, 1.42) 0.149 0.44 (0.13, 1.48) 0.173 4.55  * 0 
Maternal haemoglobin level at delivery3 0.57 (0.15, 2.17) 0.401 0.54 (0.14, 2.11) 0.369 4.29 0.694 32 
Prior stillbirth1 0.30 (0.07, 1.39) 0.103 0.32 (0.07, 1.45) 0.117 4.20 *  192 
Age of sexual debut (years) 0.42 (0.12, 1.42) 0.149 0.44 (0.13, 1.44) 0.161 4.15 0.178 0 
Placental malaria (PCR diagnosis) 0.42 (0.13, 1.44) 0.155 0.44 (0.13, 1.48) 0.171 3.20 0.737 7 
Type of personnel attending birth 0.42 (0.12, 1.42) 0.149 0.41 (0.12, 1.42) 0.145 3.09 0.433 0 
Bed net ownership 0.42 (0.12, 1.42) 0.149 0.43 (0.13, 1.45) 0.161 2.96 0.324 0 
N. gonorrhoeae co-infection (malaria and/or 
STI/RTI) 
0.42 (0.12, 1.42) 0.149 0.43 (0.13, 1.46) 0.164 2.89 *  0 
Co-infection (malaria and/or STI/RTI) 0.42 (0.12, 1.42) 0.149 0.43 (0.14, 1.36) 0.139 2.60 0.045 0 
Recruitment site 0.42 (0.12, 1.42) 0.149 0.43 (0.13, 1.48) 0.168 2.59 0.330 0 
C. trachomatis co-infection (malaria or STI/RTI) 0.42 (0.12, 1.42) 0.149 0.41 (0.12, 1.39) 0.139 2.19 *  0 
Sex of baby 0.42 (0.12, 1.42) 0.149 0.43 (0.12, 1.48) 0.168 1.89 0.673 0 
Number of lifetime sexual partners 0.42 (0.13, 1.43) 0.154 0.43 (0.13, 1.45) 0.161 1.81 0.461 6 
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Table 3.2 Potential confounding factors for stillbirth (continued) 
 
 
 
  Potential confounder 
 
Crude analysis Adjusted analysis % change in 
crude odds 
ratio5 
P-value for 
homogeneity 
Missing 
values6 Odds 
ratio 
95% CI P-value4 
Odds 
ratio 
95% CI P-value4 
STI/RTI co-infection 0.42 (0.13, 1.43) 0.153 0.43 (0.13, 1.43) 0.155 1.53 0.101 5 
Treatment of STIs/RTIs during pregnancy including 
syphilis 
0.55 (0.10, 2.88) 0.470 0.55 (0.11, 2.93) 0.481 1.35 *  258 
Syphilis at enrolment (high titre)  0.42 (0.13, 1.43) 0.153 0.42 (0.13, 1.33) 0.128 1.14 0.007 5 
Maternal age at enrolment (years) 0.42 (0.12, 1.42) 0.149 0.42 (0.12, 1.45) 0.158 0.78 0.433 0 
Prior miscarriage1 0.30 (0.07, 1.39) 0.103 0.31 (0.07, 1.39) 0.104 0.60 0.337 192 
Prior preterm birth1 0.30 (0.07, 1.39) 0.103 0.31 (0.07, 1.40) 0.105 0.52 *  192 
Bed net usage (on night prior to survey) 0.42 (0.12, 1.43) 0.152 0.42 (0.12, 1.42) 0.151 0.34 0.408 3 
Marital status 0.42 (0.12, 1.42) 0.149 0.42 (0.12, 1.44) 0.155 0.19 0.354 0 
Bacterial vaginosis and STI co-infection 0.42 (0.13, 1.43) 0.153 0.42 (0.13, 1.43) 0.153 0.12 0.372 5 
Treatment of STIs/RTIs during pregnancy excluding 
syphilis 
0.43 (0.13, 1.45) 0.161 0.43 (0.13, 1.45) 0.162 0.07 *  13 
T. vaginalis co-infection (malaria and/or STI/RTI) 0.42 (0.12, 1.42) 0.149 0.42 (0.12, 1.42) 0.149 0.00 0.998 0 
 
CI = Confidence Interval; PCR = Polymerase Chain Reaction; STI = Sexually Transmitted Infection; RTI = Reproductive Tract Infection; HIV = Human immunodeficiency virus 
1 Excludes women who have not been previously pregnant 
2 Therapy against malaria infection (apart from IPTp) after enrolment and before delivery 
3 Anaemia was defined as haemoglobin level < 11grams/decilitre 
4 Confounding is not reflected in P-values 
5 Confounding is assessed by observing the difference between the crude odds ratio and adjusted odds ratio.  When there is no difference (adjusted / crude – 1) between these two 
estimates, the observed exposure–outcome effect is not confounded by the potential confounding variable.  Variables with odds ratios that changed by 10% or more were considered a 
priori to be potential confounders and we retained for the multivariable model.  In this table, only the variable.  ‘Hypertension at enrolment or delivery’ demonstrated evidence of 
confounding on the outcome effect ‘stillbirth’. 
6 Missing values were excluded from the crude odds ratio 
* Insufficient events to perform stratified analysis for interaction 
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Table 3.3 Potential confounding factors for low birth weight 
 
 
  Potential confounder 
 
Crude analysis Adjusted analysis  % change 
in crude 
odds ratio5 
P-value for 
homogeneity 
Missing 
values6 Odds 
ratio 
95% CI P-value4 
Odds 
ratio 
95% CI P-value4 
Gravidae 0.78 (0.49, 1.23) 0.279 0.69 (0.42, 1.11) 0.122 11.86 0.952 0 
Prior miscarriage1 0.68 (0.21, 2.19) 0.513 0.64 (0.19, 2.14) 0.461 6.17 0.623 620 
Treatment of malaria infection during pregnancy2 0.78 (0.50, 1.23) 0.288 0.74 (0.47, 1.18) 0.207 4.87 0.034 3 
Co-infection (malaria and/or STI/RTI) 0.78 (0.49, 1.23) 0.279 0.74 (0.47, 1.17) 0.202 4.43 0.211 0 
Marital status 0.78 (0.49, 1.23) 0.279 0.75 (0.48, 1.18) 0.210 3.72 0.079 0 
Placental malaria (PCR diagnosis) 0.79 (0.50, 1.25) 0.310 0.77 (0.49, 1.21) 0.255 2.98 0.964 7 
Indoor residual spraying in preceding 12 months 0.73 (0.46, 1.15) 0.175 0.71 (0.45, 1.13) 0.142 2.78 0.450 26 
HIV status 0.78 (0.49, 1.23) 0.279 0.80 (0.51, 1.26) 0.331 2.51 0.622 0 
Sex of baby 0.78 (0.49, 1.23) 0.279 0.80 (0.51, 1.25) 0.322 2.16 0.364 0 
Delivery location 0.78 (0.49, 1.23) 0.279 0.79 (0.50, 1.25) 0.321 1.90 0.021 0 
Bed net ownership 0.78 (0.49, 1.23) 0.279 0.79 (0.50, 1.26) 0.324 1.88 0.354 0 
Wealth quintiles 0.78 (0.49, 1.23) 0.279 0.77 (0.48, 1.21) 0.254 1.71 0.980 0 
Maternal age at enrolment (years) 0.78 (0.49, 1.23) 0.279 0.77 (0.48, 1.23) 0.271 1.65 0.159 0 
Number of lifetime sexual partners 0.77 (0.49, 1.22) 0.265 0.78 (0.50, 1.24) 0.295 1.58 0.010 6 
Syphilis at enrolment (high titre)  0.78 (0.49, 1.23) 0.281 0.77 (0.49, 1.21) 0.253 1.54  * 5 
Delivery type 0.78 (0.49, 1.23) 0.279 0.79 (0.50, 1.24) 0.305 1.30 0.546 0 
Treatment of STIs/RTIs during pregnancy including 
syphilis 
1.09 (0.60, 1.96) 0.777 1.10 (0.61, 1.99) 0.752 1.07 0.932 258 
Bed net usage (on night prior to survey) 0.77 (0.49, 1.21) 0.253 0.76 (0.48, 1.21) 0.242 1.06 0.203 3 
Age of sexual debut (years) 0.78 (0.49, 1.23) 0.279 0.78 (0.50, 1.24) 0.295 0.81 0.775 0 
Labour type 0.78 (0.49, 1.23) 0.283 0.77 (0.49, 1.22) 0.271 0.70  * 15 
N.gonorrhoeae co-infection (malaria and/or STI/RTI) 0.78 (0.49, 1.23) 0.279 0.78 (0.50, 1.23) 0.290 0.49 0.592 0 
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Table 3.3 Potential confounding factors for low birth weight (continued) 
 
 
  Potential confounder 
 
Crude analysis Adjusted analysis  % change 
in crude 
odds ratio5 
P-value for 
homogeneity 
Missing 
values6 Odds 
ratio 
95% CI P-value4 
Odds 
ratio 
95% CI P-value4 
STI/RTI co-infection 0.78 (0.49, 1.23) 0.281 0.78 (0.49, 1.22) 0.273 0.40 0.693 5 
T. vaginalis co-infection (malaria and/or STI/RTI) 0.78 (0.49, 1.23) 0.279 0.78 (0.50, 1.22) 0.279 0.31 0.035 0 
Prior preterm birth1 0.72 (0.40, 1.29) 0.267 0.72 (0.41, 1.28) 0.266 0.29 0.019 192 
Maternal haemoglobin level at delivery3 0.80 (0.50, 1.28) 0.354 0.80 (0.50, 1.28) 0.349 0.21 0.120 32 
Bacterial vaginosis and STI co-infection 0.78 (0.49, 1.23) 0.281 0.78 (0.50, 1.22) 0.272 0.21 0.060 5 
C. trachomatis co-infection (malaria or STI/RTI) 0.78 (0.49, 1.23) 0.279 0.78 (0.49, 1.23) 0.284 0.17 0.435 0 
Hypertension at enrolment or delivery 0.76 (0.48, 1.23) 0.264 0.76 (0.48, 1.23) 0.267 0.13 0.847 86 
Type of personnel attending birth 0.78 (0.49, 1.23) 0.279 0.78 (0.50, 1.23) 0.279 0.10 0.004 0 
Treatment of STIs/RTIs during pregnancy excluding 
syphilis 
0.78 (0.49, 1.23) 0.279 0.78 (0.49, 1.23) 0.283 0.08 0.826 0 
Recruitment site 0.78 (0.49, 1.23) 0.279 0.78 (0.50, 1.22) 0.277 0.07 0.053 0 
Prior stillbirth1 0.68 (0.21, 2.19) 0.513 0.68 (0.20, 2.31) 0.531 0.02 0.876 620 
 
CI = Confidence Interval; PCR = Polymerase Chain Reaction; STI = Sexually Transmitted Infection; RTI = Reproductive Tract Infection; HIV = Human immunodeficiency virus 
1 Excludes women who have not been previously pregnant 
2 Therapy against malaria infection (apart from IPTp) after enrolment and before delivery 
3 Anaemia was defined as haemoglobin level < 11grams/decilitre 
4 Confounding is not reflected in P-values 
5 Confounding is assessed by observing the difference between the crude odds ratio and adjusted odds ratio.  When there is no difference (adjusted / crude – 1) between these two 
estimates, the observed exposure–outcome effect is not confounded by the potential confounding variable.  Variables with odds ratios that changed by 10% or more were considered a 
priori to be potential confounders and we retained for the multivariable model.  In this table, only the variable.  ‘Hypertension at enrolment or delivery’ demonstrated evidence of 
confounding on the outcome effect ‘stillbirth’. 
6 Missing values were excluded from the crude odds ratio 
* Insufficient events to perform stratified analysis for interaction 
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Table 3.4 Potential confounding factors for preterm delivery 
 
 
  Potential confounder 
 
Crude analysis Adjusted analysis  % change 
in crude 
odds ratio5 
P-value for 
homogeneity 
Missing 
values6 Odds 
ratio 
95% CI P-value4 
Odds 
ratio 
95% CI P-value4 
Prior preterm birth1 0.35 (0.11, 1.08) 0.056 0.30 (0.09, 0.96) 0.031 14.04 *  620 
Prior miscarriage1 0.35 (0.11, 1.08) 0.056 0.32 (0.10, 1.01) 0.040 8.67 0.326 620 
Gravidae 0.36 (0.23, 0.55) 0.000 0.34 (0.22, 0.52) 0.000 5.63 0.794 0 
Sex of baby 0.36 (0.23, 0.55) 0.000 0.37 (0.24, 0.57) 0.000 4.25 0.237 0 
Maternal age at enrolment (years) 0.36 (0.23, 0.55) 0.000 0.34 (0.22, 0.53) 0.000 3.67 0.285 0 
Prior stillbirth1 0.31 (0.19, 0.51) 0.000 0.30 (0.18, 0.50) 0.000 3.29 0.032 192 
Labour type 0.36 (0.24, 0.56) 0.000 0.35 (0.23, 0.55) 0.000 2.43  * 15 
Delivery type 0.36 (0.23, 0.55) 0.000 0.36 (0.24, 0.56) 0.000 2.29 0.336 0 
Syphilis at enrolment (high titre)  0.36 (0.23, 0.55) 0.000 0.35 (0.23, 0.54) 0.000 2.23  * 5 
Hypertension at enrolment or delivery 0.35 (0.22, 0.54) 0.000 0.36 (0.23, 0.55) 0.000 2.22 0.021 86 
Co-infection (malaria and/or STI/RTI) 0.36 (0.23, 0.55) 0.000 0.35 (0.23, 0.54) 0.000 2.08 0.248 0 
Type of personnel attending birth 0.36 (0.23, 0.55) 0.000 0.36 (0.24, 0.56) 0.000 1.87 0.128 0 
Number of lifetime sexual partners 0.36 (0.23, 0.55) 0.000 0.36 (0.24, 0.56) 0.000 1.57 0.297 6 
N. gonorrhoeae co-infection (malaria and/or STI/RTI) 0.36 (0.23, 0.55) 0.000 0.35 (0.23, 0.54) 0.000 1.56 0.331 0 
Age of sexual debut (years) 0.36 (0.23, 0.55) 0.000 0.36 (0.24, 0.55) 0.000 1.37 0.734 0 
Maternal haemoglobin level at delivery3 0.37 (0.24, 0.57) 0.000 0.37 (0.24, 0.57) 0.000 1.35 0.212 32 
Marital status 0.36 (0.23, 0.55) 0.000 0.35 (0.23, 0.54) 0.000 1.29 0.038 0 
Placental malaria (PCR diagnosis) 0.36 (0.24, 0.55) 0.000 0.36 (0.23, 0.55) 0.000 1.10 0.955 7 
Bed net ownership 0.36 (0.23, 0.55) 0.000 0.36 (0.23, 0.55) 0.000 1.07 0.659 0 
STI/RTI co-infection 0.36 (0.23, 0.55) 0.000 0.36 (0.23, 0.55) 0.000 0.91 0.984 5 
T. vaginalis co-infection (malaria and/or STI/RTI) 0.36 (0.23, 0.55) 0.000 0.36 (0.23, 0.55) 0.000 0.89 0.053 0 
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Table 3.4 Potential confounding factors for preterm delivery (continued) 
 
 
  Potential confounder 
 
Crude analysis Adjusted analysis  % change 
in crude 
odds ratio5 
P-value for 
homogeneity 
Missing 
values6 Odds 
ratio 
95% CI P-value4 
Odds 
ratio 
95% CI P-value4 
HIV status 0.36 (0.23, 0.55) 0.000 0.36 (0.23, 0.55) 0.000 0.84 0.805 0 
Wealth quintiles 0.36 (0.23, 0.55) 0.000 0.36 (0.23, 0.55) 0.000 0.70 0.461 0 
Recruitment site 0.36 (0.23, 0.55) 0.000 0.35 (0.23, 0.54) 0.000 0.66 0.316 0 
Indoor residual spraying in preceding 12 months 0.32 (0.21, 0.50) 0.000 0.33 (0.21, 0.50) 0.000 0.57 0.450 26 
Bed net usage (on night prior to survey) 0.36 (0.23, 0.55) 0.000 0.36 (0.23, 0.55) 0.000 0.57 0.894 3 
Delivery location 0.36 (0.23, 0.55) 0.000 0.35 (0.23, 0.55) 0.000 0.49 0.089 0 
Treatment of STIs/RTIs during pregnancy excluding 
syphilis 
0.36 (0.23, 0.55) 0.000 0.36 (0.23, 0.55) 0.000 0.18 0.623 0 
Bacterial vaginosis and STI co-infection 0.36 (0.23, 0.55) 0.000 0.36 (0.23, 0.55) 0.000 0.18 0.168 5 
C. trachomatis co-infection (malaria or STI/RTI) 0.36 (0.23, 0.55) 0.000 0.36 (0.23, 0.55) 0.000 0.09 0.903 0 
Treatment of STIs/RTIs during pregnancy including 
syphilis 
0.46 (0.27, 0.77) 0.003 0.46 (0.27, 0.77) 0.003 0.09 0.384 258 
Treatment of malaria infection during pregnancy2 0.36 (0.23, 0.55) 0.000 0.36 (0.23, 0.55) 0.000 0.05 0.172 3 
 
CI = Confidence Interval; PCR = Polymerase Chain Reaction; STI = Sexually Transmitted Infection; RTI = Reproductive Tract Infection; HIV = Human immunodeficiency virus 
1 Excludes women who have not been previously pregnant 
2 Therapy against malaria infection (apart from IPTp) after enrolment and before delivery 
3 Anaemia was defined as haemoglobin level < 11grams/decilitre 
4 Confounding is not reflected in P-values 
5 Confounding is assessed by observing the difference between the crude odds ratio and adjusted odds ratio.  When there is no difference (adjusted / crude – 1) between these two 
estimates, the observed exposure–outcome effect is not confounded by the potential confounding variable.  Variables with odds ratios that changed by 10% or more were considered a 
priori to be potential confounders and we retained for the multivariable model.  In this table, only the variable ‘Hypertension at enrolment or delivery’ demonstrated evidence of 
confounding on the outcome effect ‘stillbirth’. 
6 Missing values were excluded from the crude odds ratio 
* Insufficient events to perform stratified analysis for interaction 
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Table 3.5 Potential confounding factors for intrauterine growth retardation 
 
 
  Potential confounder 
 
Crude analysis Adjusted analysis  % change 
in crude 
odds ratio5 
P-value for 
homogeneity 
Missing 
values6 Odds 
ratio 
95% CI P-value4 
Odds 
ratio 
95% CI P-value4 
Prior miscarriage1 0.71 (0.13, 3.92) 0.697 0.90 (0.13, 6.01) 0.912 25.73 0.938 620 
Hypertension at enrolment or delivery 1.55 (0.68, 3.56) 0.295 1.68 (0.72, 3.94) 0.228 8.25 0.883 86 
Gravidae 1.85 (0.82, 4.19) 0.134 1.70 (0.75, 3.87) 0.198 7.89 0.458 0 
Maternal age at enrolment (years) 1.85 (0.82, 4.19) 0.134 1.72 (0.75, 3.90) 0.192 7.28 0.419 0 
Number of lifetime sexual partners 1.82 (0.80, 4.12) 0.148 1.91 (0.83, 4.43) 0.124 5.34 0.332 6 
Treatment of STIs/RTIs during pregnancy including 
syphilis 
3.19 (0.95, 10.74) 0.048 3.32 (0.98, 11.29) 0.042 4.11 0.724 258 
Placental malaria (PCR diagnosis) 1.88 (0.83, 4.27) 0.123 1.81 (0.79, 4.11) 0.153 4.10 0.981 7 
Co-infection (malaria and/or STI/RTI) 1.85 (0.82, 4.19) 0.134 1.78 (0.79, 4.02) 0.161 3.93 0.348 0 
Prior stillbirth1 0.71 (0.13, 3.92) 0.697 0.74 (0.13, 4.07) 0.729 3.70  * 620 
Treatment of malaria infection during pregnancy2 1.86 (0.82, 4.21) 0.131 1.79 (0.79, 4.07) 0.157 3.62 0.459 3 
Bed net ownership 1.85 (0.82, 4.19) 0.134 1.90 (0.83, 4.33) 0.122 2.51 0.609 0 
Indoor residual spraying in preceding 12 months 1.83 (0.81, 4.16) 0.142 1.79 (0.79, 4.06) 0.161 2.50 0.710 26 
Sex of baby 1.85 (0.82, 4.19) 0.134 1.89 (0.84, 4.28) 0.120 2.24 0.582 0 
Wealth quintiles 1.85 (0.82, 4.19) 0.134 1.81 (0.79, 4.13) 0.151 2.05 0.950 0 
Marital status 1.85 (0.82, 4.19) 0.134 1.81 (0.83, 3.99) 0.132 1.95 0.037 0 
Prior preterm birth1 0.71 (0.13, 3.92) 0.697 0.73 (0.13, 3.99) 0.713 1.82  * 620 
T. vaginalis co-infection (malaria and/or STI/RTI) 1.85 (0.82, 4.19) 0.134 1.88 (0.84, 4.21) 0.117 1.74 0.171 0 
Treatment of STIs/RTIs during pregnancy excluding 
syphilis 
1.91 (0.84, 4.33) 0.116 1.94 (0.85, 4.41) 0.108 1.62 0.685 13 
Delivery location 1.85 (0.82, 4.19) 0.134 1.88 (0.83, 4.26) 0.127 1.34  * 0 
Maternal haemoglobin level at delivery3 1.86 (0.82, 4.23) 0.130 1.89 (0.83, 4.27) 0.121 1.27 0.469 32 
Labour type 1.86 (0.82, 4.21) 0.132 1.88 (0.83, 4.27) 0.125 1.27  * 15 
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Table 5.5 Potential confounding factors for intrauterine growth retardation (continued) 
 
 
  Potential confounder 
 
Crude analysis Adjusted analysis 
 % change in 
crude odds ratio5 
P-value for 
homogeneity 
Missing 
values6 Odds 
ratio 
95% CI P-value4 
Odds 
ratio 
95% CI P-value4 
HIV status 1.85 (0.82, 4.19) 0.134 1.87 (0.82, 4.23) 0.128 0.98 0.757 0 
N. gonorrhoeae co-infection (malaria 
and/or STI/RTI) 
1.85 (0.82, 4.19) 0.134 1.87 (0.82, 4.24) 0.129 0.91  * 0 
Bed net usage (on night prior to survey) 1.81 (0.80, 4.10) 0.151 1.80 (0.79, 4.11) 0.159 0.59 0.328 3 
Recruitment site 1.85 (0.82, 4.19) 0.134 1.84 (0.82, 4.14) 0.134 0.51 0.058 0 
STI/RTI co-infection 1.87 (0.82, 4.24) 0.128 1.86 (0.82, 4.22) 0.129 0.31 0.407 5 
C. trachomatis co-infection (malaria or 
STI/RTI) 
1.85 (0.82, 4.19) 0.134 1.86 (0.82, 4.22) 0.134 0.26 0.398 0 
Type of personnel attending birth 1.85 (0.82, 4.19) 0.134 1.85 (0.82, 4.17) 0.134 0.24 0.057 0 
Age of sexual debut (years) 1.85 (0.82, 4.19) 0.134 1.85 (0.83, 4.17) 0.128 0.24 0.333 0 
Bacterial vaginosis and STI co-infection 1.87 (0.82, 4.24) 0.128 1.87 (0.84, 4.19) 0.121 0.16 0.135 5 
Syphilis at enrolment (high titre)  1.87 (0.82, 4.24) 0.128 1.87 (0.82, 4.24) 0.129 0.10  * 5 
Delivery type 1.85 (0.82, 4.19) 0.134 1.85 (0.82, 4.16) 0.131 0.03 0.087 0 
 
CI = Confidence Interval; PCR = Polymerase Chain Reaction; STI = Sexually Transmitted Infection; RTI = Reproductive Tract Infection; HIV = Human immunodeficiency virus 
1 Excludes women who have not been previously pregnant 
2 Therapy against malaria infection (apart from IPTp) after enrolment and before delivery 
3 Anaemia was defined as haemoglobin level < 11grams/decilitre 
4 Confounding is not reflected in P-values 
5 Confounding is assessed by observing the difference between the crude odds ratio and adjusted odds ratio.  When there is no difference (adjusted / crude – 1) between these two 
estimates, the observed exposure–outcome effect is not confounded by the potential confounding variable.   Variables with odds ratios that changed by 10% or more were considered a 
priori to be potential confounders and we retained for the multivariable model.  In this table, only the variable.  ‘Hypertension at enrolment or delivery’ demonstrated evidence of 
confounding on the outcome effect ‘stillbirth’. 
6 Missing values were excluded from the crude odds ratio 
* Insufficient events to perform stratified analysis for interaction 
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Results 
In this analysis the effects of IPTp-SP on adverse birth outcomes were explored 
depending on the status of malaria infection and curable STIs/RTIs.  Specifically, four 
adverse birth outcomes were investigated in a dose-response relationship: (i) stillbirth, 
(ii) LBW, (iii) preterm birth, and (iv) intrauterine growth retardation in seven categories 
of maternal malaria and STI/RTI categories.   
There were no significant differences in the prevalence of malaria infection and 
curable STIs/RTIs at baseline across IPTp-SP exposure groups stratified by 0 to 1 dose 
(n=126) versus > 2 doses (n=590) as shown in Table 3.6 (enrolment) and Table 3.7 
(delivery) and, separately, 2 doses (n=310) versus > 3 doses (n=280) in Table 3.8 
(enrolment) and Table 3.9 (delivery).  However, the odds of any adverse birth outcome 
amongst women who received > 2 doses compared to 0-1, presented in Table 3.10, 
were reduced 45% (OR 0.55, 95% CI: 0.36, 0.86).  The odds of any adverse birth 
outcome were reduced 12% further (57% total reduction) with > 3 doses (OR 0.43, 
95% CI 0.27, 0.68).  Two doses, compared to 0 to 1 dose, reduced the odds of preterm 
delivery by 58% (OR 0.42, 95% CI: 0.27, 0.67).  Three or more doses of IPTp reduced 
the odds of preterm birth 21% further (79% total reduction) (OR 0.21, 95% CI 0.13, 
0.35) as shown in Table 3.10.  A similar dose-response relationship was also observed 
against malaria infection and STIs/RTIs in dosing categories of 0-1 versus > 2 doses, 
and 2 versus > 3 doses.   
Across 24 of 30 infection categories, > 2 doses conferred greater protection against 
adverse birth outcomes than 0-1 dose, of which eight categories showed statistically 
significant effects as shown in Table 3.11; three categories related to any birth 
outcome (malaria only, N. gonorrhoeae and/or C. trachomatis, and no identified 
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infection), one was specific to LBW (no identified infection), and four were associated 
with preterm birth (malaria only, malaria and T. vaginalis and/or bacterial vaginosis, 
and no identified infection). 
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Table 3.6 Participant characteristics at enrolment: 0-1 dose vs. > 2 doses of IPTp-SP 
 
 
 
 
 Characteristics at enrolment 
Doses of SP received – number (%)* 
 P-value 
0-1 dose (n = 126) > 2 doses(n = 590) 
Age of participants  0.498 
Mean (SD) 25.8 (6.5) 25.4 (6.4)  
Median (IQR) 24.0 (20.0, 31.0) 24.0 (20.0, 30.0)  
Marital status  0.175 
Single 19 (15.1) 123 (20.8)  
Married, divorced/separated or 
widowed 
107 (84.9) 467 (79.2)  
Age at sexual debut  0.733 
 < 15 years of age 13 (10.3) 49 (8.3)  
> 15 years of age 96 (76.2) 455 (77.1)  
Unknown 17 (13.5) 86 (14.6)  
Number of lifetime sexual partners  0.362 
1 partner 52 (41.3) 272 (46.6)  
2 partners 45 (35.7) 161 (27.6)  
3 partners 18 (14.3) 94 (16.1)  
4 or more partners 11 (8.7) 57 (9.8)  
Gravidae  0.301 
Primigravidae 27 (21.4) 165 (28.0)  
Secundigravidae 19 (15.1) 77 (13.1)  
Multigravidae 80 (63.5) 348 (59.0)  
Wealth Quintiles  0.048 
Lowest 21 (16.7) 115 (19.5)  
Second 32 (25.4) 111 (18.8)  
Middle 31 (24.6) 113 (19.2)  
Fourth 14 (11.1) 122 (20.7)  
Highest 28 (22.2) 129 (21.9)  
Bed net ownership  0.493 
No 68 (54.0) 297 (50.3)  
Yes 58 (46.0) 293 (49.7)  
Used insecticide treated net on previous night 0.840 
No 77 (61.1) 366 (62.4)  
Yes 49 (38.9) 221 (37.6)  
Missing 0  3   
Indoor residual spraying in the previous 12 months  0.186 
No 103 (83.1) 439 (77.6)  
Yes 21 (16.9) 127 (22.4)  
Missing 2  24   
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Table 3.6 Participant characteristics at enrolment: 0-1 dose vs. > 2 doses of IPTp-SP 
(continued) 
 
  
 Characteristics at enrolment 
Doses of SP received – number (%)* 
P-value 
0-1 dose (n = 126) > 2 doses(n = 590) 
Experienced miscarriage before 0.869 
No 86 (86.9) 371 (87.3)  
Yes 13 (13.1) 54 (12.7)  
None reported by primigravidae 27  165   
Delivered a premature baby before 1.000 
No 94 (94.9) 401 (94.4)  
Yes 5 (5.1) 24 (5.6)  
Not applicable to primigravidae 27  165   
Delivered a stillborn before 0.307 
No 94 (94.9) 387 (91.1)  
Yes 5 (5.1) 38 (8.9)  
Not applicable to primigravidae 27  165   
HIV status 0.186 
Negative 105 (83.3) 519 (88.0)  
Positive 21 (16.7) 71 (12.0)  
Malaria and curable STIs/RTIs  
Malaria (PCR diagnosis) 62 (49.2) 346 (59.3) 0.047 
Syphilis (high titre) 1 (0.8) 17 (2.9) 0.223 
Neisseria gonorrhoeae 1 (0.8) 21 (3.6) 0.152 
Chlamydia trachomatis 8 (6.3) 26 (4.4) 0.357 
Trichomonas vaginalis 30 (23.8) 140 (23.7) 1.000 
Bacterial vaginosis 59 (46.8) 277 (46.9) 1.000 
 
* Age is shown as the median value with the interquartile range in parentheses.  P-values 
are from Wilcoxon rank sum test (continuous variables) or Fisher's exact test (categorical 
variables). PCR = polymerase chain reaction 
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Table 3.7 Participant characteristics at delivery: 0-1 dose vs. > 2 doses of IPTp-SP 
 
 
  
 Characteristics at delivery 
Doses of SP received – number (%)* 
 P-value 
0 - 1 dose (n = 126) > 2 doses (n = 590) 
Place of delivery  0.233 
Hospital 119 (94.4) 551 (93.4)   
Clinic 1 (0.8) 19 (3.2)   
Home 6 (4.8) 20 (3.4)   
Delivery performed by  0.240 
Doctor 3 (2.4) 38 (6.4)  
Midwife 115 (91.3) 524 (88.8)  
Family member 5 (4.0) 17 (2.9)  
Other 3 (2.4) 11 (1.9)  
Type of labour  0.296 
Spontaneous 126 (100.0) 558 (97.4)  
Induced 0 (0.0) 9 (1.6)  
Augmented 0 (0.0) 6 (1.0)  
Type of delivery  0.092 
Vaginal 123 (97.6) 551 (93.4)  
C-section 3 (2.4) 39 (6.6)  
Hypertension  0.296 
No 110 (96.5) 506 (98.1)   
Yes 4 (3.5) 10 (1.9)   
Maternal haemoglobin   0.786 
Normal 103 (85.1) 470 (83.5)   
Anaemic 18 (14.9) 93 (16.5)   
Sex of baby         0.008 
Female 78 (61.9) 287 (48.6)  
Male 48 (38.1) 303 (51.4)  
Received curative treatment for malaria infection  0.102 
No 115 (92.0) 508 (86.4)  
Yes 10 (8.0) 80 (13.6)  
Received curative treatment for any STI/RTI 1.000 
Untreated 116 (92.1) 540 (91.5)   
Treated 10 (7.9) 50 (8.5)   
 
* Age is shown as the median value with the interquartile range in parentheses.  P-values are from 
Wilcoxon rank sum test (continuous variables) or Fisher's exact test (categorical variables). PCR = 
polymerase chain reaction 
101 
 
Table 3.8 Participant characteristics at enrolment: 2 doses vs. > 3 doses of IPTp-SP 
 
 
 
 
Characteristics at enrolment 
Doses of SP received – number (%) 
 P-value 
2 doses (n = 310) > 3 doses (n = 280) 
Age of participants  0.521 
Mean (SD)* 25.6 (6.4) 25.2 (6.4)  
Median (IQR)* 25.0 (20.0, 30.0) 24.0 (20.0, 30.0)  
Marital status  0.479 
Single 61 (19.7) 62 (22.1)  
Married, divorced/separated or widowed 249 (80.3) 218 (77.9)  
Age at sexual debut   0.328 
 < 15 years of age 21 (6.8) 28 (10.0)  
> 15 years of age 241 (77.7) 214 (76.4)  
Unknown 48 (15.5) 38 (13.6)  
Number of lifetime sexual partners 0.460 
1 partner 150 (49.0) 122 (43.9)  
2 partners 83 (27.1) 78 (28.1)  
3 partners 48 (15.7) 46 (16.5)  
4 or more partners 25 (8.2) 32 (11.5)  
Gravidae 0.936 
Primigravidae 86 (27.7) 79 (28.2)  
Secundigravidae 42 (13.5) 35 (12.5)  
Multigravidae 182 (58.7) 166 (59.3)  
Wealth Quintiles 0.379 
Lowest 68 (21.9) 47 (16.8)  
Second 58 (18.7) 53 (18.9)  
Middle 59 (19.0) 54 (19.3)  
Fourth 56 (18.1) 66 (23.6)  
Highest 69 (22.3) 60 (21.4)  
Bed net ownership 0.564 
No 160 (51.6) 137 (48.9)  
Yes 150 (48.4) 143 (51.1)  
Used insecticide treated net on previous night 0.932 
No 193 (62.7) 173 (62.0)  
Yes 115 (37.3) 106 (38.0)  
Missing 2   1    
Indoor residual spraying in the previous 12 months 0.002 
No 247 (82.9) 192 (71.6)   
Yes 51 (17.1) 76 (28.4)   
Missing 12   12     
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Table 3.8 Participant characteristics at enrolment: 2 doses vs. > 3 doses of IPTp-SP 
(continued) 
 
  
Characteristics at enrolment 
Doses of SP received – number (%) 
 P-value 
2 doses (n = 310) > 3 doses (n = 280) 
Experienced miscarriage before 0.470 
No 193 (86.2) 178 (88.6)  
Yes 31 (13.8) 23 (11.4)  
None reported by primigravidae 86   79    
Delivered a premature baby before 0.297 
No 214 (95.5) 187 (93.0)  
Yes 10 (4.5) 14 (7.0)  
Not applicable to primigravidae 86   79    
Delivered a stillborn before 0.737 
No 205 (91.5) 182 (90.5)  
Yes 19 (8.5) 19 (9.5)  
Not applicable to primigravidae 86   79    
HIV status 0.528 
Negative 270 (87.1) 249 (88.9)  
Positive 40 (12.9) 31 (11.1)  
Malaria and curable STIs/RTIs  
Malaria (PCR diagnosis) 171 (56.1) 175 (62.9) 0.092 
Syphilis (high titre) 7 (2.3) 10 (3.6) 0.462 
Neisseria gonorrhoeae 15 (4.8) 6 (2.1) 0.117 
Chlamydia trachomatis 16 (5.2) 10 (3.6) 0.423 
Trichomonas vaginalis 73 (23.5) 67 (23.9) 0.923 
Bacterial vaginosis 145 (46.8) 132 (47.1) 0.934 
 
* Age is shown as the median value with the interquartile range in parentheses.  P-values are from 
Wilcoxon rank sum test (continuous variables) or Fisher's exact test (categorical variables). PCR = 
polymerase chain reaction 
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Table 3.9 Participant characteristics at delivery: 2 doses vs. > 3 doses of IPTp-SP 
 
Characteristics at enrolment 
Doses of SP received – number (%) 
 P-value 
2 doses (n = 310) > 3 doses (n = 280) 
Place of delivery  0.418 
Hospital 292 (94.2) 259 (92.5)  
Clinic 7 (2.3) 12 (4.3)  
Home 11 (3.5) 9 (3.2)  
Delivery performed by  0.782 
Doctor 20 (6.5) 18 (6.4)  
Midwife 277 (89.4) 247 (88.2)  
Family member 9 (2.9) 8 (2.9)  
Other 4 (1.3) 7 (2.5)  
Type of labour  0.920 
Spontaneous 292 (97.7) 266 (97.1)  
Induced 4 (1.3) 5 (1.8)  
Augmented 3 (1.0) 3 (1.1)  
Type of delivery  0.870 
Vaginal 290 (93.5) 261 (93.2)  
C-section 20 (6.5) 19 (6.8)  
Hypertension   0.198 
   No 276 (98.9) 230 (97.0)  
   Yes 3 (1.1) 7 (3.0)  
Maternal haemoglobin          0.429 
   Normal 249 (84.7) 221 (82.2)  
   Anaemic 45 (15.3) 48 (17.8)  
Sex of baby         1.000 
Female 151 (48.7) 136 (48.6)  
Male 159 (51.3) 144 (51.4)  
Received curative treatment for malaria infection  0.810 
No 269 (86.8) 239 (86.0)  
Yes 41 (13.2) 39 (14.0)  
Received curative treatment for any STI/RTI 0.038 
Untreated 291 (93.9) 249 (88.9)   
Treated 19 (6.1) 31 (11.1)   
 
* Age is shown as the median value with the interquartile range in parentheses. P-values are from 
Wilcoxon rank sum test (continuous variables) or Fisher's exact test (categorical variables). PCR = 
polymerase chain reaction 
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Table 3.10 Adverse birth outcomes: 0-1 dose vs. 2 doses vs. > 3 doses of IPTp-SP 
 
  
Birth 
outcome 
No. 
women 
Outcomes 
Unadjusted 
OR 
95% CI 
Adjusted 
OR1 
95% CI P-value2 
Any adverse outcome 
0-1 dose 126 58 1.00  1.00  0.002 
2 doses 310 108 0.63 0.41, 0.96 0.55 0.36, 0.86  
> 3 doses 280 84 0.50 0.33, 0.78 0.43 0.27, 0.68  
Stillbirth 
0-1 dose 126 4 1.00  1.00  0.143 
2 doses 310 2 0.20 0.04, 1.10 0.21 0.04, 1.19  
> 3 doses 280 6 0.67 0.19, 2.41 0.68 0.18, 2.57  
Low birth weight 
0-1 dose 126 32 1.00  1.00  0.261 
2 doses 310 67 0.80 0.49, 1.30 0.71 0.42, 1.19 
 
> 3 doses 280 57 0.74 0.45, 1.22 0.64 0.37, 1.09  
Preterm delivery 
0-1 dose 126 50 1.00  1.00  <0.001 
2 doses 310 71 0.45 0.29, 0.71 0.42 0.27, 0.67 
 
> 3 doses 280 37 0.23 0.14, 0.38 0.21 0.13, 0.35  
Intrauterine growth retardation 
0-1 dose 126 7 1.00  1.00  0.318 
2 doses 310 34 1.64 0.70, 3.87 1.55 0.64, 3.77 
 
> 3 doses 280 43 2.12 0.91, 4.93 1.88 0.78, 4.54  
 
IPTp-SP = Intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine; CI = 
Confidence Interval; OR = Odds Ratio 
1Adjusted for sexually transmitted and reproductive tract co-infection, gravidae and HIV co-infection. 
2P-value for likelihood ratio test 
Note: Confidence intervals that do not overlap the null value of OR = 1 are shown in bold. 
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Women who had malaria only at enrolment and received > 2 doses of versus 0-1, had 
76% lower odds of any adverse birth outcome (OR, 0.24; 95% 0.09, 0.66).  Similarly, 
women who had Neisseria gonorrhoeae and/or Chlamydia trachomatis at enrolment 
and received > 2 doses of versus 0-1, had 92% lower odds of any adverse birth outcome 
(OR, 0.08; 95% CI, 0.01, 0.64).  Participants with neither a malaria infection nor STIs/RTIs 
and who received > 2 doses, rather than 0-1 dose, had 73% fewer adverse birth 
outcomes (OR 0.27; 95% CI 0.11, 0.68).  Similarly, women with no malaria infection nor 
STIs/RTIs and who received > 2 doses had the odds of LBW reduced by 76% (OR 0.24; 
95% CI 0.08, 0.68).   
Women who had malaria only at enrolment and received > 2 doses of versus 0-1, had 
81% lower odds of preterm birth (OR,0.19; 95% CI, 0.07, 0.53); women who had malaria 
plus T. vaginalis and/or bacterial vaginosis at enrolment and received > 2 doses of 
versus 0-1, had 55% lower odds of preterm birth (OR, 0.45; 95% CI, 0.21, 0.97); women 
who had N. gonorrhoeae or C. trachomatis at enrolment and received > 2 doses of 
versus 0-1, had 93% lower odds of preterm birth (OR, 0.07; 95% CI, 0.01, 0.73); finally, 
women who had neither malaria nor any curable STI/RTI at enrolment and received > 2 
doses of versus 0-1, had 80% lower odds of preterm birth (OR, 0.20; 95% CI, 0.07, 0.54).   
 
Although less dramatic, analyses of > 3 doses versus 2 doses suggest that this dose-
response effect continued as shown in Table 3.11.  There appeared to be a trend of 
protection in 17 of 31 infection categories conferred by > 3 doses verse 2 doses.  This 
protection, however, was only significant in two infection categories in Table 3.12.  
Women who had malaria plus T. vaginalis and/or bacterial vaginosis at enrolment and 
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received ≥3 doses vs 2 doses had 67% lower odds of preterm birth (OR, 0.33; 95% CI, 
0.15, 0.73); women who had T. vaginalis and/or bacterial vaginosis at enrolment and 
received ≥3 doses vs 2 doses had 66% lower odds of preterm birth (OR, 0.34; 95% CI, 
0.13, 0.94). 
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Table 3.11 Infections and adverse birth outcomes: 0-1 doses vs. > 2 doses IPTp-SP 
 
Adverse birth outcomes 
   Categories of maternal infection 
0-1 dose IPTp-SP > 2 doses IPTp-SP 
Crude 
OR 
95% CI 
Adjusted 
OR1 
95% CI No. 
women 
No. 
outcomes 
No. 
women 
No. 
outcomes 
Any adverse outcome   
   Malaria only 20 13 129 41 0.25 0.09, 0.88 0.24 0.09, 0.66 
   Malaria and NG and/or CT 3 1 27 11 1.38 0.11, 17.09 1.17 0.09, 15.89 
   Malaria and TV and/or BV 38 15 182 67 0.89 0.44, 1.83 0.96 0.45, 2.02 
   Syphilis and any other infection(s) 1 1 17 7 0.80 0.00, 31.20 0.80 0.00, 31.20 
   NG and/or CT only 6 4 14 2 0.08 0.01, 0.80 0.08 0.01, 0.64 
TV and/or BV only 32 12 124 42 0.85 0.38, 1.91 0.72 0.32, 1.65 
No identified infection 26 12 97 22 0.34 0.14, 0.85 0.27 0.11, 0.68 
Stillbirth   
Malaria only 20 1 129 1 0.15 0.01, 2.54 0.15 0.01, 2.54 
Malaria and NG and/or CT 3 0 27 0 NA NA NA NA 
Malaria and TV and/or BV 38 0 182 3 0.81 0.09, Inf 0.81 0.09, Inf 
   Syphilis and any other infection(s) 1 1 17 0 0.06 0.00, 2.29 0.06 0.00, 2.29 
NG and/or CT only 6 0 14 0 NA NA NA NA 
TV and/or BV only 32 1 124 3 0.76 0.07, 7.86 0.76 0.07, 7.86 
No identified infection 26 1 97 1 0.26 0.02, 4.31 0.22 0.01, 3.79 
Low birth weight   
Malaria only 20 6 129 25 0.56 0.20, 1.60 0.59 0.19, 1.82 
Malaria and NG and/or CT 3 1 27 7 0.7 0.05, 8.97 0.49 0.03, 7.35 
Malaria and TV and/or BV 38 10 182 46 0.95 0.43, 2.10 1.08 0.46, 2.54 
Syphilis and any other infection(s) 1 0 17 5 NA NA NA NA 
NG and/or CT only 6 2 14 1 0.15 0.01, 2.18 0.12 0.01, 1.90 
TV and/or BV only 32 5 124 27 1.5 0.53, 4.27 1.22 0.41, 3.59 
No identified infection 26 8 97 13 0.35 0.13, 0.96 0.24 0.08, 0.68 
 
 
108 
 
Table 3.11 Infections and adverse birth outcomes: 0-1 doses vs. > 2 doses IPTp-SP (continued) 
 
  
Adverse birth outcomes 
   Categories of maternal infection 
0-1 dose IPTp-SP > 2 doses IPTp-SP 
Crude 
OR 
95% CI 
Adjusted 
OR1 
95% CI No. 
outcomes 
No. 
women 
No. 
outcomes 
No. 
outcomes 
Preterm delivery   
Malaria only 20 10 129 21 0.19 0.07, 0.53 0.19 0.07, 0.53 
Malaria and NG and/or CT 3 0 27 6 NA NA NA NA 
Malaria and TV and/or BV 38 14 182 37 0.44 0.21, 0.93 0.45 0.21, 0.97 
Syphilis and any other infection(s) 1 1 17 5 0.50 0.00, 19.50 0.50 0.00, 19.50 
NG and/or CT only 6 4 14 2 0.08 0.01, 0.80 0.07 0.01, 0.73 
TV and/or BV only 32 11 124 25 0.48 0.21, 1.13 0.43 0.18, 1.03 
No identified infection 26 10 97 12 0.23 0.08, 0.61 0.20 0.07, 0.54 
Intrauterine growth retardation   
Malaria only 20 2 129 18 0.8 0.16, 4.08 0.75 0.14, 4.05 
Malaria and NG and/or CT 3 1 27 5 0.62 0.05, 8.43 0.54 0.03, 8.43 
Malaria and TV and/or BV 38 1 182 27 5.35 0.69, 41.40 6.11 0.76, 49.13 
Syphilis and any other infection(s) 1 0 17 2 NA NA NA NA 
NG and/or CT only 6 0 14 0 NA NA NA NA 
TV and/or BV only 32 1 124 16 3.81 0.48, 30.44 3.13 0.38, 25.68 
No identified infection 26 2 97 9 0.83 0.16, 4.25 0.66 0.12, 3.57 
 
IPTp-SP = intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine; CI = Confidence Interval; OR = Odds Ratio; NG = Neisseria 
gonorrhoeae; CT = Chlamydia trachomatis; TV = Trichomonas vaginalis; BV = bacterial vaginosis; N/A = not applicable is used where there are no observations in the 
reference group (0-1 doses); Inf. = infinity is used where the sub-sample of outcomes observed is too small to produce an outer limit with certainty. 
1Adjusted for sexually transmitted and reproductive tract co-infection, gravidae and HIV co-infection. 
2Syphilis and any other infection(s) refers to any other curable sexually transmitted or reproductive tract infection and/or malaria 
Notes: (1) Confidence intervals that do not overlap the null value of OR = 1 are shown in bold; (2) Syphilis and co-infection describes pregnant women who tested 
positive for syphilis using rapid plasma regain assays and were also infected with malaria and/or another curable STI/RTI. 
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Table 3.12 Infections and adverse birth outcomes: 2 doses vs. > 3 doses IPTp-SP 
 
Adverse birth outcomes 
Categories of maternal infection 
2 doses IPTp-SP > 3 doses IPTp-SP 
 Crude 
OR 
 95% CI 
Adjusted 
OR1 
95% CI No. 
women 
No. 
outcomes 
No. 
women 
No. 
outcomes 
Any adverse outcome   
   Malaria only 66 23 63 18 0.75 0.35, 1.58  0.72 0.33, 1.56 
   Malaria and NG and/or CT 18 7 9 4 1.26 0.25, 6.36  0.93 0.17, 5.16 
   Malaria and TV and/or BV 86 36 96 31 0.66 0.36, 1.21  0.66 0.35, 1.24 
   Syphilis and any other infection(s) 7 3 10 4 0.89 0.13, 6.31  0.5 0.07, 3.72 
   NG and/or CT only 12 1 2 1 11 0.35, 345.05  16.39 0.50, 541.53 
TV and/or BV only 71 27 53 15 0.64  0.30, 1.38  0.64 0.29, 1.41 
No identified infection 50 11 47 11 1.08 0.42, 2.80  1.28 0.48, 3.43 
Stillbirth   
Malaria only 66 1 63 0 1.03 0.00, 40.32 1.03 0.00, 40.32 
Malaria and NG and/or CT 18 0 9 0 N/A - N/A - 
Malaria and TV and/or BV 86 1 96 2 1.81 0.09, 107.93 1.81 0.09, 107.93 
   Syphilis and any other infection(s) 7 0 10 0 N/A - N/A - 
NG and/or CT only 12 0 2 0 N/A - N/A - 
TV and/or BV only 71 0 53 3 5.32 0.56, Inf 5.32 0.56, Inf 
No identified infection 50 0 47 1 1.81 0.16, 20.30 2.18 0.19, 25.65 
Low birth weight   
Malaria only 66 14 63 11 0.79 0.33, 1.89 0.74 0.30, 1.86 
Malaria and NG and/or CT 18 5 9 2 0.74 0.11, 4.87 0.49 0.07, 3.62 
Malaria and TV and/or BV 86 23 96 23 0.86 0.44, 1.68 0.91 0.45, 1.86 
Syphilis and any other infection(s) 7 2 10 3 1.07 0.13, 8.98 0.53 0.06, 4.87 
NG and/or CT only 12 1 2 0 6.00 0.00, 234 6.00 0.00, 234 
TV and/or BV only 71 16 53 11 0.90 0.38, 2.14 0.90 0.38, 2.14 
No identified infection 50 6 47 7 1.28 0.40, 4.14 1.59 0.47, 5.40 
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Table 3.12 Infections and adverse birth outcomes: 2 doses vs. > 3 doses IPTp-SP (continued) 
Adverse birth outcomes 
Categories of maternal infection 
2 doses IPTp-SP > 3 doses IPTp-SP 
Crude 
OR 
95% CI 
Adjusted 
OR1 
95% CI No. 
women 
No. 
outcomes 
No. 
women 
No. 
outcomes 
Preterm delivery   
Malaria only 66 13 63 8 0.59 0.23, 1.55 0.59 0.22, 1.54 
Malaria and NG and/or CT 18 4 9 2 1.00 0.15, 6.85 0.83 0.12, 5.82 
Malaria and TV and/or BV 86 25 96 12 0.34 0.16, 0.74 0.33 0.15, 0.73 
Syphilis and any other infection(s) 7 3 10 2 0.33 0.04, 2.87 0.23 0.03, 2.06 
NG and/or CT only 12 1 2 1 11 0.35, 345.06 14.4 0.45, 463.93 
TV and/or BV only 71 19 53 6 0.35 0.13, 0.95 0.34 0.13, 0.94 
No identified infection 50 6 47 6 1.07 0.32, 3.59 1.19 0.35, 4.03 
Intrauterine growth retardation   
Malaria only 66 9 63 9 0.96 0.35, 2.63 1.01 0.35, 2.89 
Malaria and NG and/or CT 18 3 9 2 1.47 0.18, 11.72 0.64 0.07, 5.74 
Malaria and TV and/or BV 86 9 96 18 1.52 0.63, 3.65 1.54 0.61, 3.88 
Syphilis and any other infection(s) 7 0 10 2 1.31 0.09, Inf 1.31 0.09, Inf 
NG and/or CT only 12 0 2 0 N/A - N/A - 
TV and/or BV only 71 8 53 8 1.15 0.40, 3.36 1.28 0.42, 3.89 
No identified infection 50 5 47 4 0.84 0.21, 3.38 0.88 0.21, 3.70 
 
IPTp-SP = intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine; CI = Confidence Interval; OR = Odds Ratio; NG = Neisseria 
gonorrhoeae; CT = Chlamydia trachomatis; TV = Trichomonas vaginalis; BV = bacterial vaginosis; N/A = not applicable is used where there are no observations in the 
reference group (0-1 doses); Inf. = infinity is used where the sub-sample of outcomes observed is too small to produce an outer limit with certainty. 
1Adjusted for sexually transmitted and reproductive tract co-infection, gravidae and HIV co-infection. 
2Syphilis and any other infection(s) refers to any other curable sexually transmitted or reproductive tract infection and/or malaria 
Notes: (1) Confidence intervals that do not overlap the null value of OR = 1 are shown in bold; (2) Syphilis and co-infection describes pregnant women who tested 
positive for syphilis using rapid plasma regain assays and were also infected with malaria and/or another curable STI/RTI. 
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Discussion  
For more than a decade, members of the malaria in pregnancy research community 
have attempted to identify safe alternatives to SP for use in IPTp because of known 
parasite resistance to the therapy.  Several factors have complicated this task including 
the provision of ITNs to pregnant women as never before that have altered 
transmission dynamics.  Evidence from Zambia – suggesting that IPTp-SP protects 
against adverse birth outcomes among women with malaria as well as curable 
STIs/RTIs – may help to explain why clinical trials to date have not yielded a clear 
superior alternative to SP.   
  
One of the most interesting findings in this analysis was that women who received > 2 
doses and had neither malaria nor curable STIs/RTIs were more protected against any 
adverse birth outcome, LBW, and preterm delivery, compared to recipients of 0-1 
dose.  No additional benefit was conferred against non-malaria and non-STI/RTI causes 
of adverse birth outcomes when > 3 doses were administered in this setting.   
 
Although there were no statistically significant differences across IPTp-SP exposure 
groups in the baseline characteristics specific to malaria infection and curable 
STIs/RTIs, there were a few notable imbalances in sub-groups.  Confounding, however, 
is not inherently produced by imbalances in size of groups.  Rather, confounding is 
determined by comparing the difference between crude odds ratios and adjusted odds 
ratios specific to a variable of interest.206  In this way, three confounders were 
identified in three analyses, one in each:  
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(i) Hypertension at enrolment or delivery (change in crude OR = 13.39%) in the 
stillbirth analysis of Table 3.2 (pages 88-89);  
(ii) Prior preterm birth (change in crude OR = 14.04%) in the preterm delivery 
analysis of Table 3.4 (pages 92-93); and  
(iii) Prior miscarriage (change in crude OR = 25.73%) in the intrauterine growth 
retardation analysis of Table 3.5 (pages 94-95). 
Amongst women given 0-1 dose versus > 2 dose in Table 3.6, there were three 
statistically significant differences in group size: the wealth quintiles (P = 0.048), (ii) sex 
of the baby (P = 0.008), and (iii) malaria infection (P = 0.047).  The differences in 
wealth quintiles may not have had a consequential effect on outcomes because, upon 
closer review of the individual quintiles, the imbalance appears to have straddled the 
two exposure groups.  The lowest (poorest) quintile had proportionately more women 
in the > 2 dose-group; the second and third wealth quintiles had more women from 
the 0-1 dose-group; the fourth wealth quintile had more women from the > 2 dose-
group; and the highest (wealthiest) quintile has near equivalent representation from 
the two dose-groups.  Another difference was that fewer males, compared to females, 
were in the 0-1 dose exposure group, 38.1% (n = 48) to 61.9% (n = 78), respectively, 
relative to 51.4% (n = 303) males and 48.6% (n = 287) females born to mothers who 
received > 2 doses.  However, this difference in the 0-1 dose-group did not influence 
the overall protective effect of IPTp-SP.   
As for malaria infection at enrolment, 10% more women were parasitaemic who went 
on to receive > 2 doses of IPTp-SP, compared to recipients of 0-1 dose (59.3% [n = 346] 
versus 49.2% [n = 62]; (P = 0.047).  This finding, interestingly, reflects the epidemiology 
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of malaria during pregnancy.  Amongst women enrolled between 8 and 13 gestational 
weeks, 36.1% (95% CI: 22.5, 52.5) had peripheral parasitaemia.  These same women 
went onto receive a mean of 2.6 doses of IPTp-SP over the course of their pregnancies.  
However, peripheral malaria was lower, 33.5% (95% CI: 29.1, 38.3), amongst 
participants who were enrolled between 14 and 20 gestational weeks and 
subsequently received a mean of 2.4 doses of IPTp-SP during their pregnancies.  These 
two trends of parasitaemia and the number of IPTp-SP doses continued downward 
amongst women who were between 21 and 26 gestational weeks, and 27 to 31 
gestational weeks, at their time of enrolment.  Peripheral parasitaemia was 31.7% 
(95% CI: 27.5, 36.2) and 27.6% (95% CI: 21.9, 34.2), and the mean number of IPTp-SP 
doses administered until delivery was 2.2 and 1.8, respectively.  In this analysis, 
parasite load was highest amongst women enrolled in gestational week 15 with a 
mean density of 4,752 parasites per microliter of blood.  The peak parasite density 
observed was consistent with the known epidemiology of malaria infection during 
pregnancy.  Prior reports suggest that peripheral parasitaemia peaks between weeks 
nine and 16, and tapers to term.160,169  Thus, pregnant women who sought ANC 
services earlier in pregnancy were more likely to have a malaria infection and they 
were also more likely to receive more doses of IPTp-SP during pregnancy for having 
engaged the health system earlier in pregnancy. 
 
The last notable imbalance was in the proportion of pregnant women from households 
where indoor residual spraying had been applied in the previous 12 months (P-value = 
0.002); 17.1% (n = 51) of women in the 2-dose group compared to 28.4% (n = 76) in 
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the > 3-dose group.  Indoor residual spraying has reduced the incidence of infections 
by 54% over an 11–month period amongst children under the age of five in an area of 
stable transmission.207  Despite evidence of protection conferred by household 
spraying, the pregnant women resident in homes that had been sprayed and who 
went on to receive > 3 doses of IPTp-SP had higher levels of parasitaemia at booking, 
62.9% (n = 175), compared to women in the 2-dose group, 56.1% (n = 171), as 
measured by polymerase chain reaction.   
 
Observations from this analysis are biologically plausible and compelling.  Arguably, 
because only six women of the 126 in the 0-1 dose-group received no doses in study, 
the actual protective effect of IPTp-SP against malaria and curable STIs/RTIs is likely 
higher than observed levels.  It is worth noting that the number of ANC visits were not 
included in the survey and, therefore, could not be controlled for in this 
analysis.  Being the case, it is difficult to draw inferences related to a general ANC visit 
effect.  With that said, there was no apparent confounding across treatment groups in 
three key variables that reflect use of ANC services: (1) STI/RTI treatment during 
pregnancy; (2) antibiotic treatment during the pregnancy; and (3) malaria treatment 
during the pregnancy.   
Results from Zambia are insufficient to make broader policy or programmatic 
decisions.  Curable STIs/RTIs were just measured once at booking; there was no test of 
cure.  Some curable STIs/RTIs can be self-limiting which could, in part, explain 
observations.  Thus, until a candidate replacement for SP has been able to 
demonstrate superior protection against malaria infection and curable STIs/RTIs, and 
attributable adverse birth outcomes, policymakers and programme managers should 
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continue to champion the scale up IPTp-SP as part of the ANC package.  Moreover, it is 
difficult to separate the protective effect of IPTp-SP attributable to malaria versus 
curable STIs/RTIs in the absence of continuous parasite sampling throughout 
pregnancy.  It is possible that many women were exposed to malaria infection 
repeatedly during pregnancy, irrespective of their STI/RTI status, and that the benefits 
of receiving more doses of IPTp-SP translated into having greater protection against 
the effects of malaria in pregnancy than curable STIs/RTIs.  Repeated malaria infection 
may also help to explain the dose-response protective effect of IPTp-SP against 
adverse birth outcomes observed amongst pregnant women who had neither malaria 
infection nor STIs/RTIs at enrolment.  These women could have been infected by 
malaria parasites later in pregnancy, but were protected against adverse birth 
outcomes attributable to malaria if they received more doses of IPTp-SP compared to 
fewer doses.       
 
Q 4.  Prevalence of malaria and curable STIs/RTIs in pregnancy 
Methods 
Surprisingly, the prevalence of malaria infection amongst pregnant women in sub-
Saharan Africa has not been estimated recently.  Brabin et al. summarised malaria 
infection data prior to 1980160 and Steketee et al. published a review of data from 20 
studies across eight countries conducted between 1985 and 2000.18  Neither review 
contains data from 2000 onward, nor applied the PRISMA guidelines (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) that were published in 
2009 to create standard methods for systematic reviews.167  There does not appear to 
have been any prior attempt to calculate pooled prevalence estimates for curable 
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STIs/RTIs amongst pregnant women in sub-Saharan Africa.  Thus, a systematic review 
was conducted of malaria infection and curable STIs/RTIs amongst pregnant women 
attending ANC facilities from 1990 to 2011 in sub-Saharan Africa using medical subject 
headings and free text terms shown in Table 4.a.  Databases included PubMed, 
Medline, and EMBASE, as well as the WHO International Clinical Trials Registry and 
reference lists from the identified publications.   
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Table 4.a Medical subject headings and free text terms 
 
 
Infection Medical search headings  Free text terms 
Syphilis Treponema pallidum OR 
Syphilis AND “Pregnant 
Women” AND “Africa 
South of the Sahara" 
Topic=(“Syphilis” OR “Treponema pallidum”) 
AND Topic=(Prenatal OR Antenatal OR Pregnant 
or Pregnancy) OR Topic=(women) AND 
Topic=(Africa) 
Treponema pallidum AND Pregnant AND Africa  
Treponema pallidum AND Pregnancy AND Africa 
Syphilis AND Pregnant AND Africa 
Syphilis AND Pregnancy AND Africa 
Screen AND Syphilis AND Pregnant AND Africa 
Screen AND Syphilis AND Pregnancy AND Africa 
Test AND Syphilis AND Pregnant AND Africa 
Test AND Syphilis AND Pregnancy AND Africa 
Neisseria 
gonorrhoeae 
Neisseria gonorrhoeae OR 
Gonorrhea OR 
Gonorrhoea AND 
Pregnant Women AND 
“Africa South of the 
Sahara” 
Topic=("Neisseria gonorrhoeae") OR 
Topic=(Gonorrhea) OR Topic=(Gonorrhoea) 
AND Topic= (Prenatal OR Antenatal OR 
Pregnant OR Pregnancy) OR Topic=(women) 
AND Topic=(Africa) 
Neisseria gonorrhoeae AND Pregnant AND Africa 
Neisseria gonorrhoeae AND Pregnancy AND Africa 
Gonorrhoea AND Pregnant AND Africa 
Gonorrhoea AND Pregnancy AND Africa 
Gonorrhea AND Pregnant AND Africa 
Gonorrhea AND Pregnancy AND Africa 
Screen AND Gonorrhea AND Pregnant AND Africa 
Screen AND Gonorrhoea AND Pregnant AND Africa 
Test AND Gonorrhea AND Pregnant AND Africa 
Test AND Gonorrhoea AND Pregnant AND Africa 
Chlamydia 
trachomatis 
Chlamydia trachomatis 
AND Pregnant Women 
AND "Africa South of the 
Sahara" 
Topic=(“Chlamydia”) AND Topic= (trachomatis) 
AND Topic=(Prenatal OR Antenatal OR Pregnant 
OR Pregnancy) OR Topic=(women) AND 
Topic=(Africa) 
Chlamydia trachomatis AND Pregnant AND Africa 
Chlamydia trachomatis AND Pregnancy AND Africa 
Chlamydia AND Pregnant AND Africa 
Chlamydia AND Pregnancy AND Africa 
Screen AND Chlamydia AND Pregnant AND Africa 
Screen AND Chlamydia AND Pregnancy AND Africa 
Test AND Chlamydia AND Pregnant AND Africa 
Test AND Chlamydia AND Pregnancy AND Africa 
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Table 4. Medical subject headings and free text terms (continued) 
Infection Medical search headings  Free text terms Infection 
Trichomonas 
vaginalis 
Trichomonas vaginalis 
AND Pregnant Women 
AND "Africa South of the 
Sahara" 
Topic=("Trichomonas vaginalis OR 
Trichomoniasis")  
AND Topic=(Prenatal OR Antenatal OR Pregnant 
OR Pregnancy) OR Topic=(women) AND 
Topic=(Africa) 
Trichomonas vaginalis AND Pregnant AND Africa 
Trichomonas vaginalis AND Pregnancy AND Africa 
Trichomoniasis AND Pregnant AND Africa 
Trichomoniasis AND Pregnancy AND Africa 
Screen AND Trichomoniasis AND Pregnant AND Africa 
Screen AND Trichomoniasis AND Pregnancy AND Africa 
Test AND Trichomoniasis AND Pregnant AND Africa 
Test AND Trichomoniasis AND Pregnancy AND Africa 
Bacterial 
vaginosis 
Bacterial vaginosis AND 
Pregnant Women AND 
"Africa South of the 
Sahara" 
Topic=("Bacterial vaginosis") AND 
Topic=(Prenatal OR Antenatal OR Pregnant OR 
Pregnancy OR Pregnant) OR Topic=(women) 
AND Topic=(Africa) 
Bacterial vaginosis AND Pregnant AND Africa 
Bacterial vaginosis AND Pregnancy AND Africa 
Screen AND Bacterial vaginosis AND Pregnant AND Africa 
Screen AND Bacterial vaginosis AND Pregnancy AND Africa 
Test AND Bacterial vaginosis AND Pregnant AND Africa 
Test AND Bacterial vaginosis AND Pregnancy AND Africa 
Malaria Malaria AND  Pregnant 
Women AND "Africa 
South of the Sahara" 
Topic=("Malaria") AND Topic=(Prenatal OR 
Antenatal OR Pregnancy OR Pregnant) OR 
Topic=(women) AND Topic=(Africa) 
Malaria AND Pregnant AND Africa 
Malaria AND Pregnancy AND Africa 
Screen AND Malaria AND Pregnant AND Africa 
Screen AND Malaria AND Pregnancy AND Africa 
Test AND Malaria AND Pregnant AND Africa 
Test AND Malaria AND Pregnancy AND Africa 
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If two or more prevalence estimates had been reported – whether a study of 
comparative diagnostics, or use of the same diagnostic method on multiple occasions, 
or the subsequent use of a more sensitive assay – the higher/highest measurement 
was extracted.  Studies that selectively enrolled women were excluded, e.g. only 
pregnant women with HIV infection, studies of commercial sex workers, studies of 
women seeking treatment at STI and/or family planning facilities, or studies of non-
pregnant women tested in community-based surveys.  Prevalence estimates from 
these populations may overstate the burden of disease amongst pregnant women at 
ANC facilities.  Studies from South Africa were also excluded where malaria is no 
longer endemic, as well as multi-year studies that included pre-1990 data.  Records 
retrieved were all in English, although several abstracts had been translated from 
Chinese, Danish, Dutch, French, German, Italian, Portuguese and Swedish languages.  
Data were abstracted without blinding author names or publication titles.  Point 
prevalence estimates and 95% CIs were calculated for each study using the data that 
had been published.  Then a standard method for correcting errors of magnitude with 
the known sensitivity and specificity of individual assays was applied to increase the 
precision of each point prevalence estimate.208  This is done using the formula below:  
Corrected Prevalence = 
(Observed Prevalence+Specificity-1)
(Sensitivity+Specificity-1)
 
The corrected point prevalence data were then used to generate pooled prevalence 
estimates and corresponding 95% CIs.  Results were stratified by sub-region, East and 
Southern Africa versus West and Central Africa.   Sensitivity analyses were performed 
by dividing studies into two groups, those conducted from 1990 to 1999, and others 
from 2000 to 2011, to examine the potential for temporal changes in prevalence.   
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Results 
In total 171 studies met inclusion criteria, containing a total of 307 individual point 
prevalence estimates for analysis.  Search results are summarised in the PRISMA 
flowchart of Figure 4.1.  Funnel plot analysis suggested there was no evidence of 
publication bias amongst results for malaria or any of the curable STIs/RTIs.  Table 4.1 
summarises the pooled prevalence estimates of 1990-2011 and sub-analysis of data 
from 1990-1999 and 2000-2011.  Results that span the period 1990-2011 are 
presented in Figure 4.1a. and Figure 4.1b. plotted by sub-region along with the lowest 
and highest point estimates that were reported in the literature.  Sub-analysis by 
infection and sub-region are presented in Figures 4.2 to 4.8 with ‘a’ corresponding to 
data from East and Southern Africa and ‘b’ reflecting studies conducted in West and 
Central Africa.  Details of each study are presented in Tables 4.2 to 4.8 by infection.  In 
all instances, point prevalence estimates have been corrected to account for the 
variability of precision associated with each diagnostic method used.  The published 
sensitivity and specificity of these assays are summarised in Table 4.9.   
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Figure 4.1 PRISMA flowchart for systematic review 
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through other sources 
1,682 Duplicate records removed 
3,618 Records identified  
1,936 Records screened 
171 Articles met general inclusion criteria for meta-analysis 
1,484 Records excluded for not meeting 
inclusion criteria  
452 Full-text articles 
reviewed  
281 Full-text articles excluded 
197  Unrelated point estimates 
009  Ineligible country 
014  Same data published in two or more papers 
019  Some or all data prior to 1990 
042  Selective antenatal care facility enrolment 
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Table 4.1 Pooled curable STIs/RTIs and prevalence: sub-Saharan Africa 
 
 
1Note that dividing the total positive diagnoses by the total tested women does not account for diagnostic errors.  A standard method of correcting errors of known magnitude has been applied to these data 
based on the sensitivity and specificity of individual diagnostic tests.     
2The median number of women with a positive diagnosis. 
*Heterogeneity measure >97.0% 
  
Sub-region  
  Infection 
1990-2011 
Pooled mean 
prevalence 1 
95% CI 
No. of 
women 
positive  
No. of 
women 
tested 
Median 
positives 2 
Range of 
study sizes 
No. of 
countries 
No. of 
studies 
Range of ANC 
facilities  
(per study ) 
Heterogeneity 
East and Southern Africa 
  Syphilis 4.5 3.9, 5.1 8,346 136,686 54 85 – 52,405 11 41 1 – 57 * 
  Neisseria gonorrhoeae 3.7 2.8, 4.6 626 17,220 20 145 –  9,104 7 14 1 – 13 87.5% 
  Chlamydia trachomatis 6.9 5.1, 8.6 350 5,159 34 151 –  964 8 10 1 – 13 85.9% 
  Trichomonas vaginalis 29.1 20.9, 37.2 5,502 28,189 86 100 – 9,137 9 18 1 – 13 * 
  Bacterial vaginosis 50.8 43.3, 58.4 4,280 14,112 245 100 – 3,046 8 11 1 – 13 * 
  Peripheral parasitaemia 32.0 25.9, 38.0 11,688 47,443 195 86 – 5,093 8 35 1 – 10 * 
  Placental parasitaemia 25.8 19.7, 31.9 1,388 6,649 86 85 – 2,502 7 12 1 – 9 * 
West and Central Africa 
  Syphilis 3.5 1.8, 5.2 851 10,797 18 205 –  4,100 9 11 1 – 98 * 
  Neisseria gonorrhoeae 2.7 1.7, 3.7 73 2,737 17 230 –  1,160 8 5 1 – 4 67.2% 
  Chlamydia trachomatis 6.1 4.0, 8.3 357 5,414 35 261 –  1,160 8 10 1 – 4 94.7% 
  Trichomonas vaginalis 17.8 12.4, 23.1 822 9,806 57 86 – 2,657  7 12 1 – 4 * 
  Bacterial vaginosis 37.6 18.0, 57.2 1,208 7,435 138 350 – 2,657 6 7 1 – 3 * 
  Peripheral parasitaemia 38.2 32.3, 44.1 12,242 43,312 127 26 – 6,370 10 56 1 – 55 * 
  Placental parasitaemia 39.9 34.2, 45.7 4,658 27,535 168 36 – 8,310 8 23 1 – 6 * 
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Table 4.1 Pooled curable STIs/RTIs and prevalence: sub-Saharan Africa (continued) 
 
1Note that dividing the total positive diagnoses by the total tested women does not account for diagnostic errors.  A standard method of correcting errors of known magnitude has been applied to these data 
based on the sensitivity and specificity of individual diagnostic tests.      
2The median number of women with a positive diagnosis. 
*Heterogeneity measure >97.0% 
  
Sub-region  
  Infection 
1990-1999 
Pooled mean 
prevalence 1 
95% CI 
No. of 
women 
positive  
No. of 
women 
tested 
Median 
positives 2 
Range at 
study sizes 
No. of 
countries 
No. of 
studies 
Range of 
facilities  
(per study ) 
Heterogeneity 
East and Southern Africa 
  Syphilis 6.1 5.0, 7.2 6,168 97,055 79 85 – 52,405 8 21 1 – 23 * 
  Neisseria gonorrhoeae 3.7 2.7, 4.6 547 15,446 18 151 – 9,104 6 9 1 – 12 82.5% 
  Chlamydia trachomatis 9.4 6.0, 12.7 194 2,395 36 151 – 964 4 5 1 – 12 88.2% 
  Trichomonas vaginalis 32.8 18.6, 47.1 4,314 17,710 74 100 – 9,137 5 10 1 – 12 * 
  Bacterial vaginosis 51.5 35.5, 67.5 1,876 7,039 109 100 – 3,046 5 6 1 – 1 * 
  Peripheral parasitaemia 34.9 25.1, 44.7 7,563 29,068 327 102 – 5,093 7 16 1 – 10 * 
  Placental parasitaemia 25.2 16.0, 34.3 588 3,271 124 232 – 2,502 3 3 1 * 
West and Central Africa 
  Syphilis 3.8 1.5, 6.2 773 7,106 13 205 – 4,100  6 17 1 – 4  * 
  Neisseria gonorrhoeae 3.0 1.8, 4.2 70 2,507 18 350 – 1,160 7 4 1 – 4 67.2% 
  Chlamydia trachomatis 7.5 4.6, 10.0 339 4,632 44 350 – 1,160 7 5 1 – 4 94.7% 
  Trichomonas vaginalis 23.5 15.6, 31.5 721 4,585 73 86  – 1,160 6 8 1 – 4 * 
  Bacterial vaginosis 46.0 24.2, 67.8 640 2,645 132 350 – 646 5 5 1 – 3 * 
  Peripheral parasitaemia 43.4 34.1, 52.7 5,543 16,671 178 26 – 2,104 7 19 1 – 17 * 
  Placental parasitaemia 42.6 34.9, 50.3 2,445 19,582 233 64 – 8,310 6 9 1 – 2 * 
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Table 4.1 Pooled curable STIs/RTIs and prevalence: sub-Saharan Africa (continued) 
 
1Note that dividing the total positive diagnoses by the total tested women does not account for diagnostic errors.  A standard method of correcting errors of known magnitude has been applied to these data 
based on the sensitivity and specificity of individual diagnostic tests.      
2The median number of women with a positive diagnosis. 
3Not applicable as there is just one study 
*Heterogeneity measure >97.0% 
  
Sub-region  
  Infection 
2000-2011 
Pooled mean 
prevalence 1 
95% CI 
No. of 
women 
positive  
No. of 
women 
tested 
Median 
positives2 
Range at 
study sizes 
No. of 
countries 
No. of 
studies 
Range of 
facilities  
(per study ) 
Heterogeneity 
East and Southern Africa 
  Syphilis 2.9 2.1, 3.6 2,178 39,631 32 245  – 17,277 8 17 1 – 57 * 
  Neisseria gonorrhoeae 4.9 1.8, 7.9 79 1,774 21 145 – 835 6 4 1 – 13 91.9% 
  Chlamydia trachomatis 5.2 3.4, 7.1 156 2,764 25 151 – 835 6 5 1 – 13 79.6% 
  Trichomonas vaginalis 24.9 18.3, 31.5 1,188 10,479 98 151  – 2,917 8 8 1 – 13 * 
  Bacterial vaginosis 50.3 43.9, 56.7 2,404 7,073 253 247  – 2,555 6 5 1 – 13 * 
  Peripheral parasitaemia 29.5 22.4, 36.5 4,125 18,375 157 86 – 2,459 8 19 1 – 9 * 
  Placental parasitaemia 26.5 16.7, 36.4 800 3,378 58 85 – 726 3 9 1 – 9 * 
West and Central Africa 
  Syphilis 2.5 0.4, 4.6 78 3,691 21 230 – 2,133 4 5 1 – 98 88.6% 
  Neisseria gonorrhoeae 1.6 0.0, 3.3 3 230 3 230 3 1 1 – 1 NA3 
  Chlamydia trachomatis 1.9 0.2, 3.5 18 782 9 261 – 521 2 2 1 – 2 55.8% 
  Trichomonas vaginalis 4.5 2.5, 6.6 101 5,221 25 201 – 2,657 2 4 1 – 4 92.7% 
  Bacterial vaginosis 16.7 -12.6, 46.1 604 4,790 302 2,133 – 2,657 2 2 1 – 2 * 
  Peripheral parasitaemia 35.1 28.2, 41.9 6,699 26,641 97 38  – 6,370 8 36 1 – 55 * 
  Placental parasitaemia 38.0 28.4, 47.6 2,213 7,953 84 36 – 1,875 6 15 1 – 6 * 
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Figure 4.1a Curable STIs/RTIs and malaria infection: East and Southern Africa 
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Figure 4.1b Curable STIs/RTIs and malaria infection: West and Central Africa 
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Syphilis prevalence 
 
The pooled mean prevalence of syphilis in East and Southern Africa was 4.5% (95% CI: 
3.9, 5.1) as shown in Figure 4.2a with the highest estimate, 13.7% (95% CI: 9.0, 18.5), 
reported from Vilanculos, Mozambique, and based on RPR testing and confirmatory 
Treponema pallidum haemagglutination (TPHA) assays209 as presented in Table 4.2.  In 
West and Central Africa, the pooled mean prevalence of serological syphilis was 3.5% 
(95% CI: 1.8, 5.2) as shown in Figure 4.2b.  The highest point estimate of 16.3% (95% 
CI: 15.2, 17.4) was from Yaoundé, Cameroon where TPHA assays were used210 as 
presented in Table 4.2. 
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Table 4.2 Syphilis point estimates: sub-Saharan Africa  
 
 
Site 
(year study conducted) 
Reference 
(year of publication) 
No. women 
positive 
No. women 
tested 
Uncorrected 
prevalence (%) 
95% CI Diagnostic method  Corrected 
prevalence (%) 
95% CI No. ANC 
facilities 
East and Southern Africa 
19
90
-1
9
99
 
Blantyre, Malawi (1990-93) Taha (1999) 211 1001 9309 10.8 10.2, 11.4 RPR and TPHA 10.0 9.3, 10.6 1 
Umzingwane Zimbabwe (1991) Rutgers (1993) 212 197 1,433 13.8 12.0, 15.5 RPR only 10.5 8.9, 12.0 1 
Vilanculos, Mozambique (1991-92) Vuylsteke (1993) 209 29 201 14.4 9.6, 19.3 RPR and TPHA 13.7 9.0, 18.5 1 
Zambizai, Mozambique (1992-93) Cossa (1994) 213 212 1,728 12.2 10.7, 13.8 RPR and MHA-TP 11.5 10.0, 13.0 14 
Nairobi, Kenya (1992-94) Jenniskens (1995) 214 854 13,131 6.5 6.1, 6.9 RPR only 2.3 2.0, 2.5 9 
Mwanza, Tanzania (1992-93) Mayaud (1995) 215 97 964 10.1 8.2, 12.0 RPR and TPHA 9.3 7.4, 11.1 12 
Nairobi, Kenya (1992-97) Temmerman (1999) 216 2,701 52,405 5.2 5.0, 5.3 RPR only 0.7 0.7, 0.8 10 
Dar es Salaam, Tanzania (1993) Mwakagile (1996) 217 31 777 4.0 2.6, 5.4 RPR and TPHA 0.1 1.8, 4.3 1 
Blantyre, Malawi (1993) Taha (1998) 218 264 2,161 12.2 10.8, 13.6 RPR and TPHA 11.5 9.4, 17.5 1 
Debretabor, Ethiopia (1994) Azeze (1995) 219 37 270 13.7 9.6, 17.8 VDRL only 13.5 9.4, 17.5 1 
Nairobi, Kenya (1994) Thomas (1996) 220 9 286 3.2 1.1, 5.2 RPR and TPHA 2.2 0.5, 3.9 1 
Rwandan camp, Tanzania (1994) Mayaud (1997) 221 2 100 2.0 -0.7, 4.7 RPR and TPHA 1.0 -1.0, 3.0 1 
Mwanza, Tanzania (not reported) Mayaud (1997) 222 173 2,380 7.3 6.2, 8.3 RPR and TPHA 6.4 5.4, 7.4 12 
Mwanza, Tanzania (1994) Mayaud (1998) 223 55 660 8.3 6.2, 10.4 RPR and TPHA 7.5 5.5, 9.5 1 
Blantyre, Malawi (1995) Taha (1998) 218 98 808 12.1 9.9, 14.4 RPR and TPHA 11.4 9.2, 13.5 1 
Dar es Salaam, Tanzania (1995-97) Urassa (2001) 224 62 1,058 5.9 4.4, 7.3 VDRL and TPHA 5.0 3.7, 6.3 4 
Addis Ababa, Ethiopia (1995-2001) Tsegaye (2002) 225 135 4,731 2.9 2.4, 3.3 RPR and TPHA 1.9 1.5, 2.3 4 
Blantyre, Malawi (1996) Taha (1998) 218 92 829 11.1 9.0, 13.2 RPR and TPHA 10.3 8.2, 12.4 1 
Kisumu, Kenya (1996-97) Ayisi (2000) 226 65 2,844 2.3 1.7, 2.8 VDRL only 0.3 0.1, 0.5 1 
Addis Ababa, Ethiopia (1997) Kebede (2000) 227 12 410 2.9 1.3, 4.6 VDRL and TPHA or VDRL and FTA-Abs 2.0 0.6, 3.3 3 
Nairobi, Kenya (1997) Fonck (2000) 228 22 334 6.6 3.9, 9.3 RPR only 2.4 0.7, 4.0 2 
Gutu, Zimbabwe (not reported) Majoko (2003) 229 9 85 10.6 4.1, 17.1 RPR only 6.9 1.5, 12.3 23 
Kisumu, Kenya (1996-99) Ayisi (2003) 230 55 2,288 2.4 1.8, 3.0 RPR only 0.5* 0.2, 0.8 1 
Nairobi, Kenya (1997-98) Fonck (2001) 231 928 27,377 3.4 3.2, 3.6 RPR only 0.5* 0.4, 0.6 10 
Khartoum, Sudan (1999) Ortashi (2004) 232 11 151 7.3 3.1, 11.4 RPR and TPHA 6.4 1.5, 12.3 1 
20
00
-2
0
11
 
Harare, Zimbabwe (Not reported) Pham (2005) 233 74 2,969 2.5 1.9, 3.1 RPR and TPHA 1.5 1.1, 2.0 1 
Moshi, Tanzania (1999-2004)  Msuya (2007) 234 39 3,046 1.3 0.9, 1.7 RPR and MHA-TP 0.3 0.1, 0.5 3 
Gaborone, Botswana (2000-01) Romoren (2006) 235  32 703 4.6 3.0, 6.1 RPR and TPHA 3.6 2.2, 5.0 13 
Blantyre, Malawi (2000-04) Kwiek (2008) 236 198 3,824 5.2 4.5, 5.9 RPR and TPHA 4.3 3.6, 4.9 1 
Manhiça, Mozambique (2000) Menendez (2010) 237 31 258 12.0 8.1, 16.0 RPR and IgG ELISA 11.24 7.39, 15.1 1 
Harare, Zimbabwe (2002-03) Kurewa (2010) 238 8 678 1.2 0.4, 2.0 RPR and TPHA 0.2 -0.1, 0.5 3 
Mwanza, Tanzania (2002) Watson-Jones (2002) 120 106 1,809 5.9 4.8, 6.9 RPR and TPHA 5.0 3.0, 6.0 2 
Harare, Zimbabwe (2002-04) Mapingure (2010) 239 8 662 1.2 0.4, 2.0 RPR and Determine Syphilis TP 0.2 -0.1, 0.5 1 
Moshi, Tanzania  (2002-04) Mapingure (2010) 239 23 2654 0.9 0.5, 1.3 RPR and Determine Syphilis TP 0.5* 0.2, 0.8 1 
Multicentre, Tanzania (2003-04) Swai (2006) 240 1,261 17,277 7.3 6.9, 7.7 RPR only 3.2 2.9, 3.4 57 
Sofala, Mozambique (2003-04) Montoya (2006) 241 32 381 8.4 5.6, 11.2 RPR and TPHA 7.5 4.9, 10.2 6 
Rural Tanzania (2003-04) Yahya-Malima (2008) 242 21 1,296 1.6 1.0, 2.5 RPR and TPHA 0.6 0.2, 1.1 6 
Manhiça, Mozambique (2003-05) Menendez (2008) 77 122 1,030 11.8 9.9, 13.8 RPR only 8.3 4.9, 10.2 1 
Entebbe, Uganda (2004) Tann (2006) 243 4 245 1.6 0.1, 3.2 RPR and TPHA 0.7 -0.4, 1.7 1 
Multicentre, Mozambique (2004) Lujan (2008) 244 53 1,117 4.7 3.5, 6.0 RPR and TPHA 3.8 2.7, 5.0 2 
Entebbe, Uganda (2003-05) Woodburn (2009) 245 18 2,507 0.7 0.4, 1.0 RPR and TPHA 0.5* 0.2, 0.8 1 
Southern Malawi (2004-05) Van Den Broek (2009) 108 163 2,297 7.1 6.1, 8.2 VDRL only 5.9 4.9, 6.8 4 
North-west Somalia (2004) Abdalla (2010) 246 21 1,559 1.3 0.8, 1.9 RPR and TPHA 0.4 -0.1, 0.2 4 
Gondar, Ethiopia (2005) Mulu (2007) 247 5 480 1.0 0.1, 2.0 RPR and TPHA 4.5 3.9, 5.1 1 
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Table 4.2 Syphilis point estimates: sub-Saharan Africa (continued)  
Site 
(year study conducted) 
Reference 
(year of publication) 
No. women 
positive 
No. women 
tested 
Uncorrected 
prevalence (%) 
95% CI Diagnostic method  Corrected 
prevalence (%) 
95% CI No. ANC 
facilities 
West and Central Africa 
19
90
-1
9
99
 
Kinshasa, Zaire (1990) Vuylsteke (1993) 133 13 1,160 1.1 0.5, 1.7 RPR and TPHA 0.1 -0.1, 0.3 4 
Abidjan, Côte d’Ivoire (1992) Diallo (1997) 248 6 545 1.1 0.2, 2.0 RPR and TPHA 0.1 -0.2, 0.4 1 
Cotonou, Benin (1993) Rodier (1995) 249 5 205 2.4 0.3, 4.5 VDRL and TPHA 1.5 -0.2, 3.1 1 
Multicentre, Burkina Faso (1994) Meda (1997) 250 23 645 3.6 2.1, 5.0 RPR and TPHA 2.6 1.4, 3.9 2 
Libreville, Gabon (1994-95) Bourgeois (1998) 251 19 646 2.9 1.6, 4.2 RPR only 0.5* 0.05, 1.0 3 
Yaounde, Cameroon (1994-96) Mbopi Keou (1998) 210 696 4,100 17.0 15.8, 18.1 TPHA only 16.3 15.2, 17.4 1 
Bangui, Central African Rep (1996) Blankhart (1999) 252 30 451 6.7 4.4, 9.0 RPR / TPHA or VDRL / TPHA 5.8 3.6, 7.9 3 
Bobo-Dioulasso, Burkina Faso (1995-98) Sombie (2000) 253 26 10,980 0.2 0.2, 0.3 RPR and TPHA 0.5* 0.4, 0.6 3 
Enugu, Nigeria  (1997-2001) Ikeme (2006) 254 86 6,881 1.3 1.0, 1.5 VDRL only 0.5* 0.4, 0.7 1 
20
00
-2
0
11
 
Ilorin, Nigeria (2000) Aboyeji (2003) 255 4 230 1.7 0.1, 3.4 RPR and TPHA 0.8 -0.4, 1.9 1 
Maiduguri, Nigeria (1999-2008) Bukar (2009) 256 9 18,101 0.1 0.0, 0.1 RPR and TPHA 0.5* 0.4, 0.6 1 
Accra, Ghana (2000-01) Apea-Kubi (2004) 257 21 294 7.1 4.2, 10.1 RPR and TPHA 6.3 3.5, 9.0 1 
Jos, Nigeria (2002-03) Sagay (2005) 258 7 2657 0.3 0.1,  0.5 RPR and TPHA 0.5* 0.2, 0.8 1 
Multicentre, Burkina Faso (2003) Kirakoya (2010) 259 38 2133 1.8 1.2, 2.3 VDRL and TPHA 0.8 0.4, 1.2 98 
Kinshasa, DRC (2004) Kinoshita-Moleka (2008) 260 0 529 0.0 0.0, 0.0 RPR and TPHA 0.5* -0.1, 1.1 2 
Osogbo, Nigeria (2004-06) Taiwo (2007) 261 15 505 3.0 1.5, 4.5 RPR and TPHA 2.0 0.8, 3.2 2 
 
RPR = Rapid plasma reagin      
VDRL = Venereal disease research laboratory      
TPHA = Treponema pallidum haemagglutination     
MHA-TP = Micro haemagglutination assay–Treponema pallidum     
IgG = Immunoglobulin G 
ELISA=  Enzyme-linked immunosorbent assay     
FTA-Abs = Fluorescent treponemal antibody absorption    
* The adjusted point prevalence estimate was equal to zero with no variance and is not shown in corresponding figure 
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Figure 4.2a Syphilis pooled estimates: East and Southern Africa  
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Figure 4.2b Syphilis pooled estimates: West and Central Africa 
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Neisseria gonorrhoeae prevalence 
 
Amongst women in East and Southern Africa, the pooled prevalence was 3.7% (95% CI: 
2.8, 4.6) as shown in Figure 4.3a with the highest point estimate of 23.3% (95% CI: 
16.4, 30.2) observed in Manhiça, Mozambique diagnosed by culture and gram stain209 
as presented in Table 4.3.  The pooled prevalence of N. gonorrhoeae in West and 
Central Africa was 3.5% (95% CI: 1.8, 5.2) as shown in Figure 4.3b.  The highest 
individual estimate, 4.6% (95% CI: 2.8, 6.3), came from a study in Abidjan, Côte 
d’Ivoire, where culture diagnostic methods were used248 as presented in Table 4.3. 
 
133 
 
Table 4.3 Neisseria gonorrhoeae point estimates: sub-Saharan Africa 
 
 
 
 
 
 
 
Site 
(year study conducted) 
Reference 
(year of publication) 
No. women 
positive 
No. women 
tested 
Uncorrected 
prevalence (%) 
95% CI 
 
Diagnostic method  Corrected 
prevalence (%) 
95% CI No. ANC 
facilities 
East and Southern Africa 
19
90
-1
9
99
 
Blantyre, Malawi (1990-93) Taha (1999) 211 376 9104 4.1 3.7, 4.5 Culture 5.2 4.7, 5.6 1 
Vilanculos, Mozambique (1991-92) Vuylsteke (1993) 209 14 201 7.0 3.5, 10.5 Culture  8.7 4.8, 12.6 1 
Mwanza, Tanzania (1992-93) Mayaud (1995) 215 20 964 2.1 1.2, 3.0 Culture  2.6 1.6, 3.6 12 
Dar es Salaam, Tanzania (1993) Mwakagile (1996) 217 28 777 3.6 2.3, 4.9 Culture  4.5 3.1, 6.0 1 
Blantyre, Malawi (1993) Taha (1998) 218 54 2,161 2.5 1.8, 3.2 Culture  3.1 2.4, 3.9 1 
Nairobi, Kenya (1994) Thomas (1996) 220 7 286 2.5 0.7, 4.2 Culture  3.1 1.1, 5.1 1 
Mwanza, Tanzania (1994) Mayaud (1998) 223 15 660 2.3 1.1, 3.4 Culture  2.8 1.6, 4.1 1 
Rwandan camp, Tanzania (1994) Mayaud (1997) 221 3 100 3.0 -0.3, 6.3 Gram stain  0.5* -0.9, 1.9 1** 
Blantyre, Malawi (1995) Taha (1998) 218 20 808 2.5 1.4, 3. Culture  3.1 1.9, 4.3 1 
Nairobi, Kenya (1997) Fonck (2000) 228 10 334 3.0 1.2, 4.8 Culture  3.7 1.7, 5.8 10 
Khartoum, Sudan (1999) Ortashi (2004) 232 3 151 2.0 -0.2, 4.2 Culture  2.5 0.0, 5.0 1 
20
00
-2
0
11
 
Gaborone, Botswana (2000-01) Romoren (2004) 262 21 561 3.7 2.2, 5.3 LCR cervical swab 2.8 1.5, 4.2 13 
Manhiça, Mozambique (2000) Menendez (2010) 237 27 145 18.6 12.3, 25.0 Culture and gram stain  23.3 16.4, 30.2 1 
Dar es Salaam, Tanzania (2001-03) Aboud (2008) 263 1 428 0.2 -0.2, 0.7 Gram stain  0.5* -0.2, 1.2 1 
Blantyre, Malawi (2001-03) Aboud (2008) 263 2 474 0.4 -0.2, 1.0 Gram stain  0.5* -0.1, 1.1 1 
Lilongwe, Malawi (2001-03) Aboud (2008) 263 26 748 3.5 2.2, 4.8 Gram stain  0.5* -0.01, 1.0 1 
Lusaka, Zambia (2001-03) Aboud (2008) 263 10 642 1.6 0.6, 2.5 Gram stain  0.5* -0.05, 1.0 1 
Moshi, Tanzania (1999-2004) Msuya (2007) 234 17 3,046 0.6 0.3, 0.8 Culture or gram stain  0.5* 0.3, 0.8 3 
Entebbe, Uganda (2004) Tann (2006) 243 10 233 4.3 1.7, 6.9 PCR cervical swab 1.4 -0.1, 3.0 1 
Multicentre, Mozambique (2004) Lujan (2008) 244 21 835 2.5 1.5, 3.6 PCR urine 2.8 1.7, 3.9 2 
West and Central Africa 
19
90
-1
9
99
 
Kinshasa, Zaire (1990) Vuylsteke (1993) 133 19 1,160 1.6 0.9, 2.3 Culture  2.1 1.2, 2.9 4 
Ile-Ife, Nigeria (1990-91) Okonofua (1995) 264 9 86 10.5 4.0, 17.0 Gram stain 0.5* -1.0, 2.0 1 
Abidjan, Côte d’Ivoire (1992) Diallo (1997) 248 20 546 3.7 2.1, 5.2 Culture  4.6 2.8, 6.3 1 
Praia, Cape Verde (1993) Wessel (1998) 265 17 350 4.9 2.6, 7.1 PCR cervical swab 2.1 0.6, 3.6 1 
Multi- Burkina Faso (1994) Meda (1997) 250 23 645 3.6 2.1, 5.0 Gram stain  0.5* -0.05, 1.0 2 
Libreville, Gabon (1994-95) Bourgeois (1998) 251 12 646 1.9 0.8, 2.9 Culture or gram stain 0.5* -0.05, 1.0 3 
Bangui, Cent African Rep (1996) Blankhart (1999) 252 14 451 3.1 1.5, 4.7 Culture  3.9 2.1, 5.7 3 
Abidjan, Côte d’Ivoire (1996-97) Faye-Kette (2000) 266 9 551 1.6 0.6, 2.7 Gram stain  0.5* -0.1, 1.1 1 
2000-
2011 
Ilorin, Nigeria (2000) Aboyeji (2003) 255 3 230 1.3 -0.2, 2.8 Culture 1.6 -0.0, 3.3 1 
Accra, Ghana (2000-01) Apea-Kubi (2004) 
257 1 261 0.4 -0.4, 1.1 PCR cervical swab  0.5* -0.4, 1.4 1 
Kinshasa, Dem Rep Congo (2004) Kinoshita-Moleka (2008) 260 2 521 0.4 -0.2, 0.9 PCR cervical swab  0.5* -0.1, 1.1 2 
 PCR = Polymerase chain reaction 
LCR = Ligase chain reaction 
* The adjusted point prevalence estimate was equal to zero with no variance and is not shown in corresponding figure 
** Refugee camp 
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Figure 4.3a Neisseria gonorrhoeae pooled estimates: East and Southern Africa  
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Figure 4.3b Neisseria gonorrhoeae pooled estimates: West and Central Africa 
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Chlamydia trachomatis prevalence 
 
In East and Southern Africa, the pooled prevalence of C. trachomatis infection was 
6.9% (95% CI: 5.1, 8.6) as shown in Figure 4.4a.  Khartoum, Sudan, reported the 
highest prevalence estimate of 23.2% (95% CI: 16.5, 29.9) as detected by an enzyme 
immunoassay (EIA)232 as presented in Table 4.4.  In West and Central Africa, the 
pooled mean prevalence was 6.1% (95% CI: 4.0, 8.3) as shown in Figure 4.4b.  The 
highest prevalence, 16.4% (95% CI: 12.6, 20.1) based on culture or EIA, was observed 
in Pikine, Senegal267 as presented in Table 4.4. 
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Table 4.4 Chlamydia trachomatis point estimates: sub-Saharan Africa  
  
PCR = Polymerase chain reaction 
LCR = Ligase chain reaction 
EIA = Enzyme immunoassay 
* The adjusted point prevalence estimate was equal to zero with no variance and is not shown in corresponding figure  
Site 
(year study conducted) 
Reference 
(year of publication) 
No. women 
positive 
No. women 
tested 
Uncorrected 
prevalence (%) 
95% CI Diagnostic method  Corrected 
prevalence (%) 
95% CI No. ANC 
facilities 
East and Southern Africa 
19
90
-1
9
99
 
Vilanculos, Mozambique (1991-92) Vuylsteke (1993) 209 11 141 7.8 3.4, 12.2 Culture cervical swab 0.5* -0.7, 1.7 1 
Mwanza, Tanzania  (1992-93) Mayaud (1995) 215 64 964 6.6 5.1, 8.2 EIA 6.0 4.5, 7.5 12 
Nairobi, Kenya (1994) Thomas (1996) 220 25 286 8.7 5.5, 12.0 EIA 8.8 5.5, 12.0 1 
Mwanza, Tanzania (1994) Mayaud (1998) 223 39 660 5.9 4.1, 7.7 EIA 5.1 3.4, 6.8 1 
Nairobi, Kenya (1997) Fonck (2000) 228 36 334 10.8 7.5, 14.1 PCR cervical swab 10.4 7.2, 13.7 2 
Khartoum, Sudan (1999) Ortashi (2004) 232 30 151 19.9 13.5, 26.2 EIA 23.2 16.5, 29.9 1 
20
00
-2
0
11
 
Gaborone, Botswana  (2000-01) Romoren (2004) 262 42 557 7.5 5.4, 9.7 LCR cervical swab 7.6 5.3, 9.7 13 
Manhiça, Mozambique (2000) Menendez (2010) 237 15 151 9.9 5.2, 14.7 DNA ID-assay cervical swab 9.1 4.5, 13.7 1 
Lusaka, Zambia (2001-03) Aboud (2008) 263 39 642 6.1 4.2, 7.9 EIA  5.3 3.6, 7.0 1 
Dar es Salaam, Tanzania (2001-03) Aboud (2008) 263 12 343 3.5 1.6, 5.4 EIA 2.0 0.5, 3.4 1 
Blantyre, Malawi (2001-03) Aboud (2008) 263 4 474 0.8 0.0, 1.7 EIA  0.5* -0.1, 1.2 1 
Lilongwe, Malawi (2001-03) Aboud (2008) 263 2 748 0.3 -0.1, 0.6 EIA  0.5* 0.01, 1.0 1 
Entebbe, Uganda (2004) Tann (2006) 243 14 236 5.9 2.9, 9.0 PCR cervical swab 5.5 2.6, 8.4 1 
Multicentre, Mozambique (2004) Lujan (2008) 244 34 835 4.1 2.7, 5.4 PCR urine  4.3 2.9, 5.7 2 
West and Central Africa 
19
90
-1
9
99
 
Pikine, Senegal (1990) Van Dyck (1992) 267 55 377 14.6 11.0, 18.2 Culture or EIA 16.4 12.6, 20.1 1 
Kinshasa, Zaire (1990) Vuylsteke (1993) 133 60 1,160 5.2 3.9, 6.5 EIA 4.1 3.0, 5.3 4 
Abidjan, Côte d’Ivoire (1992) Diallo (1997) 248 25 452 5.5 3.4, 7.6 EIA  4.6 2.7, 6.5 1 
Praia, Cape Verde (1993) Wessel (1998) 265 46 350 13.1 9.6, 16.7 PCR cervical swab  12.9 9.3, 16.3 1 
Multicentre, Burkina Faso (1994) Meda (1997) 250 20 645 3.1 1.8, 4.4 EIA  1.4 0.5, 2.4 2 
Libreville, Gabon (1994-95) Bourgeois (1998) 251 64 646 9.9 7.6, 12.2 EIA  10.3 7.9, 12.6 3 
Bangui, CAR (1996) Blankhart (1999) 252 28 451 6.2 4.0, 8.4 Indirect immunofluorescence 4.3 2.5, 6.2 3 
Abidjan, Côte d’Ivoire (1996-97) Faye-Kette (2000) 266 41 551 7.4 5.3, 9.6 EIA  7.1 4.9, 9.2 1 
2000- 
2011 
Accra, Ghana (2000-01) Apea-Kubi (2004) 257 9 261 3.5 1.2, 5.7 PCR cervical swab  3.0 0.9, 5.1 1 
Kinshasa, DRC (2004) Kinoshita-Moleka (2008) 260 9 521 1.7 0.6, 2.9 PCR cervical swab 6.1 4.0, 8.3 2 
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Figure 4.4a Chlamydia trachomatis pooled estimates: East and Southern Africa 
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Figure 4.4b Chlamydia trachomatis pooled estimates: West and Central Africa 
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Trichomonas vaginalis prevalence 
 
The pooled prevalence of T. vaginalis infection was 29.1% (95% CI: 20.9, 37.2) amongst 
women in East and Southern Africa as shown in Figure 4.5a, compared to 17.8% (95% 
CI: 12.4, 23.1) in West and Central Africa illustrated in Figure 4.5b.  Table 4.5 shows the 
highest point estimate in East and Southern Africa was 51.7% (95% CI: 41.9, 61.5), 
reported in Blantyre, Malawi211 as diagnosed by wet-mount microscopy, whereas the 
highest prevalence estimate in West and Central Africa, 52.0% (95% CI: 47.6, 56.4), 
was in Jos, Nigeria, where the same diagnostic method was used.268  
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Table 4.5 Trichomonas vaginalis point estimates: sub-Saharan Africa  
 
* Refugee camp 
  
Site 
(year study conducted) 
Reference 
(year of publication) 
No. women 
positive 
No. women 
tested 
Uncorrected 
prevalence (%) 
95% CI Diagnostic method 
 
Corrected 
prevalence (%) 
95% CI No. ANC 
facilities 
East and Southern Africa 
19
90
-1
9
99
 
Blantyre, Malawi (1990-93) Taha (1999) 211 2,838 9,137 31.1 30.2, 32.1 Wet-mount microscopy 51.6 50.5, 52.6 1 
Vilanculos, Mozambique (1991-92) Vuylsteke (1993) 209 46 201 22.9 17.1, 28.7 Wet-mount microscopy 38.1 31.4, 44.9 1 
Mwanza, Tanzania (1992-93) Mayaud (1995) 215 264 964 27.4 24.6, 30.2 Wet-mount microscopy 45.6 42.5, 48.8 12 
Dar es Salaam, Tanzania (1993) Mwakagile (1996) 217 176 777 22.7 19.7, 25.6 Wet-mount microscopy 37.8 34.3, 41.2 1 
Blantyre, Malawi (1993) Taha (1998) 218 62 2,161 2.9 2.2, 3.6 Wet-mount microscopy 4.8 3.8, 5.7 1 
Nairobi, Kenya (1994) Thomas (1996) 220 57 286 19.9 15.3, 24.6 Wet-mount microscopy 33.2 27.8, 38.7 1 
Mwanza, Tanzania (1994) Mayaud (1998) 223 108 660 16.4 13.5, 19.2 Wet-mount microscopy 27.3 23.9, 30.7 1 
Rwandan camp, Tanzania (1994) Mayaud (1997) 221 31 100 31.0 21.9, 40.1 Wet-mount microscopy 51.7 41.9, 61.5 1* 
Mwanza, Tanzania (not reported) Mayaud (1997) 222 627 2,282 27.5 25.6, 29.3 Wet-mount microscopy 45.8 43.8, 47.8 12 
Blantyre, Malawi (1995) Taha (1998) 218 19 808 2.4 1.3, 3.4 Wet-mount microscopy 3.9 2.6, 5.3 1 
Nairobi, Kenya (1997) Fonck (2000) 228 86 334 25.8 21.1, 30.4 Wet-mount microscopy 42.9 37.6, 48.2 2 
20
00
-2
0
11
 
Khartoum, Sudan (1999) Ortashi (2004) 232 11 151 7.3 3.1, 11.4 Wet-mount microscopy 12.1 6.9, 17.4 1 
Moshi, Tanzania (1999-2004) Msuya (2007) 234 207 2,917 7.1 6.2, 8.0 Wet-mount microscopy 11.8 10.7, 13.0 3 
Gaborone, Botswana (2000-01) Romoren (2007) 269 132 703 18.8 15.9, 21.7 Wet-mount microscopy  31.3 27.9, 34.7 13 
Manhiça, Mozambique (2000) Menendez (2010) 237 78 254 30.7 25.0, 36.4 Wet-mount microscopy 51.2 45.0, 57.3 1 
Lilongwe, Malawi (2001-03) Aboud (2008) 263 180 748 24.1 21.0, 27.1 Wet-mount microscopy 40.1 36.6, 43.6 1 
Lusaka, Zambia (2001-03) Aboud (2008) 263 134 642 20.9 17.7, 24.0 Wet-mount microscopy 34.8 31.1, 38.5 1 
Blantyre, Malawi (2001-03) Aboud (2008) 263 98 474 20.7 17.0, 24.3 Wet-mount microscopy 34.5 30.2, 38.7 1 
Dar es Salaam, Tanzania (2001-03) Aboud (2008) 263 18 428 4.2 2.3, 6.1 Wet-mount microscopy 7.0 4.6, 9.4 1 
Moshi, Tanzania  (2002-04) Mapingure (2010) 239 127 2,555 5.0 4.2, 5.9 Wet-mount microscopy 8.3 7.2, 9.4 1 
Harare, Zimbabwe (2002-04) Mapingure (2010) 239 80 680 11.8 9.4, 14.2 Wet-mount microscopy 19.6 16.6, 22.6 1 
Harare, Zimbabwe (2002-03) Kurewa (2010) 238 80 678 11.8 9.4, 14.2 Wet-mount microscopy 19.7 16.7, 22.7 3 
Entebbe, Uganda (2004) Tann (2006) 243 43 249 17.3 12.6, 22.0 In-pouch culture 18.0 13.2, 22.8 1 
West and Central Africa 
19
90
-1
9
99
 
Jos, Nigeria (not reported) Ogbonna (1991) 268 156 500 31.2 27.1, 35.3 Wet-mount microscopy 52.0 47.6, 56.4 2 
Kinshasa, Zaire (1990) Vuylsteke (1993) 133 213 1,160 18.4 16.1, 20.6 Wet-mount microscopy 30.6 28.0, 33.3 4 
Ile-Ife, Nigeria (1990-91) Okonofua (1995) 264 2 86 2..3 -0.9, 5.5 Wet-mount microscopy 3.9 -0.2, 8.0 1 
Abidjan, Côte d’Ivoire (1992) Diallo (1997) 248 72 546 13.2 10.3, 16.0 Wet-mount microscopy 22.0 18.5, 25.5 1 
Multicentre, Burkina Faso (1994) Meda (1997) 250 90 645 14.0 11.3, 16.6 Wet-mount microscopy 23.3 20.0, 26.5 2 
Libreville, Gabon (1994-95) Bourgeois (1998) 251 69 646 10.7 8.3, 13.1 Wet-mount microscopy 17.8 14.9, 20.8 3 
Bangui, Central African Rep (1996) Blankhart (1999) 252 45 451 10.0 7.2, 12.7 Wet-mount microscopy 16.6 13.2, 20.1 3 
Abidjan, Côte d’Ivoire (1996-97) Faye-Kette (2000) 266 74 551 13.4 10.6, 16.3 Wet-mount microscopy 22.4 18.9, 25.9 1 
20
00
-
20
11
 
Ilorin, Nigeria (2000) Aboyeji (2003) 255 11 230 4.8 2.0, 7.5 Wet-mount microscopy 8.0 4.5, 11.5 1 
Jos, Nigeria (2002-03) Sagay (2005) 258 41 2,657 1.5 1.0, 2.0 Wet-mount microscopy 2.6 2.0, 3.2 1 
North-east Nigeria (2003-04) Nwosu (2007) 270 17 201 8.4 4.6, 12.3 Wet-mount microscopy 14.1 9.3, 18.9 1 
Multicentre, Burkina Faso (2003) Kirakoya (2008) 271 32 2,133 1.5 1.0, 2.0 In-pouch culture 1.6 1.0, 2.1 4 
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Figure 4.5a Trichomonas vaginalis pooled estimates: East and Southern Africa 
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Figure 5.5b Trichomonas vaginalis pooled estimates: West and Central Africa 
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Bacterial vaginosis prevalence 
 
The prevalence of bacterial vaginosis was higher than any other STI/RTI in both sub-
regions.  In East and Southern Africa, the pooled prevalence was 50.8% (95% CI: 43.4, 
58.4) as shown in Figure 4.6a.  The highest point estimate was 85.5% (95% CI: 82.8, 
88.1) from Blantyre, Malawi where Amsel’s criteria were used for diagnosis211 as 
presented in Table 4.6.  In West and Central Africa the pooled prevalence estimate was 
37.6% (95% CI: 18.0, 57.2) as shown in Figure 4.6b with the highest point estimate 
based on clue cell count being 74.5% (95% CI: 70.0, 79.1) in Praia, Cape Verde265 as 
presented in Table 4.6. 
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Table 4.6 Bacterial vaginosis point estimates: sub-Saharan Africa  
 
 
* Refugee camp 
  
Site 
(year study conducted) 
Reference 
(year of publication) 
No. women 
positive 
No. women 
tested 
Uncorrected 
prevalence (%) 
95% CI Diagnostic 
method 
Corrected 
prevalence (%) 
95% CI No. ANC 
facilities 
East and Southern Africa 
19
90
-1
9
99
 
Blantyre, Malawi (1990) Taha (1999) 211 640 2077 30.8 28.8, 32.8 Amsel  58.8 56.7, 60.9 1 
Blantyre, Malawi (1993) Taha (1999) 211 290 661 43.9 40.1, 47.7 Amsel  85.5 82.8, 88.1 1 
Nairobi, Kenya (1994) Thomas (1996) 220 59 286 20.6 15.9, 25.3 Clue cell count  47.7 41.9, 53.4 1 
Rwandan camp, Tanzania (1994) Mayaud (1997) 221 16 100 16.0 8.8, 23.2 Clue cell  count  35.1 25.8, 44.5 1* 
Mwanza, Tanzania (1994) Mayaud (1998) 223 159 660 24.1 20.8, 27.4 Clue cell  count 57.0 53.2, 60.8 1 
Multicentre, Zimbabwe (1999-2001) Tolosa (2006) 272 51 209 24.4 18.6, 30.2 Nugent 23.5 17.8, 29.3 1 
Moshi, Tanzania (1999-2004) Msuya (2007) 234 661 3,046 21.7 20.2, 23.2 Amsel  40.2 38.5, 42.0 3 
20
00
-2
0
11
 
Gaborone, Botswana (2000-01) Romoren (2007) 269 264 703 37.6 34.0, 41.1 Nugent 39.5 35.9, 43.1 13 
Lilongwe, Malawi (2001-03) Aboud (2008) 263 329 748 44.0 40.4, 47.5 Nugent 47.3 43.7, 50.8 1 
Blantyre, Malawi (2001-03) Aboud (2008) 263 239 474 50.4 45.9, 54.9 Nugent 55.1 50.6, 59.6 1 
Lusaka, Zambia (2001-03) Aboud (2008) 263 251 642 39.1 35.3, 42.9 Nugent 41.3 37.5, 45.14 1 
Dar es Salaam, Tanzania (2001-03) Aboud (2008) 263 255 428 59.6 54.9, 64.2 Nugent 66.2 61.7, 70.7 1 
Harare, Zimbabwe (2002-04) Mapingure (2010) 239 195 598 32.6 28.8, 36.4 Amsel 62.5 58.6, 66.4 1 
Moshi, Tanzania  (2002-04) Mapingure (2010) 239 533 2555 20.9 19.3, 22.5 Amsel  38.5 36.6, 40.4 1 
Harare, Zimbabwe (2002-03) Kurewa (2010) 238 221 678 32.6 29.1, 36.1 Amsel  62.4 58.8, 66.1 3 
Entebbe, Uganda (2004) Tann (2006) 243 117 247 47.4 41.1, 53.6 Nugent 51.4 45,1, 58.0 1 
West and Central Africa 
19
99
-
19
99
 
Praia, Cape Verde (1993) Wessel (1998) 265 107 350 30.6 25.7, 35.4 Clue cell  count  74.5 70.0, 79.1 1 
Multicentre, Burkina Faso (1994) Meda (1997) 250 83 645 12.9 10.3, 15.5 Amsel 22.2 19.0, 25.4 2 
Libreville, Gabon (1994-95) Bourgeois (1998) 251 148 646 22.9 19.7, 26.2 Nugent  21.8 18.5, 24.9 3 
Bangui, Central African Rep (1996) Blankhart (1999) 252 132 453 29.1 25.0, 33.3 Clue cell  count 70.7 66.5, 74.8 3 
Abidjan, Côte d’Ivoire (1996-97) Faye-Kette (2000) 266 170 551 30.9 27.0, 34.7 Spiegel  41.1 37.0, 45.3 1 
2000- 
2011 
Jos, Nigeria (2002-03) Sagay (2005) 258 466 2657 17.5 16.1, 18.9 Amsel 31.7 29.9, 33.5 1 
Multicentre, Burkina Faso (2003)  Kirakoya-Moleka (2008) 271 138 2,133 6.5 5.4, 7.5 Nugent  1.8 1.2, 2.3 2 
146 
 
Figure 4.6a Bacterial vaginosis pooled estimates: East and Southern Africa 
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Figure 4.6b Bacterial vaginosis pooled estimates: West and Central Africa 
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Peripheral malaria prevalence  
 
The pooled prevalence of peripheral malaria in East and Southern Africa was 32.0% 
(95% CI: 25.9, 38.0) as shown in Figure 4.7a.  The highest prevalence in the sub-region, 
87.9% (95% CI: 85.7, 90.1), was reported from Hoima, Uganda, where microscopy was 
used273 as presented in Table 4.7.  In West and Central Africa, the pooled prevalence of 
peripheral parasitaemia was 38.2% (95% CI: 32.3, 44.1) as shown in Figure 4.7b.  The 
highest point estimate was 94.9% (95% CI: 88.0, 102.0) in Ngali II, Nigeria, where PCR 
methods were used274 as presented in Table 4.7. 
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Table 4.7 Peripheral malaria point estimates: sub-Saharan Africa  
 
PCR = Polymerase chain reaction 
* The adjusted point prevalence estimate was equal to zero with no variance and is not shown in corresponding figure 
** Measured at delivery  
*** ANC delivered through facilities and out-reach teams 
Site 
(year study conducted) 
Reference 
(year of publication) 
No. women 
positive 
No. women 
tested 
Uncorrected 
prevalence (%) 
95% CI Diagnostic method Corrected 
prevalence (%) 
95% CI No. ANC 
facilities 
East and Southern Africa 
19
90
-1
9
99
 
Kilifi, Kenya (1993) Shulman (1996) 29 65 275 23.6 18.6, 28.7 Giemsa stain microscopy  28.7 23.3, 34.0 1 
Chikwawa, Malawi (1993-94) Verhoeff (1998) 38 109 575 18.9 15.7, 22.1 Giemsa stain microscopy  21.5 18.1, 24.8 1 
Chikwawa, Malawi (1993-95) Verhoeff (1999) 164 743 3,913 19.0 17.8, 20.2 Giemsa stain microscopy  21.5 20.2, 22.8 1 
Kisumu, Kenya (1994-96) Parise (1998) 74 330 736 44.8 41.2, 48.4 Giemsa stain microscopy  61.3 57.8, 64.8 2 
Hoima, Uganda (1996-98) Ndyomugyenyi  (1999) 273 530 853 62.1 58.9, 65.4 Giemsa stain microscopy 87.9 85.7, 90.1 1 
Kisumu, Kenya (1996-97) Ayisi (2000) 226 583 2,844 20.5 19.0, 22.0 Giemsa stain microscopy 23.9 22.3, 25.4 1 
Kisumu, Kenya (1996-98) Van Eijk (2001) 275 953 4,608 20.7 19.5, 21.9 Giemsa stain microscopy 24.1 22.9, 25.4 1 
Kisumu, Kenya (1996-97) Van Eijk (2003) 276 380 2,502 15.2 13.8, 16.6 Giemsa stain microscopy 15.7 14.3, 17.1 1 
Kisumu, Kenya (1996-99) Van Eijk (2002) 277 1,105 5,093 21.7 20.6, 22.8 Giemsa stain microscopy 25.7 24.5, 26.9 1 
Kigoma, Tanzania (not reported) Mnyika (2000) 278 66 705 9.4 7.2, 11.5 Giemsa stain microscopy 6.7 4.9, 8.6 1 
Blantyre, Malawi (1997-98) Rogerson (2000) 181 2,034 4,764 42.7 41.3, 44.1 PCR  41.1 39.7, 42.5 1 
Kwale, Kenya (1997-98) (Tobian 2000) 279 54 102 52.9 43.3, 62.6 PCR**  53.6 43.9, 63.3 1 
Blantyre, Malawi (1997-99) Rogerson (2000) 182 85 339 25.1 20.5, 29.7 Giemsa stain microscopy 30.9 26.0, 35.8 1 
Medani, Sudan (1997) Ahmed (2002) 280 324 550 58.9 54.8, 63.0 Giemsa stain microscopy** 82.9 80.0, 86.1 1 
Kampala, Uganda (1998) Kasumba (2000) 281 46 537 8.6 6.2, 10.9 Giemsa stain microscopy** 5.5 3.6, 7.4 1 
Manhiça, Mozambique (1998) Saute (2002) 282 156 672 23.2 20.0, 26.4 Giemsa stain microscopy 28.0 24.6, 31.4 10 
20
00
-2
0
11
 
Blantyre, Malawi (2000) Mankhambo (2002) 283 70 135 51.9 43.4, 60.3 PCR**  52.3 43.8, 60.7 1 
Multi- (stable trans), Ethiopia (2000-01) Newman (2003) 284 26 249 10.4 6.6, 14.2 Giemsa stain microscopy 0.5* -0.4, 1.5 1 
Multi-(unstable trans), Ethiopia (2000-01) Newman (2003) 284 13 713 1.8 0.8, 2.8 Giemsa stain microscopy 8.4 4.9, 11.8 3 
New Halfa, Sudan (2001-02) Elghazali (2003) 285 15 86 17.4 9.4, 25.5 Giemsa stain microscopy 19.1 10.8, 27.5 1 
Morogoro, Tanzania (2001-02) Wort (2006) 286 494 1,684 29.3 27.1, 31.5 Giemsa stain microscopy** 37.4 35.1, 39.8 1 
Multicentre, Rwanda (2002) Van Geertruyden (2005) 287 195 1,432 13.6 11.8, 15.4 Giemsa stain microscopy 13.3 11.5, 15.0 6 
Blantyre, Malawi (2002-03) Kalilani (2006) 288 372 1,172 31.7 29.1, 34.4 Giemsa stain microscopy 41.1 38.3, 44.0 2 
Multicentre, Kenya (2003) Parise (2003) 289 157 339 46.3 41.0, 51.6 Giemsa stain microscopy 63.6 58.4, 68.7 9 
New Halfa, Sudan (2003-04) Adam (2005) 290 102 744 13.7 11.2, 16.2 Giemsa stain microscopy 54.1 45.9, 62.3 1 
New Halfa, Sudan (2003-04) Adam (2005) 291 57 142 40.1 32.0, 48.2 Giemsa stain microscopy 13.4 11.0, 15.9 1 
Sofala, Mozambique (2003-04) Montoya (2006) 241 78 587 13.3 10.5, 16.0 Giemsa stain microscopy 12.8 10.1, 15.5 6 
Multicentre, Mozambique (2003-04) Brentlinger (2007) 292 255 684 37.3 33.7, 40.9 Giemsa stain microscopy 49.7 45.9, 53.4 5 
Kisumu, Kenya (2003-04) Ouma (2007) 293 123 684 18.0 15.1, 20.9 Giemsa stain microscopy 20.0 17.0, 23.0 1 
Entebbe, Uganda (2003-05) Hillier (2008) 294 268 2,459 10.9 9.7-, 2.1 Giemsa stain microscopy 9.1 7.9, 10.2 1 
Masindi, Uganda (2003-04) Ndyomugyenyi (2008) 295 281 802 35.0 31.7, 38.4 Giemsa stain microscopy 46.2 42.8, 49.7 1 
Mangochi, Malawi (2003-06) Rantala (2010) 296  51 475 10.7 7.9, 13.5 PCR 2.1 0.8, 3.4 1 
Manhiça, Mozambique (2003-05) Serra-Casas (2011) 297 120 399 30.0 25.5, 34.5 PCR 25.7 21.4, 30.0 1 
Southern Malawi (2004-05) Van Den Broek (2009) 108 572 2,297 24.9 23.1, 26.7 Giemsa stain microscopy 30.6 28.7, 32.5 4 
Mbarara, Uganda (2006-09) Piola (2009) 298 329 1197 27.5 25.0, 30.0 Giemsa stain microscopy 34.6 31.9, 37.3 1 
Mukono, Uganda (not reported) Mbonye (2008) 299 573 2,344 24.5 22.7, 26.2 Giemsa stain microscopy 30.0 28.1, 31.8 3*** 
Multicentre, Mozambique (2004) Lujan (2008) 244 53 1,117 4.7 3.5, 6.0 Giemsa stain microscopy 0.5* 0.1, 1.0 2 
150 
 
Table 4.7 Peripheral malaria point estimates: sub-Saharan Africa (continued) 
 
NR = Not reported 
** Measured at delivery 
*** ANC delivered as part of a national village-based system  
Site 
(year study conducted) 
Reference 
(year of publication) 
No. women 
positive 
No. women 
tested 
Uncorrected 
prevalence (%) 
95% CI Diagnostic method Corrected 
prevalence (%) 
95% CI No. ANC 
facilities 
West and Central Africa 
19
90
-1
9
99
 
North Kivu, DRC (NR) Meuris (1993) 300 80 461 17.4 13.9, 20.8 Giemsa stain microscopy 19.0 15.4, 22.6 1 
Freetown, Sierra Leone (NR) Morgan (1994) 301 142 768 18.5 15.7, 21.2 Giemsa stain microscopy 20.8 17.9, 23.6 1 
Ibadan, Nigeria (NR) Achidi (1997) 302 26 116 22.4 14.8, 30.0 Giemsa stain microscopy** 26.8 18.7, 34.9 1 
Dabou, Côte d’Ivoire (NR) Watson (1998) 303 11 26 42.3 23.3, 61.3 Giemsa stain microscopy 57.4 38.4, 76.4 1 
Multicentre, Nigeria (1992) Egwunyenga (1997) 304 292 656 44.5 40.7, 48.3 Giemsa stain microscopy** 60.8 57.1, 64.5 3 
Farafenni, Gambia (1994) Menendez (1994) 305 72 262 27.5 22.1, 32.9 Giemsa stain microscopy 34.6 28.8, 40.4 NA*** 
Bauchi, Nigeria (1994-95) Egwunyenga (1996) 306 181 830 21.8 19.0, 24.6 Giemsa stain microscopy 25.9 22.9, 28.9 1 
Jos, Nigeria (1994-95) Egwunyenga (1996) 306 150 652 23.0 19.8, 26.2 Giemsa stain microscopy** 27.7 24.3, 31.1 1 
Eku, Nigeria  (1994-95) Egwunyenga (1996) 306 74 423 17.5 13.9, 21.1 Giemsa stain microscopy** 19.2 15.5, 23.0 1 
Kassena-Nankana, Ghana (1994-95) Browne (2001) 307 527 928 56.8 53.6, 60.0 PCR  58.3 55.1, 61.5 17 
Yaounde, Cameroon (1994) Tako (2005) 308 405 1,895 21.4 19.5, 23.2 Giemsa stain microscopy 25.2 23.2, 27.1 2 
Multicentre, Cameroon (1995-98) Zhou (2002) 309 334 719 46.5 42.8, 50.1 Giemsa stain microscopy 63.7 60.3, 67.3 2 
Yaounde, Cameroon (1995-98) Walker-Abbey (2005) 310 77 278 27.7 22.4, 33.0 Giemsa stain microscopy 34.9 29.3, 40.5 3 
Yaounde, Cameroon (1996-2001) Tako, (2005) 308 297 1,866 15.9 14.3, 17.6 Giemsa stain microscopy 16.8 15.1, 18.5 2 
Jos, Nigeria (1997-98) Egwunyenga (2001) 311 816 2,104 38.8 36.7, 40.9 Giemsa stain microscopy 52.0 49.8, 54.1 3 
Ebolowa, Cameroon (1997-98) Salihu (2002) 312 55 125 44.0 35.3, 52.7 Giemsa stain microscopy 60.0 51.4, 68.6 1 
Bansang, Gambia (1997) Okoko (2002) 313 116 313 37.1 31.7, 42.4 Giemsa stain microscopy 49.3 43.8, 54.9 1 
Lagos, Nigeria (1998) Anorlu (2001) 314 174 477 36.5 32.2, 40.8 Giemsa stain microscopy 48.4 43.9, 52.9 1 
Agogo, Ghana (1998) Mockenhaupt (2008) 315 335 530 63.2 59.1, 67.3 PCR** 66.1 62.1, 70.1 1 
Sagamu, Nigeria (NR) Sule-Odu (2002) 316 140 564 24.8 21.3, 28.4 Giemsa stain microscopy** 30.5 26.7, 34.3 1 
Lagos, Nigeria (1999) Okwa (2003) 274 480 800 60.0 56.6, 63.4 Giemsa stain microscopy 84.6 82.1, 87.1 4 
Fako, Cameroon (1999-2001) Achidi (2005) 317 511 1,143 44.7 41.8, 47.6 Giemsa stain microscopy 61.1 58.3, 63.9 1 
Fako, Cameroon (1999-2000) Akum (2005) 318 248 735 33.7 30.3, 37.2 Giemsa stain microscopy** 44.2 40.6, 47.8 1 
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Figure 4.7a Peripheral malaria pooled estimates: East and Southern Africa 
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Figure 4.7b Peripheral malaria pooled estimates: West and Central Africa 
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Placental malaria prevalence 
 
As for placental malaria, the pooled prevalence in East and Southern Africa was 25.8% 
(95% CI: 19.7, 31.9) (Figure 4.8a).  The highest point estimate, 74.7% (95% CI: 65.5, 
84.0), from Kisumu, Kenya was based on histological diagnosis319  as shown in Table 
4.8.  In West and Central Africa, the pooled prevalence was 39.9% (95% CI: 34.2, 45.7) 
(Figure 4.8b) with the highest point prevalence of 91.6% (95% CI: 84.8, 94.4) based on 
placental histology as well as blood and impression smears from Ebolowa, 
Cameroon165 as shown in Table 4.8.  
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Table 4.8 Placental malaria point estimates at ANC: sub-Saharan Africa  
 
PCR = Polymerase chain reaction 
NR = Not reported  
** The adjusted point prevalence estimate was greater than 100 with no variance and is not shown in the corresponding figure 
*** ANC delivered as part of a national village-based system  
  
Site 
(year study conducted) 
Reference 
(year of publication) 
No. women 
positive 
No. women 
tested 
Uncorrected 
prevalence (%) 
95% CI Diagnostic method Corrected 
prevalence (%) 
95% CI No. ANC 
facilities 
East and Southern Africa 
1990-
1999 
Kisumu, Kenya (1996-99) Van Eijk (2002) 277 475 2,502 19.0 17.4, 20.5 Placental impression and blood smears  with microscopy 20.0 18.4, 21.6 1 
Blantyre, Malawi (1997-99) Rogerson (2000) 182 77 232 33.2 27.1, 39.2 Placental impression and blood smears with microscopy 35.8 29.6, 41.9 1 
Kampala, Uganda (1998) Kasumba (2000) 281 36 537 6.7 4.6, 8.8 Placental blood microscopy 8.5 6.1, 10.8 1 
20
00
-2
0
11
 
Blantyre, Malawi (NR) Rogerson (2003) 320 124 464 26.7 22.7, 30.8 Placental histology, impression, smears with microscopy 28.6 24.5, 32.7 1 
Multicentre, Kenya (NR) Parise (2003) 289 163 726 22.5 19.4, 25.5 Placental blood microscopy 34.1 30.6, 37.5 9 
Muheza, Tanzania (2002-05) Kabyemela (2008) 321 55 445 12.4 9.3, 15.5 Placental impress and blood smears with microscopy  25.8 19.7, 32.0 1 
Kisumu, Kenya (2003) Kassam (2006) 319 58 85 68.2 58.3, 78.1 Placental histology, impression, smears with microscopy 74.7 65.5, 84.0 3 
New Halfa, Sudan (2003-07) Adam (2007) 322 94 293 32.1 26.7, 37.4 Placental histology, impression, smears with microscopy 34.5 29.1, 40.0 1 
Manhiça, Mozambique (2003-05) Serra-Casas (2011) 297 110 343 32.1 27.2, 37.0 PCR 9.3 6.2, 12.4 1 
Chikwawa, Malawi (2004-05) Senga (2007) 323 124 636 19.5 16.4, 22.6 Placental blood microscopy and tissue histology 20.6 17.4, 23.7 1 
Gadarif, Sudan (2007-08) Abdelrahim (2009) 324 26 150 17.3 11.3, 23.4 Placental histology, impression, smears with microscopy 18.2 12.0, 24.3 1 
Gadafir, Sudan (2007-08) Adam (2009) 325 46 236 19.5 14.4, 25.5 Placental histology, impression,  smears with microscopy 20.6 15.4, 25.7 1 
West and Central Africa 
19
90
-1
9
99
 
North Kivu, DRC Meuris (1993) 300 242 461 52.5 47.9, 57.1 Placental histology 57.0 52.5, 61.5 1 
Ebolowa, Cameroon (1991-92) Cot (1995) 165 37 64 57.8 45.7, 69.9 Placental blood microscopy 91.6 84.8, 98.4 1 
Farafenni, Gambia (1994) Menendez (1994) 305 116 198 58.6 51.7, 65.4 Placental blood microscopy and tissue histology 64.0 57.3, 70.7 NA*** 
Basse, Gambia (NR) Rasheed (1995) 326 60 97 61.9 52.2, 71.5 Placental blood microscopy and tissue histology 67.6 58.3, 76.9 1 
Yaounde, Cameroon (1995-98) Walker-Abbey (2005) 310 229 278 82.4 77.9, 86.9 Placental blood microscopy Adjusted prevalence >100%** 3 
Yaounde, Cameroon (1996-2001) Tako (2005) 308 371 1,866 19.9 18.1, 21.7 Placental impression and blood smears  with microscopy 21.0 19.1, 22.8 2 
Bansang, Gambia (1997) Okoko (2002) 313 160 313 51.1 45.6, 56.7 Placental blood microscopy and tissue histology 55.7 50.2, 61.2 1 
Guediawaye, Senegal (1998-99) N’dao (2003) 327 674 8,310 8.1 7.5, 8.7 Placental blood microscopy 10.8 10.1, 11.4 1 
Dakar, Senegal (1998-99) N’dao (2006) 327 785 8,273 9.5 8.9, 10.1 Placental impression and blood smears  with microscopy 9.4 8.8, 10.1 1 
20
00
-2
0
11
 
Fako, Cameroon (1999-2001) Akum (2005) 318 233 711 32.8 29.3, 36.2 Placental impression and blood smears  with microscopy 23.0 20.6, 25.4 1 
Fako, Cameroon (1999-2001) Achidi (2005) 317 248 1,143 33.7 19.3, 24.1 Placental impression and blood smears  with microscopy 35.3 31.8, 38.8 1 
Agogo, Ghana (2000-01) Mockenhaupt (2006) 328 495 839 59.0 55.7, 62.3 PCR 47.5 44.1, 50.9 1 
Koupéla, Burkina Faso (2001) Sirima (2003) 72 19 61 31.1 19.5, 42.8 Placental blood microscopy 48.2 35.7, 60.8 6 
Koupela, Burkina Faso (2001) Singer (2004) 329 247 484 51.0 46.6, 55.5 PCR 36.2 31.9, 40.5 2 
Ngali II, Cameroon (2001-05) Leke (2010) 330 25 36 69.4 54.4, 84.5 Placental histology, impression, smears with microscopy 76.1 62.1, 90.0 1 
Kumasi, Ghana (2003) Owens (2006) 331 33 104 31.7 22.8, 40.6 Placental blood microscopy and tissue histology  34.2 25.0, 43.3 1 
Multicentre, Nigeria (2003-04) Mokuolu (2009) 332 267 1,875 14.2 12.7, 15.8 Placental blood microscopy and tissue histology 14.7 13.1, 16.3 4 
Ibadan, Nigeria (2003-04) Falade (2007) 333 29 171 17.0 11.3, 22.6 Method not reported  - - 1 
Ibadan, Nigeria (2003-04) Falade (2010) 334 128 983 13.1 11.0, 15.2 Placental blood microscopy  18.7 16.3, 21.2 1 
Koupéla, Burkina Faso (2004) Sirima (2006) 180 18 59 30.5 18.8, 42.3 Placental blood microscopy  47.2 34.4, 59.9 1 
Kinshasa, Dem Rep Congo (2004) Lukuka (2006) 335 42 196 21.4 15.7, 27.2 Placental impression and blood smears with microscopy  22.7 16.8, 28.6 4 
Owerri, Nigeria (2004-05) Ukaga (2007) 336 175 586 29.9 26.2, 33.6 Placental blood microscopy  46.1 42.1, 50.2 2 
Benin City, Nigeria (2004-05) Enato (2007) 337 14 199 7.0 3.5, 10.6 Placental blood microscopy  9.0 5.0, 13.0 1 
Fako, Cameroon (2007) Anchang-Kimbi (2009) 338 185 306 60.5 55.0, 65.9 Placental histology, impression, smears with microscopy  66.1 60.8, 71.4 1 
Benin City, Benin (2009) Aziken (2011) Aziken 84 371 22.6 18.3, 26.9 Placental blood microscopy  34.4 34.2, 45.7 1 
155 
 
Figure 4.8a Placental malaria at ANC: East and Southern Africa  
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Figure 4.8b Placental malaria at ANC: West and Central Africa 
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 Table 4.9 Diagnostic methods used: sensitivity and specificity 
Infection Diagnostic method Sensitivity (%) Specificity (%) Source 
Syphilis Treponema pallidum haemagglutination (TPHA) only* ~100 ~100 210 
Rapid plasma reagin (RPR) only 86-100 93-98 339 
Venereal disease research laboratory (VDRL) only 78-100 98 339 
RPR or VDRL and TPHA ~100 ~100 - 
RPR and TPHA ~100 ~100 - 
RPR and Determine Syphilis TP ~100 ~100 - 
RPR and Microhemagglutination assay–Treponema pallidum (MHA-TP) ~100 ~100 - 
RPR and Immunoglobulin G (ELISA test) ~100 ~100 - 
Neisseria 
gonorrhoeae 
Gram stain 50-70 50-70 340 
Culture or gram stain (based on less precise, i.e. mean of gram stain) 50-70 50-70 - 
Polymerase chain reaction (PCR) with urine 36-75 98-100 341 
Culture  ~80 100 342 
Culture and gram stain (based on more precise, i.e. mean of culture)  ~80 100 - 
Ligase chain reaction (LCR) with cervical swab 95-100 98-100 342 
PCR with cervical swab 89-97 94-100 342 
Chlamydia 
trachomatis 
Indirect immunofluorescence 46-64 94-98 343 
Culture cervical swab 74-90 98-99 342 
Enzyme immunoassay (EIA) 71-87 97-99 342 
Culture cervical swab or EIA (based on the less precise, i.e. mean of EIA) 71-87 97-99 - 
PCR urine  78-89 99-100 341 
LCR cervical swab 90-97 99-100 342 
PCR cervical swab 99 99-100 342 
DNA ID-assay cervical swab ~100 ~100 - 
Trichomonas 
vaginalis 
Wet-mount microscopy 38-82 100 342 
In-pouch culture 96 100 344 
Bacterial 
vaginosis 
Clue cells > 20% of epithelium 40 97 345 
Unspecified clue cell count NA NA - 
Amsel criteria: 3 or 4 of 4 51 98 345 
Spiegel criteria 75 100 346 
Nugent score >7 of 10 86-89 94-96 347,348 
* TPHA is a confirmatory assay and is not recommended for use alone.  Authors of the one paper who reported using TPHA alone wrote that a positive TPHA was considered to be 
related only to syphilis.210  Thus, sensitivity and specificity of TPHA only, in this epidemiological context, are assumed to be similar to RPR and TPHA or VDRL and TPHA. 
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Table 4.9 Diagnostic methods used: sensitivity and specificity (continued) 
 
 
 
 
 
 
 
 
 
Infection Diagnostic method 
 
Sensitivity (%) Specificity (%) Source 
Peripheral 
parasitaemia 
Giemsa stain microscopy 50-90 ~95 349-351 
Polymerase chain reaction 91 91 296 
Antigen assay  (reported as equal to microscopy) 
Rapid diagnostic test (as reported) 89 76 - 
Placental 
parasitaemia 
Diagnostic method not reported NA NA - 
Placental blood microscopy 63 98-99 320 
Polymerase chain reaction 93-99 73-76 352 
Placental histology 91 98-99 320 
Placental blood microscopy and tissue histology (based on histology) 91 ~100 - 
Placental histology, impression, smears w/ microscopy (based on histology) 91 ~100 - 
Placental impression and blood smears with microscopy (based on impression) 91 ~100 338 
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Discussion 
This systematic review and meta-analysis of malaria infection and curable STIs/RTIs 
spanning a 20-year period suggests the prevalence remains high at the population 
level amongst pregnant women attending ANC facilities in sub-Saharan Africa.  The 
GRADE method of assessing data quality that is commonly applied to evidence from 
clinical trials was not considered appropriate for this analysis.  GRADE requires ranking 
evidence by outcomes of interest, scored as high, intermediate, low, or very low.  
Such, ‘quality scores’ could have been assigned to point prevalence estimates, but that 
could have introduced a degree of subjectivity.  In this context, quality ranking in the 
context of prevalence estimates was driven by the diagnostic method used rather than 
any other factor.  Thus, an objective alternative was used: the precision of each point 
prevalence estimate was adjusted using a standard method for correcting errors of 
known magnitude before incorporating data into the random effects models.  This 
method has been used previously with prevalence data from Tanzania to compare 
STI/RTI estimates derived by disparate diagnostic tests.  Uncorrected and corrected 
point prevalence estimates in this meta-analysis are shown by study in prevalence 
Tables 4.2 to 4.8.   
Diagnostic methods have changed for many pathogens over the period covered in the 
systematic review.  In recent years, for example, the advent of molecular tests such as 
PCR and LCR (ligase chain reaction) has allowed researchers to detect infection where 
older diagnostic methods may have failed to do so.  Although statistical adjustments 
for diagnostic errors can make data more comparable, the pooled prevalence of 
curable STIs/RTIs and malaria infection is still probably an underestimate of the true 
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burden of disease.  The degree to which this occurred is a function the specific 
infection and the assay used in diagnosis. 
Amongst syphilis studies, 45 of 59 used the non-treponemal RPR or VDRL (venereal 
disease research laboratory) tests confirmed by a Treponema-specific test, reflecting 
wide acceptance of the diagnostic gold standard.  However, because biological false-
positive non-treponemal tests can be produced by concurrent malaria infection, as 
well as other infections such as bejel (T. pallidum subspecies endemicum), pinta (T. 
pallidum subspecies carateum), and yaws (T. pallidum subspecies pertenue), the 
burden of syphilis in 15 studies – one-quarter of all data syphilis points – that did not 
use treponemal confirmatory testing may be overstated.  Corrected prevalence 
estimates for these studies are lower are than the uncorrected numbers originally 
reported. 
The most common assay used to test for N. gonorrhoeae was culture which tends to 
under-estimate true prevalence.  This was corrected in 14 studies, slightly increasing 
those prevalence estimates.  The next most frequent assay used was gram stain.  The 
eight studies that employed this method overstated prevalence; gram stain methods 
have poor sensitivity and specificity in low prevalence settings and among women.  
Thus, gram stain will routinely overstate the true prevalence in an ANC setting; the 
method is more appropriate to use at STI clinics with ureteral samples from 
men.  Prevalence estimates based on DNA amplification methods (PCR and LCR) were 
often corrected downward, which may be the result of detecting non-viable fragments 
of bacteria (personal communication; Professor David Mabey).   An exception is PCR 
diagnosis of N. gonorrhoeae with urine samples from women; the assay has been found 
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to under-estimate true prevalence (personal communication; Professor Rosanna 
Peeling) that resulted in an upward correction.    
Compared to assays used to for other infections in the systematic review, the tools to 
detect C. trachomatis were most likely captured the true prevalence.  Of 24 total 
studies, enzyme immune-assays were used in 14 studies and eight studies employed 
DNA amplification.  When corrected, prevalence estimates were commonly lower.   
 Wet-mount microscopy, as previously noted, was used in all but two studies reporting 
trichomoniasis prevalence, a method that notoriously lacks sensitivity compared to 
culture or molecular tests.353,354  Corrected prevalence estimates were nearly twice as 
high as uncorrected measures.  In contrast, in-pouch methods are very precise, 
resulting in only minor adjustments to two corrected estimates.   
Bacterial vaginosis was diagnosed using four different methods: (i) Nugent’s score, (ii) 
Spiegel’s criteria, (iii) Amsel’s criteria, and (iv) clue cell prevalence estimates.  Nugent’s 
score is the preferred method and was applied in studies reporting the seven highest 
rates of infection in East and Southern Africa.  Correction of Nugent’s score prevalence 
estimates were slightly increased in high prevalence areas, but reduced where the 
uncorrected prevalence was single digit.  The other methods – Spiegel’s criteria (n = 1), 
Amsel’s criteria (n = 8), and clue cell count (n =5 ) – are not nearly as precise as 
Nugent’s scoring.  Consequently, the corrected prevalence for these assays was nearly 
double the uncorrected measures. 
Even with correction, peripheral parasitaemia may be under-represented in this meta-
analysis for two reasons.  Prior reports of malaria in pregnancy have described the 
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peak prevalence as occurring between weeks 9-16, declining until term.  Indeed, 
secondary analyses of data from Zambia as part of the third research question found 
the highest prevalence of malaria infection to be amongst pregnant women who 
enrolled in the study during gestational week 15.  Despite this known variation over 
the course of pregnancy, studies identified through systematic review did not report 
the specific gestational age of participants when peripheral parasitaemia was 
measured.  Another important source of under-estimated disease burden comes from 
the fact that most malaria diagnoses were based on microscopy without molecular-
test correction.  A study of pregnant women in Blantyre, Malawi, illustrates the extent 
to which under-diagnosis may occur with conventional microscopy; peripheral 
parasitaemia was found in 51.9% (43.4, 60.3) of women using PCR, while microscopy 
only detected infection in 14.9% (11.8, 18.0) of pregnant women.283  Overall, 
peripheral malaria was measured by microscopy only in 63 studies whereas 10 studies 
included PCR.  Corrected microscopy estimates were higher than uncorrected 
measures.  In contrast, PCR methods were corrected downward slightly, potentially 
accounting for an overstated prevalence attributable to the detection of non-viable 
parasite DNA fragments.  
Histology was used to measure placental malaria in over 14 studies, or one-third 
overall, while microscopy and placental smears were the primary means of 
measurement in 11 and 8 studies, respectively.  In all instances, corrected estimates 
were higher than uncorrected measures. 
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Dual prevalence in the sub-regions 
Overall, pregnant women in East and Southern Africa had a higher prevalence of 
STIs/RTIs compared to expecting mothers in West and Central Africa.  Several factors 
may contribute to this difference that are related to exposure including: (i) higher 
prevalence of STIs/RTIs circulating at the community level, (ii) patterns of male 
circumcision, (iii) sexual behaviour related to age of sexual debut, (iv) age at first 
marriage, (v) premarital sex, (vi) total lifetime partners, and (vii) concurrent sex 
partners.  The prevalence of HIV, for example, remains substantially higher in East and 
Southern Africa compared to the West and Central sub-region.  Indeed, the Joint 
United Nations Programme on HIV/AIDS estimates that 34% of the world’s HIV-
positive population were living in 10 countries of Southern Africa in 2010.355  Although 
the AIDS epidemic in East and Southern Africa has declined over the past decade, the 
prevalence remains higher than in West and Central Africa.   
Evidence from this meta-analysis also suggests that peripheral and placental malaria is 
slightly higher in West and Central Africa compared to the East and Southern sub-
region.  This may be due to greater seasonal intensity of transmission within West and 
Central Africa.  Recent declines in malaria transmission within selected locales of Africa 
will likely translate into fewer pregnant women acquiring immunity from one 
pregnancy to the next.  Thus, all women in their reproductive years, rather than just 
primi- and secundigravidae, may remain vulnerable to the consequences of malaria 
infection in the years ahead until the absolute risk of exposure is negligible.  This may 
be of particular concern if interest wanes in the provision of IPTp-SP in geographic 
areas where malaria transmission intensity is very low. 
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HIV and malaria infection interact to increase placental parasitaemia and the incidence 
of LBW.230   Infection by P. falciparum also increases viral load amongst HIV-positive 
pregnancy women.356  Recent evidence suggests that malaria parasites may be more 
likely to develop wild-type mutations following exposure to IPTp-SP when 
administered to HIV-positive women.357   Despite the known interaction between 
STIs/RTIs and HIV, presumptive treatment of STIs/RTIs amongst pregnant women in 
Rakai, Uganda, did not reduce the incidence of maternal to child transmission of 
HIV.358  However, malaria chemoprophylaxis was not provided in that study and, 
therefore, the potential modulating effect of malaria on vertical transmission in the 
presence of STIs/RTIs remains unknown.   
Interestingly, just five publications of the 171 studies of the systematic review 
reported the prevalence of syphilis and malaria among participants,108,226,237,241,244 and 
only one paper reported the incidence of malaria and STI/RTI co-infection, a 
prospective cohort study of pregnant women in Tanzania.  Co-infection was found 
amongst 48.3% of RPR-positive women who had placental parasitaemia; 35.0% of RPR-
negative women had malaria-infected placentas (P < 0.001).146  Separate analysis of 
the Zambia data used in the third research question showed that 38.7% (95% CI: 35.7, 
41.6) of pregnant women were co-infected with malaria parasites and at least one 
curable STI/RTI, whereas half that number, 18.9% (95% CI: 16.5, 21.2), were infected 
with malaria parasites only.202  This strengthens the evidence base for combination 
treatment that addresses the dual burden of malaria infection and curable STIs/RTIs 
and, indeed, evidence from Zambia shows that IPTp-SP is protective against this dual 
burden. 
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This systematic review and meta-analysis has limitations, not the least of which is the 
inherent delay between gathering evidence at the field level and publication.  This is 
consequential because HIV-prevention campaigns, including STI/RTI screening and 
treatment programmes, have made inroads in reducing transmission in many settings.  
To capture these reductions, more data from the recent past are needed.  Another 
limitation is that, even after stratifying by geography and age of study, heterogeneity 
amongst studies persisted.  Consequently, random effects models were used, rather 
than fixed effects, but these produced wide confidence intervals in some instances.  
Finally, evidence was limited to English-language sources and abstracts that had been 
translated into English.  
Considering the 171 studies of this systematic review, there is wide variability in 
prevalence estimates that has been extracted from a range of populations that cover 
large geographic areas over a 20-year period.  Stratification of data into sub-regions 
has value for policymakers and programme managers for planning purposes as well as 
advocacy.  Presenting the range of prevalence estimates by infection and sub-region 
has particular public health value that highlights inequities that merit intervention. 
 
Q 5.  Effect of azithromycin on curable STIs/RTIs in pregnancy 
Methods 
The effect of azithromycin monotherapy on malaria infection was summarised in the 
Literature Review section of this thesis.  However, given the high dual burden of 
malaria infection and curable STIs/RTIs amongst pregnant women, would azithromycin 
be an efficacious drug against curable STIs/RTIs to be included as part of IPTp?  A 
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systematic review and meta-analysis was conducted to characterise the in vitro and in 
vivo effect of azithromycin against the curable STIs/RTIs of interest.   
PubMed, MEDLINE and EMBASE were searched between April and May 2013 using 
medical subject headings and free-text terms as shown in Table 5.1.  Searches were 
limited to the English language.  With each query, the infection and causal organism 
were used together; for example, ‘Syphilis’ OR ‘Treponema pallidum’ were combined 
with search terms ‘azithromycin’ OR ‘macrolide’.  Reference lists were also reviewed 
for additional documents.  As with prior systematic reviews, publication and author 
names were not blinded, but data abstraction was done in duplicate.   
Table 5.1 Medical subject headings and free text terms 
Infection Medical search headings Free text terms 
Syphilis Topic=(“Syphilis” OR 
“Treponema pallidum”)  
Treponema pallidum OR Syphilis AND 
azithromycin OR macroide 
Neisseria 
gonorrhoeae 
Topic=("Neisseria 
gonorrhoeae") OR 
Topic=(Gonorrhea) OR 
Topic=(Gonorrhoea)  
Neisseria gonorrhoeae OR gonorrhoea 
OR gonorrhea AND azithromycin OR 
macroide 
Chlamydia 
trachomatis 
Topic=(“Chlamydia”) OR 
Topic= (trachomatis)  
Chlamydia trachomatis OR chlamydia 
AND azithromycin OR macroide 
Trichomonas 
vaginalis 
Topic=("Trichomonas 
vaginalis") OR 
Topic=(“Trichomoniasis”) 
Trichomonas vaginalis OR 
trichomoniasis AND azithromycin OR 
macroide 
Bacterial vaginosis Topic=("Bacterial 
vaginosis") OR 
Topic=(“Vaginalis 
bacterial”) 
Bacterial vaginosis OR Vaginalis 
bacterial AND azithromycin OR 
macroide 
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Results 
As shown in Figure 1 below, a total of 122 articles met inclusion criteria for the 
systematic review.     
Figure 5.1 PRISMA flowchart for systematic review 
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Syphilis and azithromycin  
In vivo evidence 
The WHO recommends treating pregnant women who have a syphilis infection with 
2.4 million units (mµ) of benzanthine penicillin G (BPG) administered by intramuscular 
injection.109  Thus, the focus of in vivo evidence from this systematic review reflects 
findings from six clinical trials that reported outcomes amongst non-pregnant adults 
following treatment with BPG, azithromycin, or a combination of BPG and 
azithromycin as shown in Table 5.2a.  The oldest data are from a trial in the United 
States (1993 to 1997) in which individuals who learned they had been exposed to 
infectious-stage syphilis through sexual intercourse in the preceding 30 days were 
given either 1 g azithromycin (n = 40) or BPG (n = 23).  Three months post-treatment, 
RPR and fluorescent treponemal antibody absorption tests were negative for all 
participants in both treatment groups.359  Another trial, also in the United States and 
during the same period of time, was designed to measure treatment outcomes in a 
population at high risk of contracting STIs/RTIs.  Diagnostic methods were not 
reported, but the trial was suspended after two of the first 12 patients given 1 g 
azithromycin went on to fail their tests of cure, whereas all 13 participants were cured 
using BPG (P = 0.18).360  A three-arm trial of early syphilis in the United States then 
compared treatment outcomes amongst patients given BPG, versus 2 g azithromycin 
once, versus 2 g azithromycin on two occasions with one week in between doses.  RPR 
and fluorescent treponemal antibody absorption tests showed that cure was achieved 
in 85.7% (n = 14; 95% CI: 60.0% to 95.7%) of patients given BPG, 94.1% (n = 17; 95% CI: 
72.7% to 98.6%) amongst recipients of 2 g azithromycin once and 82.8% (n = 29; 95% 
CI: 65.3% to 92.3%) in participants who twice received 2 g azithromycin.361    
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Table 5.2a Syphilis RCTs of azithromycin vs. benzathine penicillin G  
Low-risk and unspecified low-risk populations and high-risk populations 
 
Reference Country Year(s) Regimen  No. cured 
of treated 
Percent 
cured  
95% CI Diagnostic methods 
used 
Follow up  Stage of infection 
Specified low-risk populations 
Hook (2010) 362 Madagascar 
United States 
2000-2007 2 g azithromycin       
2.4 mµ BPG 
180/232     
186/237 
77.6%  
78.5% 
71.8% to 82.5%                 
72.8% to 83.2% 
RPR and FTA-ABS   6 months  Primary, secondary, 
early latent syphilis 
Kiddugavu (2005) 363 
 
Uganda 1994-1998 1 g azithromycin 
2.4 mµ BPG 
1 g azithromycin plus 2.4 
mµ BPG 
55/94         
66/93      
221/313 
58.5%  
71.0%   
70.6% 
48.4% to 68.0%   
61.0% to 79.2% 
65.3% to 75.4% 
TRUST and TPHA                
(initial TRUST titres ≤ 
1:2) 
10 months  Serologic syphilis 
1 g azithromycin 
2.4 mµ BPG 
1 g azithromycin plus 2.4 
mµ BPG 
38/71         
31/75      
169/309 
53.3%  
41.3%  
54.7% 
42.0% to 64.7% 
30.9% to 52.7% 
49.1% to 60.2% 
TRUST and TPHA               
(initial TRUST titres ≥ 
1:4) 
10 months  Serologic syphilis 
Unspecified low risk populations 
Klausner (2006) 360 United States 2004 
 
1 g azithromycin 
2.4 mµ BPG  
10/12 
13/13 
83.3% 
100.0% 
54.6% to 95.0%  
NA 
NR NR  Exposed to infectious 
syphilis 
Hook (2002) 361   
 
United States 1995-1997 2 g azithromycin  
2 g azithromycin (x2) 
week apart 2.4 mµ BPG 
14/14         
19/22              
               
100.0% 
86.4% 
 
 
NA    
66.4% to 95.0% 
 
 
RPR and MHA-TP or 
FTA-ABS  
12 months  Primary, secondary, 
early latent syphilis 
Hook (1999) 359   United States 1995-1997 1 g azithromycin              
2.4 mµ  BPG     
40/40         
23/23 
100.0% 
100.0 
NA                
NA 
RPR and FTA-ABS  3 months  Exposed to infectious 
syphilis 
High-risk population 
Riedner (2005) 364 Tanzania 2000-2003 2 g azithromycin       
2.4 mµ BPG 
159/163    
157/165 
97.5%  
95.2% 
93.9% to 99.0%               
90.7% to 97.5% 
RPR and PCR 9 months  Primary, secondary, 
higher titre latent 
syphilis 
 
2.4 mµ BPG = 2.4 million units benzathine penicillin G; RPR = Rapid plasma regain; FTA-AB S= Fluorescent treponemal antibody-absorption; TRUST = Toluidine Red Unheated Serum Test; TPHA = Treponema pallidum haemagglutination; 
MHA-TP = Microhaemagglutination assay-Treponema pallidum; PCR = Polymerase chain reaction; NR = Not reported; NA = Not applicable 
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Three trials have investigated BPG versus azithromycin in sub-Saharan Africa, the first 
being a community-randomised trial in Uganda (1994 to 1998) amongst non-pregnant 
adults with serological syphilis.  Diagnosis pre- and post-treatment were based on 
toluidine red unheated serum tests (TRUST) and TPHA assays.  Treatment efficacy 
varied across regimens depending on TRUST titres at enrolment.  Amongst patients 
with initial titres < 1:2, BPG cured 71.0% (n = 93; 95% CI: 61.0% to 79.2%) of cases, 
compared to 58.5% (n = 94; 95% CI: 48.4% to 68.0%) in patients given 1 g 
azithromycin, and 70.6% (n = 313; 95% CI: 65.3% to 75.4%) of participants treated with 
1 g azithromycin plus BPG.   If titres at enrolment were > 1:4, the efficacy of BPG was 
reduced to 41.3% (n = 75; 95% CI: 30.9% to 52.7%).  Treatment efficacy was also lower 
amongst groups given azithromycin, but higher than BPG alone.  Recipients of 1 g 
azithromycin alone had a cure rate of 53.3% (n = 71; 95% CI: 42.0% to 64.7%), whereas 
1 g azithromycin plus BPG cured 54.7% of cases (n = 309; 95% CI: 49.1% to 60.2%).363 
These results were followed by a trial in Tanzania (2000 to 2003) amongst patients 
from high-risk populations.  All 328 subjects had a titre of at least 1:8 on RPR tests; 106 
had baseline titres of > 1:64, levels indicative of active syphilitic lesions.  Serological 
cure was observed in 97.5% (n = 163; 95% CI: 93.9% to 99.0%) of participants treated 
with 2 g azithromycin versus 95.2% (n = 165; 95% CI: 90.7% to 97.5%) in the BPG group 
as measured by RPR test and TPPA assays.364   
The most recent study comparing the efficacy of azithromycin versus BPG is a multi-
centre trial (2000 to 2007) in Madagascar (n = 421) and North America (n = 94) 
amongst HIV-negative participants with early syphilis.  Serological cure was reported in 
77.6% of subjects given 2 g azithromycin (n = 232; 95% CI: 71.8% to 82.5%) and 78.5% 
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(n = 237; 95% CI: 72.8% to 83.3%) in the BPG group based on RPR testing.  Non-serious 
adverse events were reported by 61.5% (n = 174; 95% CI: 55.7% to 67.0%) of 
individuals treated with 2 g azithromycin, most of whom had self-limiting 
gastrointestinal discomfort.  In contrast, 46.1% (95% CI: 40.6% to 52.1%) of BPG 
recipients reported non-serious adverse events.362   
In vitro evidence 
Fourteen in vitro studies met inclusion criteria, seven with isolates from low-risk and 
unspecified low-risk populations, Table 5.2b, and seven from high-risk or mixed-risk 
groups, Table 5.2c.  The first report to associate azithromycin treatment failure with 
A→G mutations at the 2058 position of the 23S rRNA gene of T. pallidum came from 
surveillance monitoring in San Francisco.365  Retrospective analysis revealed that 4.0% 
(N = 25; 95% CI: 0.9% to 19.6%) of isolates had A→G mutations between 1999 and 
2002.  In 2003, the proportion of isolates with A→G mutations increased to 36.7% (N = 
30; 95% CI: 21.9% to 54.6%); by 2004, 56.1% (N = 66; 95% CI: 44.0% to 67.3%) had 
selected for resistance.365  In Dublin, however, 88.2% (N = 17; 95% CI: 65.3% to 96.4%) 
of isolates already had A→G mutations by 2002.366   
Macrolide resistance has been strongly associated with prior use in the previous year.  
Isolates from Seattle (2001 to 2005) were two-times more likely to be resistant if 
patients had been treated with macrolides in the past 12 months (RR = 2.2; 95% CI: 1.1 
to 4.4; P = 0.02).367  This relationship persisted over the decade.  Mutations A2058G 
and A2059G, which are associated with clinical failures of azithromycin, were found in 
88.9% (N = 36; 95% CI: 74.6% to 95.5%) of isolates from 2001 to 2010 amongst 
patients exposed to macrolides in the preceding 12 months, whereas 61.2% (N = 98; 
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95% CI: 51.3% to 70.4%) of isolates from individuals who had not received prior 
macrolide treatment contained the same mutations.368  Similar mutations were found 
amongst T. pallidum isolates from eight cities across China (2008 to 2011).  A2058G 
was present in 97.0% individuals who had taken macrolides in the previous 12 months 
versus 62.5% of patients who had not (N=211; OR=19.65; 95% CI: 5.8 to 66.9).369  In 
Taiwan (2009 to 2011) the opposite was observed; not one single A2058G or A2059G 
mutation was found amongst 211 isolates tested from a population where only one 
person had been given macrolide therapy in the previous year.370  Similarly, there was 
no evidence of resistance amongst 141 amplified samples from HIV-negative 
heterosexual patients in Madagascar.371  Although use of macrolides in the previous 
year was not reported, the Essential Drugs List of the Malagasy Ministry of Health does 
not include macrolides.372 
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Table 5.2b Azithromycin and syphilis: low-risk populations 
 
 
 
 
Reference Country  Year(s) Specimen 
source 
Sample 
size 
Resistant 
mutation 
Number 
resistant 
Percent 
resistant 
95% CI Additional details 
Low-risk populations 
Chen (2013) 373 United States 2007-2009 Surveillance   129 A2058G   
A2058G 
A2059G 
83              
67              
17 
64.3% 
51.9% 
13.2% 
55.8% to 72.1%   
43.4% to 60.4%    
8.4% to 20.1% 
From patients with primary of secondary syphilis 
attending STI clinics 
Van Damme 
(2009) 371 
Madagascar NR Randomised 
clinical trial 
186 23S rRNA  0 0.0% NA DNA of T. pallidum was detected in 141 samples; 
61% of patients were male; 98% were heterosexual 
Unspecified low-risk populations 
Mϋller (2012) 374 South Africa  
Lesotho 
2005-2010 Surveillance   100 A2058G 
A2059G 
1                   
0 
1.0%               
0.0% 
0.0% to 5.4% 117 ulcer specimens collected of which 100 were 
positive for T. pallidum. 
A2058G 
Prevalence 
Workgroup 
(2012) 375 
United States 2007-2009 Surveillance   141 A2058G 75 53.1% 45.0% to 61.2% From patients with primary of secondary syphilis 
attending STI clinics; MSM were nearly 6 times more 
likely to have resistant syphilis compared to 
heterosexual women and men 
Matějková (2009) 
376 
Czech Republic 2005-2008 Passive case 
detection 
22 23S rRNA 
A2058G 
A2059G 
8                   
4                   
4 
36.4%         
18.2%        
18.2% 
19.7% to 57.3% 
7.5% to 38.8%    
7.5% to 38.8% 
  
 
Martin (2009) 377 China 2007-2008 Passive case 
detection 
38 A2058G 38 100.0% NA Patients presenting to STI clinic with symptoms 
compatible with primary syphilis 
Lukehart (2004) 
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United States  PCR to detect 23S rRNA gene mutations; 
confirmation of azithromycin resistance was 
conducted through intradermal rabbit inoculation.   
 
San Francisco        
San Francisco        
Seattle 
Baltimore 
1999-2002 
2003 
2001-03 
1998-2000 
Surveillance  
 
25 
30 
23 
19 
23S rRNA 1 
11 
3 
2 
4.0% 
36.7% 
13.0% 
10.5% 
1.0% to 19.6% 
21.9% to 54.6% 
4.7% to 32.3% 
3.2% to 31.7% 
Ireland  
 
Dublin 2002 Surveillance   17 23S rRNA 15 88.2% 65.3% to 96.4% 
Multiple locations 1912-1987 Historical  18 23S rRNA 1 5.6% 1.3% to 2.6% 
 
rRNA=Ribosomal ribonucleic acid; NA=Not applicable; DNA=Deoxyribonucleic acid; STI=Sexually transmitted infection; MSM=Men who has sex with men; PCR=Polymerase chain reaction  
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 Table 5.2c Azithromycin and syphilis: high- and mixed-risk populations  
Reference Country Year(s) Specimen 
source 
Sample 
size 
Resistant 
mutation 
Number 
resistant 
Percent 
resistant 
95% CI Additional details 
High-risk populations 
Tipple (2011) 378 United 
Kingdom 
2006-2008 Cross-sectional  18 23S rRNA  
A2058G 
12                     
11 
66.6%           
61.1% 
43.4% to 83.7%  
38.4% to 79.7% 
Specimens from men, 94.1% were MSM 
Rekart (2003) 379 Canada 2000 Mass drug 
administration  
25 23S rRNA   0 0.0% NA 1.8 g azithromycin given to sex workers and 
clients (N = 4,384) 
Mixed-risk populations 
Chen (2012) 369 China 2008-2011 Cross-sectional  211 A2058G 194 91.9% 87.2% to 95.1% 391 samples collected; 6.1% from FSW, 71.8% 
reported sex with FSW, and 1.4% were MSM 
Muldoon (2012) 
380 
Ireland 2009-2010 Cross-sectional  29 A2058G 27 93.1% 77.9% to 97.9% 34.6% (36/104) of samples were positive for T. 
pallidum by PCR; 29 sequenced 
Martin (2010) 381 Canada 2007-2009 Cross-sectional  43 A2058G 7 16.3% 8.2% to 30.1% 449 samples collected from 374 patients; 43 were 
positive for T. pallidum and sequenced.   
Mitchell (2006) 382 United States 2000-2002                     Retrospective  25               23S rRNA   1 4.0% 1.0% to 19.6% Patients (N = 1,308) diagnosed primary or 
secondary syphilis; all treatment failure and 
resistance in MSM/bisexual patients 2003   32 13 40.6% 25.5% to 57.9% 
2004 66 37 56.1 44.0% to 67.4% 
Morshed (2006) 
383 
Canada 2000-2003   Retrospective  47 23S rRNA   1 2.1% 0.5% to 11.1% MSM patients presenting to STI clinic with 
primary or secondary syphilis 
2004 9 4 44.4% 18.7% to 73.8% 
 
rRNA=Ribosomal ribonucleic acid; MSM=Men who have sex with men; NA=Not applicable; PCR=Polymerase chain reaction; FSW=Female sex worker; STI=sexually transmitted infection 
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Neisseria gonorrhoeae and azithromycin 
In vivo evidence 
The WHO recommends the treatment of pregnant women with N. gonorrhoeae 
infection using 400 mg cefixime as a single dose, or 125 mg ceftriaxone by 
intramuscular injection.110  However, azithromycin has been used for the treatment of 
gonorrhoea amongst non-pregnant adults during the past two decades.  Eleven trials 
were identified by systematic review as shown in Table 5.3a.  Nine trials between 1989 
and 1999 were conducted amongst attendees of STI clinics using 1 g azithromycin.  
Three of these trials were open label without comparators,384-386 whereas six were 
two-arm trials that compared azithromycin to ciprofloxacin and/or doxycycline.387-392  
Meta-analysis using random effects models175 suggests that the pooled efficacy of 
azithromycin against N. gonorrhoeae was 97.0% (N = 539; 95% CI: 95.5% to 98.5%).  
This is slightly higher than 96.5% (N = 539; 95% CI: 94.3% to 97.6%) reported in a 2010 
review393 that added numerators and divided by the sum of denominators amongst 
the same nine trials.  However, the methods used in that review were dubious, failing 
to account for heterogeneity across study populations and giving equal weight to all 
trials regardless of their individual study precision.  Nevertheless, it is unlikely the 
same efficacy would be observed today using 1 g azithromycin in high-income 
countries following 25 years of cumulative drug pressure.  However, the 
epidemiological context in sub-Saharan Africa is different where azithromycin use has 
been almost exclusively limited to trachoma eradication campaigns.394  
 
Two RCTs investigated the use of 2 g azithromycin amongst patients at STI clinics.  The 
first was a multi-centre trial in the United States (1991 and 1992) in which 98.9% 
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(N=374; 95% CI: 97.3% to 99.6%) of patients were cured.395  A similar RCT in New Delhi 
(2005 and 2006) involved 42 participants.  The reported loss to follow up was high, 
52.4%, but all 22 subjects who returned for a test of cure had their N. gonorrhoeae 
infections cleared.396   
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Table 5.3a Neisseria gonorrhoeae RCTs of azithromycin 
 
Reference 
(year of 
publication) 
Country Year(s) Azithromycin dose No.  of 
cured 
evaluated 
Percent 
cured 
95% CI Diagnostic methods Additional details 
Dose of 2 g azithromycin 
Khaki (2007) 
396 
India 2005-2006 2 g 22/22 100% NA Gram stain 
TOC days 5-7 
 
Handsfield 
(1994) 395 
United 
States 
1991-1992 2 g 370/374 98.9% 97.3% to 99.6%   
Dose of 1 g azithromycin 
Rustomjee 
(2002) 392 
South Africa 1999 1 g 30/31 
 
96.8%  83.8% to 99.2% LCR for NG/CT  
TOC day 14  
 
100% (n = 21) NG infections cured  
100% (n = 14) CT infections cured 
90.0% (n = 10; 95% CI: 58.7 to 97.8%) co-infections cured 
Swanston 
(2001) 386 
Trinidad and 
Tobago 
1996 1 g 125/127 
 
98.4%  94.5% to 99.5% ELISA for NG Culture for CT; 
TOC days 7-10 
100% (n = 115) NG infections cured 
95.7% (n = 23; 95% CI: 78.9 to 99.0%) CT infections cured 
88.3% (n = 12; 95% CI: 54.6 to 95.0%) co-infections cured 
Gruber (1997) 
391 
Croatia 1994-1995 1 g  48/50 96.0% 86.5% to 98.8% Culture and gram-stain for 
NG; TOC day 14 
 
Gruber (1995) 
390 
Croatia 1991-1993 1 g 24/24 96.0% 80.4% to 99.1% Culture and gram-stain for 
NG; TOC day14 
 
Steingrimsson 
(1994) 389 
Iceland NR 1 g 27/28 96.4% 82.4% to 99.2% Culture for NG w/ DFA; 
Culture for CT; TOC day 28 
92.4% (n = 79; 84.4 to 96.4%) CT infections cured 
Waugh (1993) 
385 
United 
Kingdom 
1990-1991 1 g 85/89 95.5%  89.0% to 98.2% Culture and gram-stain for 
NG; Culture for CT; 
TOC day 10 
100% (n = 22) NG/CT co-infections cured 
 
Odugbemi 
(1993) 384 
Nigeria 1989-1990 1 g 114/120 95.0%  89.5% to 97.6% Culture for NG; TOC day 14  
Steingrimsson 
(1990) 388 
Iceland NR 1 g (day 0) 11/12 91.7% 64.0% to 98.1% Culture for NG/CT; 
TOC day 28 
97.7% (n = 44; 88.2 to 99.5%) CT infections cured 
500 mg (day 0 x 2) 7/8 87.5% 51.8% to 97.2% 96.3% (n = 27; 81.7 to 99.1%) CT infections cured 
500 mg (day 0)  
250 g (day 1 & 2) 
7/7 100% NA 88.0% (n = 25; 69.8 to 95.6%) CT infections cured 
Lassus (1990) 
387 
Finland NR 1 (day 0) 15/15 100% NA Culture and gram-stain for 
NG/CT  w/ DFA; TOC day 14 
100% (n = 12) CT infections cured 
100% (n = 5) co-infections cured 
500 mg (day 0) 
250 mg (days 1 & 2) 
14/14 100% NA 100% (n = 9) CT infections cured 
83.3% (n = 6; 95% CI: 42.1 to 96.3%) co-infections cured 
 
TOC = Test of cure;  NG = Neisseria gonorrhoeae; CT = Chlamydia trachomatis; LCR = Ligase chain reaction; DFA = direct fluorescent antibody; ELISA = Enzyme-linked immunosorbent assay; NR = Not reported ; NA = Not applicable 
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In vitro evidence 
Several in vitro studies have documented the loss of N. gonorrhoeae sensitivity to 
azithromycin over the past decade.  There are no standard breakpoints of minimum 
inhibitory concentrations (MIC) used to categorize N. gonorrhoeae resistance to 
azithromycin, but > 1 µg/mL and > 2 µg/mL have both been used.397  This section 
summarises key regional observations from 36 in vitro studies as shown in Tables 5.3b 
and 5.3c.   
The Public Health Agency of Canada reported that 0.17% (N = 40,875; 95% CI: 0.001% 
to 0.002%) of N. gonorrhoeae samples were resistant to azithromycin between 2000 
and 2009.  The numeric mode of the MIC shifted from 0.25 µg/mL in 2001 to 0.5 
µg/mL between 2007 and 2009.398  During the same 10-year period, the Centers for 
Disease Control and Prevention in the United States reported that 0.04% (N = 87,566; 
95% CI: 0.03% to 0.06%) of N. gonorrhoeae isolates tested had MICs ≥8 µg/mL 
(including 25 with 8 µg/mL and 14 with 16 µg/mL).399  This did not include five cases of 
azithromycin resistance reported later that had been found between August and 
October 2009 amongst men who have sex with men.  Three samples investigated had 
MICs of 8 µg/mL, whereas two had MICs of 16 µg/mL.400   
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Table 5.3b Azithromycin and Neisseria gonorrhoeae: low-risk populations  
 
 
 
Reference 
(year of publication) 
Country Year(s) Sample size MIC range 
(µg/mL) 
% strains susceptible Additional details 
Olsen (2013) 401 Vietnam 2011 108 NR 62% 11%  isolates fully resistant, 29% intermediate susceptibility 
Lahra (2012) 402 Australia 2011 3,293 ≤4 98.1% Isolates from all states in Australia 
Sethi (2013) 403 India/Pakistan/Bhutan 2007-2011 65 0.016 to 4.0 76.9% 7.7% isolates fully resistant, 15.4% intermediate susceptibility 
Lo (2012) 404 Hong Kong 2010 485 <0.25 to >256 69.7% --  
Lefebvre (2011) 405 Canada 2010 831 ≤16 98.7% -- 
Hottes (2013) 406 Canada 2006-2011 1,837 0.064 to16 99% Elevated MIC showed increasing trend over time 
CDC (2011) 400 United States 2002-2009 87,566  99.9% 39 (0.04%) had MICs ≥8 µg/mL (25 with 8 µg/mL; 14 with 16 µg/mL) 
Yuan (2011) 407 China 2008-2009 318 NR 94.7% -- 
Takahashi (2013) 408 Japan 2007-2009 52 0.016 to 1 100% 100% of isolates from mena 
Herchline (2010) 409 United States 2006-2008 286 0.032 to 1.0 99.0% Median MIC 0.125 µg/mL 
Cole (2010) 399 Europe (17 nations) 2006-2008  3,528 ≤256 2.0% to 7.0% High resistance (>256  µg/mL) in 4 isolates from Scotland and 1 in Ireland  
Olsen (2012) 410 Guinea-Bissau 2006-2008 31 NR 100% Of resistant strains, 2 had MIC >64 µg/mL 
Tanaka (2011) 411 Japan 2001- 2009 242 0.004 to 1.0 99.9% Modal shift of MIC was 0.25-0.5 µg/mL 
Martin (2011) 398 Canada 2000-2009 40,875 ≤64 99.8% 100% isolates susceptible also to cefixime, ceftriaxone and spectinomycin.  
Bala (2011) 412 India 2000-2009 274 NR 99.7% One isolate was resistant to azithromycin, quinolones and penicillin  
Chisholm (2009) 413 United Kingdom 2001-2007 108 <0.03 to >256 94.0% 6/108 isolates had MIC >256  µg/mL ; Shift to high level resistance 
Khaki (2007) 414 India 2004-2005 60 0.016 to 0.25 100% -- 
Enders (2006) 415 Southern Germany  2004-2005 65 0.016 to 5.0 100% 100% of isolates susceptible to azithromycin 
Vorobieva (2007) 416 Russia 2004 76 NR 100% Although all susceptible, reduced susceptibility seen in 14%  
Sutrisna (2006) 417 Indonesia 2004 163 NR 100% 53% resistant to ciprofloxacin  
Martin (2004) 418 Western Europe 2004 965 NR 91.8% 31.2% (Austria 30/96) to 0% (France 0/101, Greece 0/79, Portugal 0/17) 
Chaudhary (2005) 419 Nepal 2003 16 0.008 to 0.5 100% No isolates resistant, but 3/16 (19%) had reduced susceptibility 
Chen (2009) 420 Taiwan 1999-2004 65 NR 100% -- 
Hsueh (2005) 421 Taiwan 1999-2003 55 0.03 to 9.0 72.7% -- 
Aydin (2005) 422 Turkey 1998-2002 78 0.004 to 0.25 100% 100% of isolates from mena 
Moodley (2001) 423 South Africa 1995-2000 58 0.015 to 1.0 100% 37% (37/100) resistant to penicillin; tetracyclines reduced susceptibility.  
Kobayashi (2003) 424 Japan 1995-1999 699 0.015 to 1 100% 100% of isolates from mena   
Llanes (2003) 425 Cuba 1995-1999 52 0.064 to 0.5 76.9% 23.1% intermediate susceptibility: MIC= 0.125 (10 isolates) MIC= 0.5 (2 isolates) 
Sosa (2003) 426 Cuba 1995-1999 91 0.063 to 4.0 90.1% Isolates with reduced susceptibility also resistant to penicillin and tetracycline 
Dillon (2001) 427 Brazil 1998 81 0.032 to 0.5 100% 28% reduced susceptibility 
Zarantonelli (1999) 428 Uruguay 1996-1997 51 0.032 to 0.5 100% Decreased susceptibility (MIC 0.025 to 0.5) in 72%;  isolates from mena   
Young (1997) 429 Scotland 1996 67 0.023 to 0.75 100% Isolates randomly selected from with penicillin MIC≥1 
Mehaffey (1996) 430 United States NR 105 0.06 to 2.0 100% Two tests compared. Data from agar dilution method not Etest.  
Dillon (2001)  Guyana & St Vincent 1992-1996 136 0.032 to 8.0 85.5% & 97.0% 2 isolates had MIC =8ug/L. 49% (67/137) reduced susceptibility (combined) 
Van Rijsoort-Vos (1995) 431 Netherlands 1991-1993 114 0.03 to 1.0 100% 1 isolate reduced susceptibility  
Ison (1993) 432 South Africa 1989-1990 192 0.03 to 1.0 100% Study in migrant mine-workers (men only)b 
 
MIC = Minimum inhibitory concentration; NR = Not reported;  CDC = Centers for Disease Control and Prevention ; aSexual practices were not reported; isolates are assumed not to be from men who have sex with men; bDislocated males workers are amongst high-risk 
populations;. 
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Table 5.3c Azithromycin and Neisseria gonorrhoeae: high-risk populations 
 
 
 
Reference 
(year of publication) 
Country Year(s) Sample size MIC range 
(µg/mL) 
% of strains 
susceptible 
Additional details 
High-risk populations 
CDC (2011) 400 United 
States  
2009 55 NR 90.9% 9.1% resistant (95% CI: 4.0 to 19.6%); of 5 resistant (all from MSM), 3 
had MIC equal to 8ug/mL and 2 had MIC equal to 16ug/ml 
Starnino (2009) 433 Italy 2007-2008 219 1.0 to 256.0 90.0% 72.7% (95% CI: 51.6 to 86.8%) of resistant isolates from MSM 
Donegan (2006) 434 Bali 2004 147 0.013 to 0.512 100% Study in FSWs; prevalence of NG estimated to be 35-60% 
Morris (2009) 435 United 
States 
2000-2002 79 0.03 to 0.5 100% Increased MIC values seen in MSM subject isolates 
Ieven (2003) 436 Indonesia  1996 267 0.032 to 0.5 100% Study in FSWs; prevalence of NG estimated to be 18-44% 
CDC (2000) 437 United 
States 
1999 12 1.0 to 4.0 NR Median MIC was 2.0ug/mL. 6 of 12 samples were from men who had 
sex with a CSW; 2 of 12 were from HIV positive men 
Mixed-risk populations 
Bruck (2012) 438 United 
Kingdom 
2005-2006 147  NR 99.3% Mixed male heterosexual, MSM and female heterosexual isolates 
Dan (2010) 439 Israel 2002-2007 406 0.023 to 8.0 91.8% Mixed male heterosexual, MSM and female heterosexual; resistance 
to azithromycin did not appear to rise over 5 year period 
McLean (2004) 440 United 
States 
1999-2001 1,248 ≤4 97.4% Mixed high risk and low risk population.  Median MIC was 2.0ug.mL 
Arreaza (2003) 441 Spain 1992-2001 63 0.03 to 4.0 96.8% 58.7% of strains had reduced susceptibility (0.25-1.0ug/ml). 50% of 
resistant isolates were from FSW 
 
* Mixed-risk population; MIC = Minimum inhibitory concentration; NR = Not reported; MSM = Men who have sex with men; FSWs = Female sex workers; NG = Neisseria gonorrhoeae; CSW = Commercial 
sex worker (gender not specified);  CDC = Centers for Disease Control and Prevention 
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Gonococcal resistance may have appeared in Europe slightly before North America.  
Analysis of isolates from 17 European countries suggests that 3.2% (N = 836; 95% CI: 
0.02% to 0.05%) of gonococcal isolates were resistant to azithromycin in 2006.  By 
2007, 6.8% (N = 973; 95% CI: 0.05 to 0.09) of samples were resistant.  Sampling in 2008 
found 1.8% (N = 940; 95% CI: 0.01% to 0.03%) of isolates to be resistant.  However, 
only 5.2% (95% CI: 4.1% to 6.8%) of strains tested in the same year were fully 
susceptible to azithromycin and ciprofloxacin.  Four isolates from Scotland and one 
from Ireland exhibited MICs >256 mg/l.399   
 
Gonococcal isolates from South America and Cuba exhibited high but stable levels of 
resistance between 2000 and 2009 in most settings.442  Collectively, azithromycin 
resistance was 13.0% (N = 8,373; 95% CI: 12.3% to 13.7%) based on data from six 
countries including Chile, an outlier.  Averaged over the decade, 26.7% (N = 3,116; 95% 
CI: 25.2% to 28.3%) of samples from Chile were resistant, rising to 45.6% (N = 463; 95% 
CI: 41.1% to 50.1%) in the most recent data from 2009.  Meta-analysis using random 
effects models, excluding data from Chile, suggests that only 4.4% (N = 5,257; 95% CI: 
3.9% to 5.1%) of isolates were resistant over the decade. 
 
All 60 gonococcal isolates from India between 2004 and 2005 were susceptible to 
azithromycin.414  Published analysis of samples collected from India, Pakistan and 
Bhutan between 2007 and 2011 found that 76.9% (N = 65; 95% CI: 65.3% to 85.5%) 
were susceptible.  Results were not stratified by country and, therefore, it is unknown 
whether the sensitivity of isolates from India had changed during the same period.403  
Applying the more conservative breakpoint of > 1 µg/mL to the in vitro studies 
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identified in this systematic review, 35% (7 of 20) of the in vitro studies reported 
upper-range MICs that included gonococcal isolates resistant to azithromycin.  This 
percentage does not include 16 studies identified and included in Tables 5.3b and 5.3c 
that did not report MICs. 
 
Chlamydia trachomatis and azithromycin 
In vivo evidence  
The WHO recommends treating pregnant women with C. trachomatis infection using  
1 g azithromycin as a single oral dose.110  There were eight RCTs in the literature that 
reported the treatment efficacy of 1 g azithromycin amongst pregnant women 443-450  
as summarised in Table 5.4a.  Meta-analysis using random effect models suggests the 
pooled treatment efficacy was 92.1% (N = 268; 95% CI: 88.4% to 95.7%).  The 
estimated efficacy would be higher if two trials from the United States had been 
excluded.  The first trial (1995 to 1997) reported a three-week test of cure rate to be 
88.1% (N = 42; 95% CI: 74.9% to 94.7%).446  The second trial (1998 to 2000) was 
terminated early, however, as tests of cure conducted four or more weeks post-
treatment showed that only 63.3% of infections had been cleared (N = 55; 95% CI: 
50.4% to 75.1%).444  These results need to be interpreted with caution because no 
distinction was made between treatment failures and new infections.  Moreover, sex 
partners were referred to treatment centres, and only 35% of women were seen by 
trial staff within seven days of the scheduled test of cure.  
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Table 5.4a Azithromycin and Chlamydia trachomatis in pregnant women 
 
Reference 
(year of 
publication) 
Country Year(s) No. cured of 
evaluated 
Cured (%) 95% CI Diagnostic method Birth outcomes Additional details 
Kacmar  (2001) 443 United 
States 
1998-2000 18/19 94.7% 84.4% to 100%* Ligase chain 
reaction; TOC 28-
42 days 
NR 52.6% (n = 19; 95% CI: 31.5% to 72.8%) had side effects; 
passive or active solicitation not reported; 13.6 weeks 
(±8.0 SD) mean gestational age at enrolment  
Jacobson (2001) 
444 
United 
States 
1998-2000 35/55 63.6% 47.7% to 79.6% DNA LCx STD 
assay; TOC 28 days 
13.3% (6/45) 
preterm 
10.1% (n = 55; 95% CI: 5.2% to 21.9%) had side effects; 
passive or active solicitation not reported; 20.6 weeks  
(± 8.8 SD) mean gestational age at enrolment  
Wehbeh (1998) 445 United 
States 
NR 26/27 96.3% 89.0% to 100%* Culture NR 100% (n=27) of partners treated 
Adair (1998) 446 United 
States 
1995-1997 37/42 88.1% 77.7% to 98.5% DNA assay; TOC 28 
days 
NR 11.9% (n = 5; 95% CI: 5.3% to 25.1%) had side effects; 
passive or active solicitation was not reported; 21.6 
weeks (±9.5 SD) mean gestational age at enrolment; 
54.8% (n = 23) of partners treated 
Edwards (1996) 448 United 
States 
1993-1994 61/65 93.8% 87.8% to 99.9% DNA assay; TOC 14 
days 
9.2% (6/65) preterm, 
3 due to PROM;  
Mean gestational 
age at delivery 38.8 
wks ±1.6 
20.4 weeks mean gestational age at enrolment 
Rosenn (1995) 449  United 
States 
1994-1995 21/23 91.3% 79.3% to 100%* PCR; TOC 21 days NR 19.3 weeks (± 3.5 SD) mean gestational age at 
enrolment 
Gunter (1996) 447 United 
States 
NR 22/22 100.0% NA DNA assay; TOC 14 
days 
NR 13.6% (n = 3; 95% CI: 5.0% to 33.6%) had 
gastrointestinal side effects; passive or active 
solicitation not reported 
Bush and Rosa 
(1994) 450 
United 
States 
NR 15/15 100.% NA DNA assay; TOC 14 
days 
NR 0% of women experienced side effects; 100% (n = 15) 
of partners treated 
Rahangdale (2006) 
451 
United 
States 
1999-2000 137/141 97.2% 94.4% to 99.9% DNA assay; TOC 
days 7-20; 21-34; 
35-55; >56 
7.5% (16/221 'any' 
preterm 
azithromycin)  
13.1% (n = 191; 95% CI: 9.0% to 18.6%) also had BV  
14.1 weeks (± 6.3 SD) mean gestational age at 
enrolment 
Miller (1995) 452 United 
States 
1993-1994 132/138 95.6% 92.2% to 99.1% DNA assay; TOC 
10-14 days 
15.2% (19/125) 
preterm 
5.5% (n = 146; 95% CI: 2.8% to 10.4%) had side effects; 
23.9% (n = 138; 17.6% to 31.7%) women also had NG; 
17.4% (4/17) reported side effects (all GI); mean 
gestational age at enrolment not reported 
 
Note that all studies used 1 g of azithromycin delivered as 1 dose; CI = Confidence interval; TOC = Test of cure; NR = Not reported; DNA = Deoxyribonucleic acid; PROM = Preterm premature rupture of the membranes; SD = 
Standard deviation; NG = Neisseria gonorrhoeae; BV = Bacterial vaginosis; GI = gastrointestinal; Upper confidence interval exceeded 100% and, therefore, was cut-off. 
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Studies investigating sexual activity following treatment may help to explain post-
treatment infections; misclassification of treatment failures and de novo infections 
may have been at play.  A trial in Seattle (1998 to 2003) found that persistent or 
recurrent chlamydial or gonorrhoeal infection occurred in 7.6% (N = 289; 95% CI: 5.1% 
to 4.9%) of female patients who reported no sexual intercourse after treatment.453  
Another study reported that 19.0% (N = 79; 95% CI: 11.9% to 29.0%) of women were 
positive for C. trachomatis three months after treatment using 1 g azithromycin.  Of 
these women, 13.3% (N = 15; 95% CI: 4.0% to 38.3%) reported being inactive sexually 
during the post-treatment period.454  These findings may be attributable to: (i) false 
reporting of sexual contact, (ii) treatment failure, or (iii) may lend credence to the 
hypothesis that C. trachomatis enters a latent asymptomatic state which is 
undetectable by culture or, possibly, Nucleic Acid Amplification Tests for a time-limited 
period and can later reactivate.455   
 
In vitro evidence 
Specific thresholds for antimicrobial susceptibility and resistance of C. trachomatis are 
not universally standard, although MICs of > 4 μg/ml (microgram per millilitre) are 
often used to characterize therapeutic failure.456-459  The lowest concentration of 
antimicrobial needed to inhibit chlamydial development is between 0.03 and 
0.125μg/ml, whereas the minimum bactericidal concentration (MBC; also referred to 
as the minimum chlamydicidal concentration, or MCC), is between 0.06 and 
0.5μg/ml.460,461  Current evidence from in vitro studies suggest that azithromycin 
maintains high and widespread treatment efficacy against C. trachomatis as 
summarised in Table 5.4b.  One exception, however, is a study of six isolates from 
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three patients who experienced treatment failure in Russia (2000 to 2002).  Four 
isolates were resistant to azithromycin, doxycycline and ofloxacin at MICs and MBCs > 
5.12μg/ml.462  Not surprisingly, in vitro resistance appears to be more common 
amongst isolates from individuals with greater severity of disease or recurrent 
disease.463  A study in the United States during the early 1990s described decreased 
susceptibility and emerging resistance to azithromycin and doxycycline in isolates from 
women with mucopurulent cervicitis, whereas isolates from women with 
asymptomatic infections remained susceptible.464     
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Table 5.4b Azithromycin and Chlamydia trachomatis: low-risk populations  
Reference 
(year of 
publication) 
Country Year(s) Azithromycin Other macrolides 
 
Additional details 
MIC (μg/ml) MBC/MCC (μg/ml) MIC (μg/ml) MBC (μg/ml) 
No resistance observed 
Ljubin-Sternak 
(2012) 465 
Croatia 2010 0.064 to 0.125 0.064 to 2.0 Doxycycline: 0.016 to 0.064 0.032 to 1.0 24 urogenital strains assessed  
Donati (2010) 466 Italy 2005-2006 0.25 to 0.5  0.5 to 1.0  Doxycycline: 0.03 to 0.06 
Erythromycin: 0.5 to 1.0 
0.06 to 0.125  
1.0 to 2.0 
All serovars had comparable susceptibilities.  
Azithromycin and doxycycline bactericidal with MBC at 1-
2 times the MIC. (50 strains) 
Hong (2009) 467 Ethiopia 2006 0.25 to 0.5 0.25 to 1.0 Doxycycline: 0.015 to 0.03 0.03 to 0.06 Azithromycin unchanged between pre- and post-mass 
biannual treatment of trachoma (10 strains) 
Samra (2001) 459 Israel 1997-1999 0.06 to 0.125  0.06 to 0.25  Doxycycline: 0.125 to 0.25           
Tetracyclines: 0.25 to 0.5 
0.125 to 4.0          
0.25 to 4.0  
Smallest MBC and MIC difference in azithromycin vs. 
doxycycline (4 dilutions differences; 50 isolates) 
Lefèvre (1993) 
468 
 
France NR 0.06 to 0.125 0.25 to 0.5 Clarithromycin: 0.008  
Erythromycin : 0.06 to 0.125 
Tetracyclines: 0.125 to 0.25 
0.03 to 0.125  
0.25 to 2.0 
1.0 to 4.0 
15 clinical isolates tested 
Agacfidan (1993) 
469 
United 
States 
1993 ≤0.06 to 1 0.12 to 2.0 Doxycycline: 0.015 to 0.06   
Tetracyclines: 0.03 to 0.12 
0.015 to 0.06       
0.06 to 0.12 
Azithromycin highly active against CT in isolates from 
urethral and cervical samples (azithromycin 10 strains,  
doxycycline  22 strains, tetracycline 22 strains)  
Scieux (1990) 470 United 
Kingdom 
1990 0.064 to 0.25 2.0 to 8.0 Doxycycline: 0.016 to 0.064 
Erythromycin: 0.064 to 0.128 
0.5 to 8.0 
0 to 64.0 
10 strains used from the United States 
Resistance observed 
Bhengraj (2010) 
464 
India 2006-2007 0.12 to 8 ≤ 8.0 Doxycycline: 0.025 to 8.0) ≤8.0 Decreased antimicrobial susceptibility in recurrently 
infected female patients (21 isolates)  
Misyurina (2004) 
462 
Russia 2000-2002 >5.12 > 5.12 Erythromycin: > 5.12 >5.12 Isolates from salpingitis, endocervicitis, and urethritis 
showed resistance (6 isolates) 
Somani (2000) 
458 
United 
States 
1995-1998 0.5 to >4.0 > 4.0 Doxycycline: 0.125 to > 4.0 >4.0 Resistance of strains causing relapsing or persistent 
infection in 3 patients (3 isolates) 
Rice (1995) 463 United 
States 
1995 0.125 to 2.0 0.5 to > 4.0 Doxycycline: 0.008 to 0.06 0.015 to 4.0 Isolates susceptible to azithromycin and doxycycline in 
asymptotic infection  
 
MIC = Minimum inhibitory concentrations; MBC = Minimum bactericidal concentration; MCC = Minimum chlamydicidal concentrations; NR = Not reported; CT = C. trachomatis; PID = Pelvic inflammatory disease 
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Trichomonas vaginalis  
In vivo evidence 
Trichomonas vaginalis is a protozoal infection that produces cervicitis and non-
gonococcal urethritis.  Treatment of pregnant women with T. vaginalis infection after 
the first trimester, per WHO recommendations, requires the administration of 2g 
metronidazole as a single dose, or 400-500 mg twice daily for seven days, or 300 mg 
clindamycin orally twice a day for seven days.110  If treatment is imperative during the 
first trimester of pregnancy, the single-dose regimen of 2 g metronidazole orally is 
recommended.110  Azithromycin has not been used directly for prevention or 
treatment purposes because T. vaginalis is anaerobic.  Nevertheless, azithromycin has 
demonstrated prophylactic protection against T. vaginalis in studies of mass STI/RTI 
treatment as summarised in Tables 5.5a and 5.5b. 
In Kenya (1998 to 2002), 1 g azithromycin was compared to placebo and administered 
once per month to 466 HIV-negative female sex workers.471  At the end of the trial, HIV 
incidence was the same across treatment groups, the primary endpoint, but the risk of 
T. vaginalis was reduced by one-half amongst female sex workers who were given 
azithromycin versus placebo (RR = 0.56; 96% CI, 0.40 to 0.78; P < 0.001).  
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Table 5.5a RCTs of azithromycin combinations amongst pregnant women 
  
Reference 
(year of 
publication) 
Country Year(s)  Regimen Number of cases post treatment (%) 
 
Additional details 
Treponema 
pallidum* 
Neisseria 
gonorrhoeae 
Chlamydia 
trachomatis 
Trichomonas 
vaginalis 
Bacterial 
vaginosis 
Luntamo 
(2010) 107 
Malawi 2003-
2006 
Intervention 
1 g AZ x 2 + SP monthly  
NR 0.5%  
(2/391) 
0.3%  
(1/391) 
11.0%  
(46/419) 
NR Significant protection against T. vaginalis 
P = 0.05 
Intervention 
SP monthly             
NR 2.1%  
(8/384) 
0.3%  
(1/384) 
15.1%  
(62/411) 
NR 
Control 
SP x 2  
NR 0.7%  
(3/391) 
0.3%  
(1/391) 
16.7%  
(69/411) 
NR 
van den 
Broek (2009) 
108 
Malawi 2004-
2005 
 
Intervention 
1 g AZ x 2 + SP x2 
NR NR NR NR NR No difference in preterm birth (16.8% 
versus 17.4%); potential explanatory 
factors include use of sub-optimal 
syphilis treatment 2,472 
Control 
SP x 2 
NR NR NR NR NR 
Gray (2001) 
358 
Uganda 1994-
1998 
Intervention 
1 g AZ + 250 mg CIPX +  2g MTZ 
3.4% (57/1,677) 0.9%  
(14/1,503) 
1.1%  
(16/1,503) 
4.7%  
(4/1,779) 
36.3%  
(645/1,779) 
Neonatal death RR=0.83; 95% CI: 0.71 to 
0.97; Low birth weight RR=0.68; 95% CI: 
0.53 to 0.86; Preterm delivery RR=0.77; 
95% CI: 0.56 to 1.05.  Vertical 
transmission of HIV was no different 
between intervention and control 
groups. 
Control 
Iron-folate + 100 mg  MBZ x2 
3.3% (46/1,376) 1.7%  
(24/1,394) 
2.7% 
(38/1,394) 
15.9%  
(248/1,569) 
48.5%  
(764/1,576) 
Wawer 
(1999) 473 
Uganda 1994-
1998 
Intervention 
1 g AZ + 250 mg CIPX + 2 g MTZ 
6.0% (80/1,323) 1.0%  
(8/770) 
1.2%  
(9/770) 
5.3%  
(72/1,350) 
39.1%  
(533/1,364) 
Vertical transmission of HIV was no 
different between intervention and 
control groups. Control 
Iron-folate + 100 mg  MBZ x2 
7.1% (75/1,056) 2.1%  
(15/714) 
3.5%  
(25/714) 
17.4%  
(198/1,137) 
52.8%  
(609/1,154) 
  
*2.4mµ  benzathine Penicillin G was administered to pregnant women in all treatment groups per national guidelines (exception being 108); AZ = Azithromycin; SP = Sulphadoxine-pyrimethamine; NR = Not reported; RR = Risk ratio; CI = Confidence 
interval; CIPX = Ciprofloxacin; HIV = Human immunodeficiency virus  
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Table 5.5b RCTs of azithromycin combinations amongst commercial sex workers 
  
Reference 
(year of 
publication) 
Country Year(s)  Regimen Proportion of cases cured (cases pre-treatment / cases post-treatment) 
 
Additional details 
Syphilis* N. gonorrhoeae C. trachomatis T. vaginalis 
Bacterial 
vaginosis 
Kaul (2004) 
471 
Kenya 1998-
2002 
Intervention 
1 g AZ monthly (multi-yr pd) 
3.9% 2.6% 1.1% 11.3% 53.0% Incidence reported per 100 
women-years  
Control 
Placebo 
3.8% 5.7% 6.5% 20.4% 57.4% 
Labbe (2012) 
474 
Benin 
Ghana 
2001 Intervention 
1 g AZ or 500 g CIPX monthly for 
9 mo alternating AZ & CIPX 
NR 5.6%  
(7/126) 
1.6%  
(2/126) 
NR NR Significant protection 
against NG P = 0.05 
Control 
Placebo 
NR 12.5%  
(14/112) 
2.7%  
(3/112) 
NR NR 
Cowan 
(2005) 475 
Zimbabwe NR Intervention  
1 g AZ + 2 g MTZ + 500 mg CIPX  
Base: 5.0% 
(2.8, 8.7%); 
V2, V3, V4 = 
NR in any 
form 
Base: 1.9% (0.5, 
3.4%); graphs 
contain visible 
inaccuracies for  
V2, V3, V4 
Base: 1.7% (0.3, 
3.0%); graphs 
contain visible 
inaccuracies for  
V2, V3, V4 
Base: 19.3% (15.2, 23.4%) 
V2: 4.3% (7.7 to 2.2%)  
V3: 12.6% (17.7 to 8.8%) 
V4: 11.5% (15.7 to 7.8%) 
-- -- 
Intervention 
1 g AZ + 2 g MTZ  
Wi (2006) 476 Philippines 2001 Intervention  
1 g AZ one 
time 
Prior to 
intervention 
NR 18.3%  
(207/1,130) 
28.6%  
(323/1,130) 
NR NR -- 
1 mo post-
intervention 
11.9%    
(82/687) 
15.1%  
(104/687) 
Williams 
(2003) 477 
South 
Africa 
1998-
2000 
Intervention  
1 g AZ 9x 
in 9 mo 
Prior to 
intervention 
9.8% 
(68/691) 
6.9% 
(48/691) 
7.9% 
(55/691) 
NR NR HIV prevalence amongst 
CSW in the mining 
community was 68.6% 9 mo post-
intervention 
18.7% 
(166/893) 
8.6% 
(77/893) 
13.8% 
(123/893) 
Steen (2000) 
478 
South 
Africa 
1996-
1997 
Intervention  
1 g AZ 
every mo 
for 9 mo 
Prior to 
intervention 
NR 17.3% 
(70/407) 
14.3% 
(58/407) 
NR NR Pre-intervention NG and/or 
CT = 24.9% (101/407);  
Post-intervention NG and/or 
CT = 5.7% (6/108) 
9 mo post-
intervention 
4.7% 
(5/108) 
0.9% 
(1/108) 
 
Note that none of the azithromycin combinations summarised are contraindicated in pregnancy 
*2.4 mµ  benzathine Penicillin G was administered to commercial sex workers who tested positive for syphilis in all treatment groups per national guidelines; AZ = Azithromycin; NR = Not reported; CIPX = Ciprofloxacin; MTZ = Metronidazole; 
HIV = Human immunodeficiency virus; Note that italicized values are approximate based on enlarged graphs published in Cowan et al and percentages in parentheses reflect the 95% confidence intervals 475;  V2, V3, V4 = Visit 2, Visit 3, and 
Visit 4; HIV = Human immunodeficiency virus; NG = Neisseria gonorrhoeae; CT = C. trachomatis; CSW = Commercial sex worker 
190 
 
A similar observation was made in a three-arm IPTp trial conducted in Malawi (2003 to 
2006) in a low-risk population of pregnant women.107  Participants received standard 
IPTp-SP, or monthly IPTp-SP, or monthly IPTp-SP plus 1 g azithromycin during two 
antenatal visits.  The prevalence of T. vaginalis at delivery was 16.7% (n = 411; 13.5% 
to 20.7%), 15.1% (n = 411; 95% CI: 12.0% to 18.9%), and 11.0% (n = 419; 95% CI: 8.3% 
to 14.3%), respectively.  Thus, compared to recipients of monthly IPTp-SP alone, 
women who received monthly azithromycin plus IPTp-SP had 35% (RR = 0.65; 0.46 to 
0.93; P = 0.02) fewer T. vaginalis infections at delivery.   
A cluster randomised trial in Uganda (1994 to 1998) compared the incidence of HIV 
infections amongst non-pregnant adults who received three antibiotics (1 g 
azithromycin, 250 mg ciprofloxacin, and 2 g metronidazole) or multi-vitamins plus 
antihelminth treatment.473  Although the trial was terminated early for lack of 
protection against the primary endpoint (incidence of vertical transmission of HIV 
infection), the incidence of several curable STIs/RTIs was lower in the control group, 
most notably T. vaginalis.  The cumulative incidence of newly diagnosed T. vaginalis 
infection was 4.8 per 100 person years (116/2397 person-years) in the intervention 
group, compared to 9.1 per 100 person-years (182/1993 person-years) in the control 
group (RR=0.52; 0.35 to 0.79).  The same combination of antimicrobials (azithromycin, 
ciprofloxacin, and metronidazole) was provided to female sex workers in rural 
Zimbabwe as a one-time treatment followed by three monthly check-ups.475  The 
prevalence of T. vaginalis pre-dose was just under 20% and then decreased to 
approximately 5% at visit 2.  It rose to nearly 13% at visit 3, and dropped again to just 
over 10%, one-half of the pre-treatment levels.   
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Bacterial vaginosis  
The WHO recommendations are to treat bacterial vaginosis in pregnant women, 
preferably after the first trimester, using: (i) 200 or 250 mg metronidazole three times 
per day for seven days, or (ii) 5 g metronidazole gel (0.75%) applied intravaginally 
twice a day for five days, or (iii) 300 mg clindamycin 300 mg orally twice a day for 
seven days.109  As with T. vaginalis, 2g metronidazole orally is recommended if 
treatment is imperative during the first trimester of pregnancy.109  Bacterial vaginosis 
has no single causative agent, but is thought to result from destabilization of 
Lactobacillus species (spp.) which leads to secondary colonization of anaerobic 
organisms that include Gardnerella vaginalis, Bacteroides spp., Mobiluncus spp. and 
Mycoplasma hominis.  These changes in flora accompany an increase in vaginal 
pH.479,480   
 In vivo evidence 
There were no trials identified by systematic review that attempted to measure the 
treatment efficacy of azithromycin alone against bacterial vaginosis.  However, one 
study in the United States (2002 to 2005) investigated the use of azithromycin as a 
partner drug with metronidazole for the treatment of symptomatic bacterial vaginosis.  
Non-pregnant women were randomised into four treatment groups and received 750 
mg metronidazole once per day for 7 days, or metronidazole once per day for 7 days 
plus 1 g azithromycin on days 1 and 3, or metronidazole for 14 days, or metronidazole 
for 14 days plus azithromycin on days 1 and 3.481  There was no additional benefit of 
cure observed amongst women who received metronidazole plus azithromycin 
compared to metronidazole alone.  Because bacterial vaginosis is a syndrome that 
involves multiple micro-organisms, antibiotic treatment is challenging.  However, 
192 
 
comparable data from other related macrolides do suggest potential therapeutic 
benefit for azithromycin in the treatment of bacterial vaginosis as shown in Table 5.6 
Analysis of azithromycin against the anaerobic and carboxyphilic bacteria which 
replace the normal vaginal flora may provide a better understanding as to the 
potential role of azithromycin against bacterial vaginosis.   
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Table 5.6 Macrolides and isolates of key organisms in bacterial vaginosis
Unspecified low risk population 
 
 
Reference 
(year of publication) 
Country Year(s) 
Minimum inhibitory concentrations of specific macrolides (µg/mL) 
Azithromycin Erythromycin Clarithromycin Roxithromycin Clindamycin* Telithromycin* 
Gardnerella vaginalis Jones (1988) 482 United Kingdom NR < 0.03 to 0.125  < 0.03 to 0.06      NR NR NR NR 
Shanker (1982) 483 Australia NR NR 0.007 to 0.06 NR NR 0.007 to 0.06 NR 
Ridgway (1987) 484 *  NR NR 0.008 to 0.016 NR 0.016 NR NR 
Bacteroides species Jones (1998) 482 United Kingdom NR 0.06 to16 < 0.03 to 32 NR NR NR NR 
Dubreuil (1987) 485 England, France, 
Germany, Japan 
NR NR 0.003 to > 64 NR 0.003 to > 64 NR NR 
Maskell (1990) 486 United Kingdom NR 0.5 to > 16 < 0.25 to 16 NR NR NR NR 
Chang (1995) 487 Taiwan 1989-
1992 
1 to > 256 0.25 to > 256 ≤0.03 to > 256 0.25 to > 256 NR NR 
Ednie (1997) 488 United States NR 1 to > 64 0.5 to > 64 0.5 to > 64 2 to > 64 ≤ 0.06 to > 64 NR 
Mikamo (2003) 489 Japan 2000 0.125 to 32 0.125 to 32 0.063 to16 NR NR 0.032 to 16 
Marina (2009) 490 Bulgaria 1983-
2007 
NR 0.5 to > 64 NR NR 0.125 to 32 NR 
Chen (1992) 491 Australia 1986- 
1991 
0.5 to 128 0.25 to 128 NR NR NR NR 
Wexler (2001) 492 United States NR NR NR NR NR NR 0.25 to > 64 
Mycoplasma hominis Ridgway (1987) 484 United Kingdom NR NR >32 NR 8 to16 NR NR 
Mobinculus species Spiegel (1987) 493 United States NR NR ≤0.2 to > 200 NR NR ≤ 0.015 to 4 NR 
 
*Not a macrolide but has similar mechanism of action and included for comparability; NR=Not reported 
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Discussion 
This systematic review of in vivo efficacy and in vitro sensitivity of azithromycin against 
curable STIs/RTIs suggests the compound is an attractive option for preventing and 
curing T. pallidum, N. gonorrhoeae and C. trachomatis infections.  Prior to the advent 
of antiretroviral therapies for HIV, the management of curable STIs/RTIs received 
notable importance as trials showed that treatment of N. gonorrhoeae, C. trachomatis, 
and T. vaginalis reduced the genital viral load of HIV amongst men and women.494-497  
Thus, groups at high-risk for transmitting HIV have since been targeted by treatment 
campaigns using 1 g azithromycin.  It is not surprising, therefore, that changes in 
azithromycin sensitivity in high-income settings have often been observed first 
amongst members of high-risk groups who may have had compromised immunity 
attributable to HIV infection.  Pregnant women attending ANC facilities in sub-Saharan 
Africa do not share this risk profile.  Thus, on this basis alone, it is less likely that the 
use of azithromycin in combination with an antimalarial compound, would be a 
catalyst for the rapid selection of azithromycin resistance, although such a potential 
cannot be ruled out. 
 
The potential benefits of using azithromycin as part of an enhanced IPTp regimen may 
be best viewed through prior experience with mass drug administration amongst 
pregnant women as noted in the prior section on T. vaginalis.  In the context of the 
AIDS epidemic and before the age of antiretroviral therapies, investigators attempted 
to prevent vertical transmission of HIV by providing pregnant women in Uganda 1 g 
azithromycin, in combination with 250 mg ciprofloxacin and 2 g metronidazole.358  The 
data safety monitoring board suspended the trial early for reasons of futility, despite 
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having cut neonatal deaths by 17% (RR = 0.83; 95% CI: 0.71 to 0.97), decreased the 
incidence of LBW by 32% (RR = 0.68; 95% CI: 0.53 to 0.86), and reduced the incidence 
of preterm delivery by 23% (RR = 0.77; 95% CI: 0.56 to 1.05).  These impressive results 
were achieved at a time when neither IPTp-SP nor insecticide treated bed nets for the 
control of malaria in pregnancy had been deployed. 
 
If azithromycin is provided as part of IPTp alongside a partner antimalarial drug, there 
are several key factors to consider that are pathogen specific.  Regarding syphilis, no 
less than 1 g azithromycin should be used alongside 2.4 mµ BPG for three reasons: (i) 
combination therapy has been shown to achieve higher rates of cure than either 
therapy alone,498 (ii) use of azithromycin with BPG would likely reduce selection of the 
AG mutation associated with azithromycin and preserve T. pallidum sensitivity, and 
(iii) most importantly, only BPG can be expected to cure congenital infection if the 
placenta has been invaded by spirochetes.111   
 
As for N. gonorrhoeae, 1 g azithromycin may be just above the minimum inhibitory 
concentration of fully susceptible strains and, therefore, more than 1 g azithromycin 
may be preferable from the standpoint of reducing selection pressure.  However, a 
single 2 g dose may not be well tolerated as six in ten patients reported self-limiting 
gastrointestinal discomfort when treated for syphilis infection with such a regimen.  
Splitting the dose over two days may improve tolerability.  This is an important issue 
based on the experience of azithromycin plus chloroquine in which 1 g azithromycin 
was given on three consecutive days.  Treatment-related adverse events were 
experienced by nearly seven of ten women, 68.9% in total (n = 996).  The most 
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frequent events were vomiting, dizziness, headache, and asthenia amongst 44.6%, 
31.4%, 15.3%, and 15.2% of azithromcycin plus chloroquine recipients, respectively.116  
If the partner antimalarial drug is dihydroartemisinin-piperaquine, therapy that 
requires a three-day course, a split dose of 500 mg might be considered for each of the 
three days to achieve optimal tolerability.  This would also simplify dosing, and likely 
improve compliance and adherence to the regimen.   
 
A regimen of 1 g azithromycin, would be protective against C. trachomatis and, 
although the data are limited and the mechanism of action is not understood, 1 g 
azithromycin may protect against T. vaginalis based on reports from Malawi amongst 
pregnant women107 and commercial sex workers in Kenya.471  It is curious, however, 
that T. vaginalis infection during pregnancy is associated with adverse birth outcomes, 
but the first-line treatment of 2 g metronidazole does not always improve birth 
outcomes.  A trial in Uganda reported that pregnant women treated for T. vaginalis 
infection were 2.5 times more likely to deliver a LBW infant than untreated women 
(RR = 2.49; 95% CI: 1.12 to 5.50).499  The authors suggest this may be attributable to 
metronidazole exposure.  Another trial in the United States reported an increase in the 
risk of preterm delivery amongst pregnant women exposed to metronidazole for the 
treatment of asymptomatic trichomoniasis compared to those who were not treated 
(RR = 1.8; 95% CI: 1.2 to 2.7)500.  In contrast to these findings from a high-income 
setting, data from a multi-centre trial in sub-Saharan Africa suggests that treatment of 
T. vaginalis infection using metronidazole does not increase the chances of preterm 
birth.501  Apart from bacterial vaginosis, which is not transmitted through sexual 
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contact, re-infection will remain a risk for pregnant women and, therefore, providers 
should continue to offer education and screening as appropriate. 
 
None of the studies identified in this review indicate that azithromycin offers 
preventive or curative effect against bacterial vaginosis, the most prevalent of curable 
STIs/RTIs.  Antibiotic therapy with metronidazole has only been shown to reduce the 
risk of preterm delivery by one-half (RR = 0.53; 95% CI: 0.34 to 0.84) amongst pregnant 
women with bacterial vaginosis (Nugent score 7 to 10) or intermediate flora (Nugent 
score 4 to 6).502  A Nugent score of 0 to 3 is considered normal,503 for which no 
protection against adverse birth outcomes has been observed.   
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Summary discussion 
Since the WHO first recommended IPTp in 2004 for pregnant women resident in 
malaria endemic areas during antenatal visits, clinical researchers have been trying to 
identify replacements for SP.116,154,504-506  These efforts have proven elusive in large 
part because IPTp-SP has only been viewed as intervention that reduces the 
consequences of malaria infection on pregnancy outcomes.  This has led investigators 
to assume that there must be a threshold of malaria transmission intensity in sub-
Saharan at the population level below which IPTp-SP no longer protects against the 
incidence of LBW.  There does not appear to be one based on evidence presented in 
this thesis as well as unpublished findings from analysis of Multiple Indicator Cluster 
Surveys (Eisele TP, personal communication).  Evidence presented in this thesis does 
suggest that the protective effect of IPTp-SP against LBW is under threat by a higher 
prevalence of the biomarker A581G associated with SP resistance.  However > 2 doses 
of IPTp continues to protect primi- and secundigravidae against the incidence of LBW 
in areas where A581G can be found in over one-half of malaria parasites.   
 
This protection could extend to higher prevalence levels, but there are no data 
available to support or refute this assertion.   However, in areas with a prevalence of 
the A581G mutation > 10.1%, IPTp-SP may not have a beneficial effect on LBW.   This 
observation needs to be interpreted with caution because there were no data in areas 
with a prevalence between 10% and 50%.    
 
 
199 
 
IPTp-SP continues to proect against the incidence of LBW across all malaria 
transmission intensities, as well as in the presence of the A581G mutation, particularly 
amongst primi- and secundigravidae, because the causes of LBW are multifactorial.  
This has long-been assumed, but the secondary analysis of data from Zambia in this 
thesis is the first evidence that IPTp-SP is protective against adverse birth outcomes 
related to curable STIs/RTIs.   
 
The systematic review and meta-analysis of the dual burden of malaria and curable 
STIs/RTIs produced the first published pooled estimates of peripheral (N = 90,755; 94 
studies; 16 countries) and placental (N = 34,184; 35 studies; 13 countries) malaria 
infection amongst women attending ANC facilities in sub-Saharan Africa.  The pooled 
estimates fall within the range of point estimates contained in prior reviews by Brabin 
and Steketee et al.  This was also the first such meta-analysis of curable STIs/RTIs in 
the region, producing pooled estimates for syphilis (N = 147,477; 50 studies; 18 
countries), N. gonorrhoeae (N = 19,957; 19 studies; 12 countries), C. trachomatis (N = 
10,573; 22 studies; 15 countries), T. vaginalis (N = 37,995; 35 studies; 15 countries), 
and bacterial vaginosis (N = 21,547; 23 studies; 13 countries).  For syphilis, N. 
gonorrhoeae, and C. trachomatis infections, the pooled prevalence estimates for East 
and Southern Africa, as well as West and Central Africa, all fell between the lowest and 
highest point estimates for the sub-Saharan region presented in the 2005 review of 
curable STIs/RTIs by Mullick et al.168  However, pooled prevalence estimates for T. 
vaginalis in both sub-regions were greater than highest point estimate reported by 
Mullick et al., as was the pooled prevalence of bacterial vaginosis in East and Southern 
Africa compared to Mullick’s highest point estimate.  It is not possible to assess 
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whether this reflects a regional trend, or if the review by Mullick et al. understated the 
prevalence of T. vaginalis and bacterial vaginosis.   
 
Since publication of the systematic review and meta-analysis, Davey et al. conducted a 
similar analysis for the period 2010 to 2015.507  Their sub-regions were slightly 
different and ‘Southern Africa’ included South Africa, the only sub-Saharan country 
excluded from the analysis presented in this thesis because malaria is no longer 
endemic there.  The authors stated, “Other systematic reviews of STI prevalence in 
pregnant women have found similarly high rates of STIs.  A review article by Chico et 
al. in 20129 found that the prevalence of syphilis was 3.5%, CT was 6.1%, and TV was 
17.8% amongst pregnant women in West and Central Africa.” 
 
The fact that only one study of the 171 identified in the systematic review of malaria 
and curable STIs/RTIs actually reported the incidence of co-infection is partially the 
result of researchers operating in scientific silos.  Investigating co-infections that cut 
across disciplines requires researchers to become subject matter experts in more than 
one field, or to work in multi-disciplinary teams.  Neither approach is easy, but either is 
necessary since IPTp-SP contributes to preventing adverse birth outcomes attributable 
to malaria infection and curable STIs/RTIs in pregnancy.  Importantly, even if 
sulphadoxine is only partially protective against a broad-spectrum of gram-positive 
and gram-negative bacteria, dosing at each scheduled ANC visit from the second 
trimester to delivery may be sufficient to curb bacterial densities, thus directly 
reducing the incidence of adverse birth outcomes.  It is possible, as well, that reduced 
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bacterial densities produced by sulphadoxine exposure also inhibit maternal 
inflammatory responses to infection that are known to trigger preterm birth.508   
However, can we do better?   
 
In the case of curable STIs/RTIs, the ANC package recommended by the WHO includes 
screening for syphilis and the provision of BPG to women who test positive.  Screening 
and treatment would need to continue even if dihydroartemisinin-piperaquine plus 
azithromycin were used because insufficient quantities of azithromycin perfuse the 
placenta to cure congenital cases.  However, azithromycin would be curative of 
maternal syphilis, N. gonorrhoeae, C. trachomatis, and potentially T. vaginalis.  
Management of bacterial vaginosis in pregnancy may be more difficult.  Treatment of 
women who have Nugent scores of 1-3 has not reduced the incidence of preterm 
birth.  Based on evidence from this monograph, it would appropriate to conduct in 
vitro sensitivity testing of sulphadoxine with isolates from T. pallidum, N. gonorrhoeae, 
C. trachomatis, T. vaginalis, and organisms associated with bacterial vaginosis 
including G. vaginalis, Bacteroides spp., Mobiluncus spp. and M. hominis.   
 
In light of the protection against curable STIs/RTIs conferred by IPTp-SP, it would be 
appropriate to conduct in vitro sensitivity testing of sulphadoxine versus azithromycin 
exposed to the five curable STIs/RTIs of interest and, potentially, other pathogens to 
begin to elucidate the range of protective effect pregnant women are benefitting from 
in countries where IPTp-SP is policy.   
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HIV-infected pregnant women also need an alternative to SP.  At present, HIV-infected 
women are given cotrimoxazole against opportunistic infections; IPTp-SP is contra-
indicated for these women out of concerns related to potential sulpha-toxicity if both 
therapies are used concomitantly.  The combination of dihydroartemisinin-
piperaquine plus azithromycin may represent a therapy that could be used alongside 
cotrimoxazole.  Drug-drug interaction studies would need to confirm the safety of such 
use and, importantly, that maternal viral load is not adversely impacted.  Thus, studies 
are now needed to determine whether dihydroartemisinin-piperaquine plus 
azithromycin would be a better alternative to SP for IPTp. 
 
There are concerns that use of azithromycin may select for resistances in the 
pneumococcus.  A single 1g dose of azithromycin clears ocular strains of Chlamydia 
that cause trachoma.  During the past two decades, azithromycin has been distributed 
in trachoma-endemic areas as part of the WHO-led trachoma elimination 
programme.509  Mass distribution has been shown also to reduce the incidence of 
respiratory infections,510 diarrhoea,511 and malaria.512  These secondary benefits likely 
underlie the statistically significant reductions in all-cause childhood mortality 
reported in Ethiopia following trachoma treatment campaigns where odds were cut by 
one-half (OR = 0.51; 95% CI: 0.29-0.90) in a clinical trial513 and 35% (OR = 0.35; 95% CI: 
0.17–0.74) in a cohort study.  However, there is significant evidence of clonal 
expansion of pneumococcal multi-locus sequence types ermB and mefA/E associated 
with resistance in the same geographic areas where four rounds of mass drug 
administration with azithromycin have been conducted.514  Follow up surveillance 
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studies of six or more months post-exposure have found that the prevalence of 
resistant isolates do return to pre-dosing levels.515,516  Importantly, there is no 
evidence of noticeable increases in pneumococcal resistance over time in countries 
that have participated in mass campaigns where over 500 million doses have been 
administered to date.517  Regardless, to address this concern, trials that investigate the 
use of dihydroartemisinin-piperaquine plus azithromycin should test for macrolide 
resistance in the pneumococcus pre- and six or more months post-exposure.  In 
addition, if dihydroartemisinin-piperaquine plus azithromycin were to be adopted for 
preventive care as part of the ANC package, then countries should collect biological 
samples on a semi-annual basis from pregnant women at sentinel sites with the 
objective of monitoring in vivo and in vitro sensitivity to curable STIs/RTIs as well as 
pneumococcal infections. 
Descriptive epidemiological studies are needed to understand better the extent to 
which symptomatic versus asymptomatic curable STIs/RTIs contribute to adverse birth 
outcomes.  Such studies would be incomplete if the prevalence of co-infections were 
not also considered.  The apparent failure to reduce the incidence of adverse birth 
outcomes following treatment for one infection may be masked by the presence of co-
infection(s) that will only be mitigated with the use of combination therapies and 
consideration of downstream outcomes.   
 
Finally, discussion of the future of IPTp, with SP or an alternative, needs to be placed in 
the context of broader malaria elimination efforts.  As malaria transmission intensity 
decreases in endemic areas, pregnant women will be exposed to fewer infective bites.  
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This may mean that primi- and secundigravidae will not develop the protective 
immunoglobulin G that is associated with maternal parity and the var 2 CSA gene.  
Consequently, future multigravidae may be at greater risk of adverse birth outcomes 
attributable to malaria than multigravidae of today, warranting close surveillance at 
national and district levels of malaria cases by gravidae. 
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Conclusions 
Evidence presented in this doctoral thesis suggests that IPTp-SP continues to provide 
valuable protection against the incidence of LBW amongst all gravidae until very low 
levels of malaria transmission and that this protective effect persists amongst primi- 
and secundigravidae in areas where one-half of malaria parasites carry the ‘super 
resistant’ A581G mutation.  Amongst multigravidae, however, there is only evidence of 
continued protection against LBW in areas where < 10.1% of malaria parasites express 
the A581G mutation.  The actual threshold for multigravidae may be higher, but is 
unknown with data that are currently available.   
There has long been speculation that sulphadoxine, the antibiotic component of SP, is 
protective against more pathogens than simply malaria infection.  Evidence presented 
in this thesis supports the assertion that SP is, indeed, also protective against the 
adverse birth outcomes attributable to curable STIs/RTIs.  This finding would 
encourage improved operational planning and coordination between National Malaria 
Control Programmes and Maternal and Reproductive Health Programmes, and provide 
greater impetus to scale up the antenatal coverage of IPTp-SP.  Regardless, the dual 
burden of malaria infection and curable STIs/RTIs is a public health concern and 
continues to exact a high toll on pregnancies in sub-Saharan Arica.  Use of 
dihydroartemisinin-piperaquine plus azithromycin as IPTp could be superior to IPTp-SP 
in safeguarding against adverse birth outcomes attributable to malaria and curable 
STIs/RTIs.  Head-to-head clinical research between SP and dihydroartemisinin-
piperaquine plus azithromycin with robust microbiology is required to chart the 
pathway forward.  
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